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ABSTRACT
The general aim of this work was to synthesise novel B-ring-modified analogues of
castanospermine with the longer term view of creating selective glucosidase inhibitors.

A minor aspect was to begin the synthesis of casuarine 114 from castanospermine 1.
Various approaches were tried to introduce a leaving group at the 1-position of
castanospermine 1, with a view to elimination across the C1-C2 bond, although without
success.

All B-ring-modifying studies required the synthesis of the hydroxyallyl piperidine 11
Synthesis of the T B D M S and T M S protected allylpiperidines 155 and 156 from
castanospermine 1 was achieved in 6 steps and with 4 9 % and 4 6 % overall yields
respectively. A model tetrahydroisoquinoline intermediate 116, containing the principal
amine and alkene functional groups for subsequent reactions, was prepared from
1,2,3,4-tetrahydroisoquinoline in 5 1 % over 2 steps.

Ring closing metathesis studies with the tetrahydroisoquinoline system allowed for
formation of the benz-fused quinolizine 177 and the azepine-fused isoquinoline
derivative 178. Attempts to cyclise related amide dienes using this reaction were
unsuccessful.

Application of the ring closing metathesis reaction to the

castanospermine-derived system produced the novel trimethoxyhydroxy quinolizine
117 with a synthetically useful alkene moiety in the ring-expanded B-ring.

Free-radical cyclisation of allyl o-bromoamides was first investigated with the model
system to produce exclusively the 5-exo-trig cyclised product as a mixture of
diastereomers. Separation of these diastereomers and debenzoylation led to the benzfused tropane ring system 200, constituting a short and convenient approach to this ring

vi

system. Application of this reaction to the castanospermine derived system was carried
out with both the hydroxy amide 201 and the TBDMS-protected amide 202.
Cyclisation with these derivatives gave mixtures of the 5-exo 204 and 6-endo 205
products, with the 5-exo favoured for 201, although at the expense of
diastereoselectivity, and 6-endo favoured for 202. Demethylation of 204 has led to

isolation of a mixture of di-demethylated products, representative of a new range of
poly-oxygenated tropane derivatives which could act as possible glucosidase enzyme
inhibitors.

Synthesis of several 1,3-dipoles, and their attempted subsequent intramolecular

cyclisation, was undertaken on the model 1-allyl-tetrahydroisoquinoline-based system

Isolation of several nitrones and oximes was successful but no cycloaddition could b
observed.

A novel pyrido-fused 1,4-thiazinone 243 was also prepared from the castanosperminederived carbamate 153.
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CHAPTER 1

GENERAL INTRODUCTION
1.1 CASTANOSPERMINE: AN OVERVIEW

Castanospermine 1 (figure 1.1) is a water-soluble polyhydroxylated alkaloid first
Castanospermum

isolated in 1981 from the immature seeds of the Australian legume
australe.1

HO

OH

HO

H

OH

r H
HO°
1-deoxynojirimycin 2

OH

D-glucose

Figure 1.1: Comparison of the stereochemistry of the hydroxyl groups of
castanospermine 1 with 1-deoxynojirimycin 2 and D-glucose

C o m m o n l y k n o w n as the Moreton Bay Chestnut, or Black Bean, C. australe is found in
the rainforest and riverside areas of North-Eastern Australia. The seeds, found in the
giant pods (figure 1.2) of the tree, have been eaten by horses and cattle resulting in
gastrointestinal irritation and even death when the unripe seed is consumed. Australian
Aborigines have used the seeds as a food source after preparation by soaking and
roasting.2 This m a y be sufficient to leach out the toxic water-soluble alkaloids.

In 1988 castanospermine 1 was also isolated from the dried pods of the South American
legume Alexa leiopetala, and tentatively identified in seven other Alexa species.3 This
discovery prompted a review of the chemotaxonomy of the Castanospermum

and Alexa

genera which concluded that Alexa w a s misplaced in the Dussia alliance and has
subsequently been placed in the Angylocalyx alliance along with Castanospermum

and

that the two species share a c o m m o n ancestor on the old South Panagean continent.4

1

Figure 1.1.2: Pods of Castanospermum australe.

2

The absolute configuration of castanospermine wasfirstdetermined by synthesis,5 and
further confirmed by X-ray crystallography,6 to be 2(5), 3(R), 4(R), 5(R), 6(S). This
corresponds to the configuration of 1-deoxynojirimycin 2 (DNJ) (figure 1.1).

The biological activity, and indeed usefulness, of castanospermine is a direct result of
the ability of the alkaloid to inhibit a-glucosidases, and in particular the glycoprotein
processing enzyme, glucosidase I. This activity, in turn, is probably due to the
structure having significant similarity to the natural substrate, D-glucose (figure 1.1).

1.2 GLYCOSIDASES AND THEIR INHIBITORS

1.2.1 Glycosidase Inhibitors

Glycosidases are simply enzymes that cleave bonds between sugar residues.
W e use a variety of these to break d o w n disaccharides and carbohydrates in our gut, the
resulting monomers being readily absorbed through the intestinal wall and thus becoming
available for use by our body. Lysosomes contain glycosidases which are involved in
the catabolism and re-cycling of saccharides in cells. Other glycosidases are used by
cells to process the glycan section of glycoproteins, another important goup of complex
macromolecules (see Section 1.2.3).

During many early searches for plant alkaloids, those that were soluble in the water
fraction were often neglected.

It was not until techniques such as ion-exchange

chromatography were developed that purification and isolation of these compounds
became facile and the 1980's then saw the discovery of a wealth of water-soluble
alkaloids. M a n y of these alkaloids, also k n o w n as aza-sugars or amino-sugars, have
been found to inhibit a range of glycosidases by mimicking their respective natural sugar
substrates. These inhibitors exhibit a variety of ring structures and are grouped as
3

pyrrolidines, piperidines, nortropanes, pyrrolidines and indolizidines, which can be
represented by 2,5-dihydroxymethyl-3,4-dihyroxypyrrolidine

( D M D P ) 3, D N J 2,

calystegine Q 4, australine 5 and castanospermine 1 respectively (figure 1.3). O n closer
examination of these compounds there appears to be a c o m m o n positioning of the
hydroxyl groups. This positioning is also observed in glucose (figure 1.1) and thus one
m a y expect all these compounds to exhibit glucosidase inhibitory activity. Indeed this is
the case.

HO

OH
HO
OH
= H

HO

N

HO'

OH

DMDP 3

DNJ 2

H

calystegine C t 4

PH

HO«

HO*'
australine 5

castanospermine 1

Figure 1.3: Representative structures of pyrrolidines, piperidines, nortropanes,
pyrrolizidines and indolizidines.

An in-depth review in this area has been presented elsewhere and is beyond the scope o
this introduction.7

1.2.2 Glycosidase Inhibitors in the Treatment of Diabetes Mellitus

Diabetes can be divided into two distinct disorders. Insulin-dependent diabetes mellitus
( I D D M or type I diabetes), where the patient fails to produce insulin completely, and is
thus dependent on exogeneous insulin injections, and non-insulin dependent diabetes

4

mellitus ( N I D D M or type II diabetes) where patients are still able to produce insulin
but not adequately respond to increases in blood glucose levels.

There are four main classes of drugs currently available for treatment of N I D D M .
These are the sulphonylureas which stimulate insulin secretion, the biguanides which
improve insulin sensitivity, oc-glucosidase inhibitors which slow carbohydrate breakdown (and thus intestinal glucose absorption following a meal), and insulin itself which
further modulates plasma glucose levels and is used specifically to target basal fasting

levels (figure 1.4). a-Glucosidase inhibitors represent the most recent addition to the
drug classes.

Exogenous
Insulin

Plasma
Insulin

Biguanides

*—
CO

o
'•4—1

CD

•
glycogenosis

+
Tissues

Utilization

Plasma
Glucose
Level

k_

Liver

o
a>
co

3

1

signal

c,
o
a.
in

co

Pancreas

c

o
o

a-Glucosidase
inhibitors

co

n
Intestines
<

Figure 1.4: Points of action of the four main anti-diabetic drug classes

The modern Western diet is based on highly refined foods. Starch (a-amylose) and
sugar (sucrose) are our major sources of exogenous glucose. Almost every packaged

food found on the supermarket shelf contains some added sugar. Such a refined source
of glucose leads to its rapid absorption following a meal giving a spike, or sharp rise of
blood glucose called a hyperglycemic response. In a normal healthy person this does
not cause a problem due to a rapid insulin response. However, this response is retarded
in an N I D D M patient. Control of dietary intake of sugar is thus a major aspect of
diabetes management for these patients. A s already noted, this is not always possible
w h e n relying on pre-packaged "convenience" foods.

Inhibitors of intestinal a-glucosidases are able to slow the breakdown of ingested
carbohydrates, thus slowing the absorption of glucose across the intestinal wall and
exerting an anti-hyperglycemic effect.

Such inhibitors are not expected to reduce

calorific intake by completely preventing absorption, but simply increase the length, and
thus time, over which glucosidase activity occurs. Incomplete absorption would lead to
the presence of sugar and other easily digestible carbohydrates in the colon and side
effects such as flatulence, meteorism, and diarrhea.8 Indeed such side effects have been
noted but appear to be transient and highly dose-dependent.9

Of the cc-glucosidase inhibitors investigated for their anti-diabetic properties, acarb
(Bay g 5421) is by far the most studied and has been approved for clinical use in m a n y
countries for some time.9 It is a potent a-amylase inhibitor. The two deoxynojirimycin
derivatives miglitol 7 (Bay m 1099) and emiglitate 8 (Bay o 1248), and the valiolamine
derivative voglibose 9 ( A O - 1 2 8 ) 1 0 have all undergone clinical development (figure 1.5).
D N J 2 and valiolamine 10 (figure 1.6) themselves were found to exhibit only transient in
vivo effects due to their rapid rates of uptake.

6

OH OH

OH OH
OEt

emiglitate

8

CH2OH
*OH
HO^

h\
OH

CH3

voglibose

CH2OH
OH 'Q~^X-0
HO

HO'

9

CH2OH

OH0--T-\^0
acarbose

HO-^f-WOH
OH

6

Figure 1.5: Structures of four key a-glucosidase inhibitors posessing antihyperglycemic
properties.
OH OH

NH2
Figure 1.6: Valiolamine 10

Acarbose 6, miglitol 7 and emiglitate 8 have all been found to cause liver lysosomal
glycogen accumulation upon treatment.11-12 Consequences of long-term treatment may
involve symptoms similar to those found in the human glycogen storage disease, type II
glycogenosis or Pompe's disease. Researchers at the Merrel Dow Institute focussed
their attention on longer-acting and more selective sucrase inhibitors which had little

no effect on lysosomal a-glucosidases but were potent in their action against intestinal
a-glucosidases. Castanospermine 1 was first revealed to possess long-acting intestinal
effects13'

14

although it still inhibited the lysosomal a-glucosidases. Several glucose-

7

castanospermine derivatives, such as 11 and 12,15 and an N-glucosyl-DNJ derivative 13
(MDL 73945)16 (figure 1.7) were developed which had the desired selectivity.

7-oc-glucosylcastanospermine

8-cc-glucosylcastanospermine

11

12

M D L 73945

13

Figure 1.7: Structures of several selective intestinal a-glucosidase inhibitors.

Observation of traditional Chinese medicine and natural product isolation has led to
Japanese workers identifying fagomine 14 (figure 1.8) as the active anti-hyperglycemic

agent in Mulberry leaves, and has led to further testing of a second natural source of
compound, Xanthocercis zambesiaca, from southern Africa.17 Natural products and
traditional medicines may yet reveal more anti-hyperglycemic agents as starting points
in this relatively new class of anti-diabetic drugs.
HO OH
= H I

H O v A = ^1
Figure 1.8: Fagomine 14

1.2.3 Glycoprotein Processing of JV-Linked Oligosaccharides

Many iminosugars, including castanospermine, have been found to inhibit enzymes in
the glycoprotein processing pathway.

8

Glycoproteins form a large and complex group of proteins, the carbohydrate
components of which play a crucial role in a diverse array of biological activities
including cell-cell interactions, molecular recognition, enzymatic reactions and protein
folding. T h e formation of JV-linked glycan structures, whether complex, hybrid or highmannose type (figure 1.9), begins with a c o m m o n pathway (scheme l.l).18"20

This

pathway is initiated by the transfer 'en bloc' of Glc3Manc)(GlcNAc)2 from dolicol to
target asparagine residues on the nascent polypeptide. Glucosidase I then specifically
cleaves the outer a-1,2- linked glucose residue.21-24 This enzyme is loosely bound to
the membrane in the lumen of the endoplasmic reticulum (ER) and is inhibited by
castanospermine 1 and deoxynojirimycin 2.

Man
Man
Man

Man Man
Man Man
.Man
Man
GlcNAc
GlcNAc
— Asn—

high-mannose glycan

SA
Gal
GlcNAc
•

SA
Gal
GlcNAc
i

Man

Man

Man
GlcNAc
GlcNAc
— Asn—
complex glycan

SA
Gal
GlcNAcMan ^Man
Man
.Man
Man
GlcNAc
GlcNAc
— Asn—
hybrid glycan

Figure 1.9: Representative structures of high-mannose, complex and hybrid glycans.

(Man=mannose, Glc=glucose, Gal=Galactose, SA=sialic acid, Asn=asparagine, GlcNAc=
acetylglucosamine)

Glucosidase II, also in the lumen of the E R , sequentially cleaves the remaining a-1,3linked glucose residues to give GlcMan9(GlcNAc)2-protein then Manc)(GlcNAc)2protein.21> 25> 26 Bromoconduritol 15 (figure 1.10) selectively inhibits glucosidase II
leading to mono-glucosylated products of the type GlcMan6-9(GlcNAc)2-protein.27
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HO

Figure 1.10: Bromoconduritol 15: a selective glucosidase II inhibitor.
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Scheme 1.1: Gycoprotein processing of asparagine linked oligosaccharides.

(Man=mannose, Glc=glucose, Asn=asparagine, GlcNAc=A^-acetylglucosamine, Dol=do
P=phosphate)

Calnexin, a membrane-bound protein chaperone, and calreticulin, its soluble homologue,
recognize the terminal carbohydrate chain of GlcMan9(GlcNAc)2-protein and promote
protein folding.28

The mechanism by which this occurs has been found to be a

combination of aggregation inhibition, prevention of premature

oxidation and

suppression of degradation of incompletely folded glycoproteins.29 Thus this terminal
GlcMan recognition sequence is necessary for the tertiary structure of m a n y proteins.
In a quality control role, UDP-Glc:glycoprotein glucosyltransferase is able to recognize
improperly folded proteins and return the outer glucose residue to the later
9(GlcNAc)2-protein

Man8.

species. The former deglucosylated glycan is also the common

intermediate precursor for the high-mannose glycans.

An alternative processing pathway has been identified recently. This involves an
endomannosidase which is able to instigate the internal cleavage of outer Glci.3-Man
saccharide after binding by calreticulin, a molecular chaperone, obviating the need for
glucosidase II.30 Utilization of this alternative pathway for processing of viral envelope
glycoproteins has been found to be highly dependent on the host cell line.31

oc-l,2-Mannosidases in the ER and Golgi apparatus (designated ER and Golgi
mannosidase I), cleave the outer four mannose residues. These enzymes are inhibited by
1-deoxymannojirimycin 16 3 2 and kifunensine 1733(figure 1.11).

HO
OH
= H

HO
OH
= H
HO.

HO.
HO'
1-deoxymannojirimycin 1 6

kifunensine 1 7

Figure 1.11: Mannosidase I inhibitors.

A n e w glucose residue is then transferred to the depleting mannose chain leaving two
terminal mannose residues which are sequentially cleaved by mannosidase II, acting as

3 0009 03278969 0 11

both an a-1,3- and a-l,6-mannosidase. Swainsonine 18,34> 35 an alkaloid isolated from
the legume Swainsona

canescens,36 and mannostatin A

19,37>

38

from the soil

microorganism Streptoverticillium verticillus,39 are inhibitors of this enzyme (figure
1.12).

HO„..(/Ny.,OH

yj..f

.OH
CH3S
swainsonine 18

NH2

mannostatin A 19

Figure 1.12: Mannosidase II inhibitors.

Transferases are then utilized to build up the distinct carbohydrate chain for each
specific glycoprotein.

1.2.4 a-Glucosidase I and II

To date, there are several inhibitors selective for glucosidase I but only one that is
only slightly selective for glucosidase II. In order to fully study the effects of these
enzymes it is necessary to find highly specific inhibitors for each. Furthermore, it is
necessary

for

therapeutic

uses,

specifically

anti-HTV,

anti-cancer

and

immunosuppression, to find inhibitors which do not interfere with other a-glucosidases
in the body.

Obviously, a crystal structure of the active sites of glucosidase I and II would great
facilitate the design of n e w effective inhibitors. Unfortunately such information is, as
yet, unavailable40 and w e must base our design on analysis of current inhibitors. W h a t
is k n o w n about the enzymes is, however, presented here.
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Glucosidase I has been purified, using deoxynojirimycin-based affinity chromatography,
from the microsomalfractionsof calf liver,41 m u n g bean seedlings,42 bovine 43 and rat44
m a m m a r y tissue. Generally it has been found to be a tetramer with a total mass of 320350kDa, and a subunit mass of 83-85kDa. High specificity for the substrate has been
demonstrated together with a lack of requirement for metal-ions. p H optima range from
6.2 in the calf liver sourced enzyme 4 5 to 6.6-7.0 for the bovine m a m m a r y sourced
version. The presence of a high mannose chain has been shown by strong binding of the
enzyme to concanavalin A-Sepharose.

Cloning and expression studies of glucosidase I from human hippocampus indicated the
enzyme w a s a type II transmembrane glycoprotein with a single hydrophobic transmembrane domain (amino acids 38-58) and a short (ca. 37 amino acids) cytosolic tail.
This 9 5 k D a form showed a single N-glycosylation site of the type Asn-Xaa-Thr/Ser at
Asn 655, which carried a high-mannose oligosaccharide.46

Further studies by Vijay et al. revealed glucosidase I to be a transmembrane endoplas
reticular glycoprotein with a luminal catalytic domain, of which a water-soluble 39kDa
catalytically active domain could be released with trypsin. Residues at or near the active
site have been elucidated and include cysteine, arginine and tryptophan.47

Purification and structural elucidation, by NMR studies and modeling, of the substrat
for glucosidases I and II has revealed the glucosyl cap to have a single, well-defined
conformation.48

Early studies demonstrated the synonymity of glucosidase II with neutral cc-glucosid
AB.49

Glucosidase II has been found to have a molecular weight of 290kDa with a

subunit mass ranging from 67kDa, from the rat-sourced enzyme, to lOOkDa from pig.49
It w a s also shown to run as a doublet of activity on native gel electrophoresis. Vijay et
al. later determined the enzyme, isolated from bovine m a m m a r y gland, to consist of two
13

glycosylated subunits of 62 and 64kDa each, and to have a p H optimum of 6.6-7.0.50

Calvo et al. determined the presence of both a high (site 2) and low-affinity (sit

active site on the enzyme.51 From further kinetic studies it was concluded that the

native substrate is bound with the terminal glucose residue in site 2 and the prec

glucose in site 1, and that each glucose residue is cleaved sequentially (figure 1
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Figure 1.13: Model for Substrate Binding to Glucosidase II.51>52

1.2.5 Polvhydroxylated Alkaloids as Inhibitors of Glycoprotein Processing

Due to the necessity for the cleavage of the outer two glucose residues of the fir

species for correct folding of many proteins, we are primarily interested in inhib

enzymes involved in the early steps of the glycoprotein processing pathway. Thus th
focus here is on inhibitors of glucosidase I and II.

After numerous studies on the activity of glucosidase I inhibitors on the free enzy

(table 1.1), castanospermine 1 remains the most effective with an IC50 of 0.1-0.5u
55

However, studies on cell cultures reveal many acylated derivatives to be more

effective. This is thought to be due to the increased uptake of these compounds

followed by internal enzyme cleavage of the esters to produce free castanospermine
the active compound.55
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Table 1.1: Polyhydroxylated Alkaloid Inhibitors of Glucosidase I and II
INHIBITOR

GLUCOSIDASE I

castanospermine 1
H
H0

GLUCOSIDASE II REFERENCE

lC5o (»AM)

IC50 (MM)

0.1-3

5-75

54, 55

° H 0H

H0C^
6-O-butanoyl- 20

0.8

6-0-isobutanoyl- 21

4

6-0-pentanoyl- 22

9

6-O-hexanoyl- 23

10

6-0-octanoyl- 24

11

6-O-decanoyl- 25

16

6-O-hexadecanoyl- 26

4

6-0-hex-3-enoyl- 27

3

6-0-cyclopropanoyl- 28

10

6-0-benzoyl- 29

6

6-0-(o-methyl)benzoyl- 30

19

6-0-(m-methyl)benzoyl- 31

11

6-0-(p-methyl)benzoyl- 32

65

7-6>-(p-methyl)benzoyl- 33

6

1-O-butyl- 34

NI

6-O-benzylcarbamate- 35

NI

7-O-benzylcarbamate- 36

NI

6-O-phenylpropenoyl- 37

14

6-<9-(o-trifluoromethyl)phenylacetyl 3 8

1

1-epi- 39

1

6-epi- 40

NI

1-deoxy- 41

240

NI

1
15

1-deoxynojirimycin 2

3

20

0.3

130

0.1 (Ki)

15 (Ki)

0.09 (Ki)

15

41, 45, 56-58

HOuOH

HOX.NH

N-methyl- 42

Af-butyl- 43
AVV-dimethyl- 44

0.4

Af-hexyl- 45

0.13 (Ki)

Af-decyl- 46

0.4 (Ki)

N-dodecyl- 47

8

Af-decanoyl- 48

70 (Ki)

NI
54

iV-S-carboxypentyl- 49
Af-methyl-Af-S-carboxypentyl-SO

8

NI

1.4 (Ki)

NI

3-epi- 51

NI

4-epi- 52

NI

5-epi- 53

NI

3-epi-5-deoxy- 54

NI

4-epi-5-deoxy- 55

NI

5-deoxy- 56

NI

7-0-(p-D-glucopyranosyl)-D-

3-4

1

3.9

3-4

glycero (6-GlcDNJ or M D L 25637) 57
homonojirimycin 58

59

HO ., OH

HO-LNH
CH 2 OH

JV-methyl- 59

1.0

16

1-deoxymannojirimycin 16

190 (Ki)

45

HO u OH

17 (Ki)
HO*LNH

100 (Ki)
AT-methyl- 60
A^-5-carboxypentyl- 61
1,4-dideoxy-1,4-imino-D-arabinitol 62
HO

20

60

OH

V-NH
56

AT-methyl- 63

310

AA-butyl- 64

200

3-epi- 65

470

2,5-dideoxy-2,5-imino-D-mannitol(2,5-

NI

56

dideoxymethyl-3,4dihydroxypyrrolidine, or D M D P ) 3
HO

OH

V-NH
HO-"

N-methyl- 66

NI

tf-butyl- 67

NI

68

0.4

55

HO u OH
HOrXv^J
H Vj

HO u OH
55
N

H0\ >

HyJ
RO

R = H 69
R = B z 70

30
20

australine 5
H

J

0.2

NI

61

9 H OH
CH2OH

17

AMmtyl-deoxygalactonojirimycin 71

NI

NI

62

2-epi-swaisonine (Glc-swainsonine) 72

NI

NI

63

Less work has been carried out on effective inhibitors of glucosidase II, and there is a
particular need for selective and potent inhibitors of this enzyme. O f the glucosidase I
inhibitors, only M D L 25637 57 was found to inhibit glucosidase II more effectively
(table 1.1), albeit with only moderate selectivity.

Studies of glycoprotein processing inhibition by castanospermine in cell culture has
involved a variety of cell-types including plant cells,64 h u m a n hepatoma cells,65 and
mouse melanoma BioTio cells,55 together with a range of virally infected mammalian cell
lines (see Section 1.2.6). Decreased secretion of s o m e glycoproteins w a s demonstrated
in the h u m a n hepatoma cell line.65 These studies have allowed castanospermine 1 to act
as a reliable benchmark for comparing activities of other inhibitors, such as 1deoxynojirimycin 2 derivatives66 and 2,5-dihydroxymethyl-3,4-dihydroxypyrroline 3.67

Several inhibitors have been found to be highly selective for either mannosidase I or II.
Swainsonine 18, the first inhibitor of glycoprotein processing34 to be isolated36- 68> 69 is
a selective mannosidase II inhibitor35 with an IC50 of 5 u M . 6 3 2-isp/-swainsonine was
also found to exhibit the same selectivity but with reduced activity (IC50 of 2 9 0 u M
against mannosidase II).53 Another effective mannosidase II inhibitor, with an IC50 of
0.09jiM, mannostatin A 19 w a s isolated from the microorganism Streptoverticillium
verticillus?1 1-Deoxymannojirimycin 16 w a s the first mannosidase I inhibitor to be
reported.32

Another valuable set of inhibitors includes those that affect the alternative processing
endomannosidase. A systematic study to find inhibitors by preparing analogues of the
disaccharide product of e n z y m e cleavage led to three inhibitors with ICso's in the
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micromolar range.

These were l,5-anhydro-2-deoxy-3-(9-(a-D-glucopyranosyl)-D-

arabino-hexitol 73 (Glcalh3ddMan), l,5-anhydro-2-deoxy-3-0-(a-D-glucopyranosyl)D-arabino-hex-1-enitol 74 (Glccdh3Glucal), l,5-dideoxy-3-0-(a-D-glucopyranosyl)-l,5imino-D-mannitol hydrochloride 75 (Glccdh3DNJ) with ICso's of 3.8, 2.3 and 1.7uM
respectively.70

1.2.6 Glucosidase I Inhibitors in the Treatment of HIV and other viruses

To date, humans have been relatively unsuccessful in treating viral infections.
Prevention by means such as immunization and safe practices has been the most
effective means of dealing with such diseases. However, with the prevalence and spread
of the deadly h u m a n immunodeficiency virus (HIV), a concerted world-wide effort has
gone into the discovery of n e w anti-viral agents, and in particular anti-HIV agents.

The life-cycle of retroviruses, such as HIV (figure 1.14),71 allowed for the developm
of anti-viral drugs with a wide variety of actions.

De Clercq postulated that most anti-HIV drugs could be placed into one of ten classes
according to the stage at which they interfere with this cycle. B y 1995 however, of the
four drugs licenced for clinical use in the U.S.A. ( A Z T 76, d d C 77, d4T 78 and ddl
79)(figure 1.15), all were from only one class, namely the reverse transcriptase
inhibitors.72

Presumably this is due to reverse transcriptase being specific to

retroviruses and thus drugs targeting this enzyme are less likely to disrupt normal
mammalian processes. Unfortunately, this is not entirely true as these drugs do incur
side-effects.
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Figure 1.14: Life-cycle of a retrovirus.

A n ideal drug would specifically target the H I V virus, have minimal effects on normal
cellular and body processes, and have good bio- and oral-availability. In addition to
these requirements, there is a need for drugs which display novel modes of action due
the continuing and problematic emergence of viral resistance.72'

73

Furthermore, such

drugs would allow for the development of synergistic drug regimes.
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NH;
N

Zidovudine, A Z T 7 6
(3'-azido-2',3'-dideoxythymidine)

Zalcitabine, d d C 7 7
(2',3'-dideoxycytidine)

0

H
HO

XV

^
Stavudine, d 4 T 7 8
(2',3'-didehydro-2',3,-dideoxythymidine)

Didanosine, ddl 7 9
(2',3'-dideoxyinosine)

Figure 1.15: Drugs licenced for clinical anti-HIV therapy in 1995.

Although castanospermine 1 w a s found to have n o effect on infectivity of the influenza
virus,74 several groups tested the compound for anti-HIV activity. This was based on

the observation that the highly glycosylated surface glycoprotein gpl20 is required to
bind to the CD4 receptor of the host cell, and that this process is necessary for
infectivity. Indeed, syncytium formation and infectivity were decreased by the
presence of castanospermine I.75-78 It was also found that for the related glucosidase

inhibitor, 1-deoxynojirimycin 2, binding to the CD4 receptor still occurred but that t
ensuing syncytium formation was retarded.79 This new mode of action was used to
determine the importance of protein TV-glycosylation for HIV infectivity80"82 and was
used in synergistic studies.83 As could be predicted, castanospermine 1 exhibited a
strong synergistic effect at low concentrations, in combination with AZT 76.84

Synergistic studies are likely to continue with the inference of lower doses of each d

and hence reduced toxicity. Further to this is evidence that such therapies retard the
development of drug-resistant strains.73
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Through N O E N M R experiments, it has been found that W-alkylation of D N J 2 has the

effect of forcing the C-6 hydroxy into an axial position (figure 1.16). This conformati
is suggested to be responsible for the increased a-glucosidase inhibitory and anti-HIV

activity of these derivatives, together with explaining why castanospermine 1, with its
equivalent C-l hydroxy group (figure 1.16) maintaining an axial conformation, is
superior to DNJ 2 in this regard.60 N-Butyl- 1-deoxynojirimycin 43 was shown to
eliminate the HIV virus from cell culture by the same mechanism85 and clinical trials
were initiated.86 Further studies into 1-deoxynojirimycin analogues were carried out.87

H 0

HO

1

43

Figure 1.16: Structures of Castanospermine 1 and TV-butyl-DNJ 43 showing the axial
positions of their CI and C-6 hydroxyls respectively.

Later studies revealed that N-butyl-DNJ 43 only affects the oligosaccharide composition
of the gpl20 protein, and not other aspects of the processing of this envelope
glycoprotein.88

Workers at the Merrell Dow Institute focussed their efforts on castanospermine
derivatives and found 6-0-butyrylcastanospermine 20 (table 1.1) to be the most
effective anti-HIV agent in v/vo.89'93 This compound subsequently underwent clinical

trials and reached phase II before gastro-intestinal side-effects forced its discontin

These effects were identical to those found for TV-butyl- 1-deoxynojirimycin 43 and were

due to inhibition of intestinal maltases and sucrases.74 A specific glucosidase I inhib
that does not affect these intestinal enzymes, or an equivalent pro-drug, is thus the
target for future development in this area. A^-Butyl-1-deoxynojirimycin 6-phosphate 80
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has been identified as a possible pro-drug.72 It has also been postulated that most
compounds can be turned into an anti-HIV agent provided they have hydroxy groups
available for sulphate attachment. Such groups exert their activity by disrupting gpl20C D 4 binding.94

Finally, the application of glucosidase I inhibitors to other viruses, where highly
glycosylated envelope proteins have been implicated in infectivity, has been undertaken.
These include targeting of gpl30 of the feline immunodeficiency virus,95 gp70 of the
immunodeficiency disease-inducing feline leukemia virus,96 g B envelope proteins of the
herpes simplex virus type-2, 97 the fusion protein of the measles virus,98 the promembrane

and

envelope proteins

of the dengue virus,99

glycoprotein

B

of

cytomegalovirus, a m e m b e r of the herpes virus group,100- 101 and the hemaglutinins of
the influenza virus.102 In these studies, activity w a s often related to the inefficient
folding of the glycoproteins.

1.2.7 Glycoprotein Processing Inhibitors in the Treatment of Cancer

Inhibitors of the glycoprotein processing pathway such as castanospermine 1, 1deoxynojirimycin 2 and swainsonine 18, have been shown to exhibit anti-cancer activity
by at least three distinct mechanisms.

Swainsonine has been shown to act as an immunomodulator by decreasing the amount of
sialic acid on the surface glycoproteins of malignant and foreign cells and thus making
them more susceptible to lysis by natural killer cells.103'104 D u e to this novel m o d e of
action, swainsonine 18 has been involved in two phase I clinical trials. Swainsonine 18
has also been shown to stimulate the proliferation of bone marrow cells, the mechanism
of which is, as yet, unknown. 1 0 5
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Metastasis and tumor growth are both important for the pathogenicity of cancer. Both
swainsonine 18 and castanospermine 1 were shown to inhibit metastasis.106 It was
determined that this m a y be due to inhibiting the transformation of the surface
glycoprotein gpl20 into a more highly sialylated and p-l-6-linked branched glycan.107
Castanospermine 1 has also been shown to inhibit angiogenesis, thus depressing tumor
growth. 108

Castanospermine 1 has been shown to retard growth of certain tumor lines that have
arisen by activation of protooncogenes which encode for glycoproteins such as growth
factor receptors.109 Presumably this occurs through altering the glycan structure of
such receptors.

These glycoprotein processing inhibitors have thus shown novel modes of anti-cancer
action and m u c h interest remains in their use in this field.

1.2.8 Glycoprotein Processing Inhibitors in Prolonging Allograft Survival

Dr. Grochowicz and his group at the Transplantation Research Unit at the Royal
Newcastle Hospital have undertaken a series of studies on the use of castanospermine 1
in prolonging allograft survival in rats. After initial positive findings with kidney
allografts,110 focus w a s then directed towards pancreas allografts which are noted as
being more difficult to maintain viability than heart allografts.111 It w a s found that at
the low dose of 50mg/kg per day, subcutaneously administered over thefirst7 days
after transplantation, rejection w a s postponed to day 21 compared to day 11 for the
control group. 112

Studies with heart transplants found castanospermine 1 prolonged

allograft survival in a dose-dependent manner. 113 Investigation into the mechanism of
action revealed down-regulation of the surface glycoproteins C D 5 4 on graft endothelium
and alloreactive cells, and C D l l a on leucocytes.114 Both of these proteins have been
found to exert a unique and vital role in the rejection process.
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A later study also

revealed down-regulation of the ligand-receptor adhesion molecule pair, LFA-1 aICAM-1.

It was concluded that castanospermine 1 m a y be useful as a transplant

immunosuppressant, probably in combination with interleukin 2 secretion inhibitors.115

1.3 SYNTHESIS OF CASTANOSPERMINE AND RING-MODIFIED
ANALOGUES

Since the isolation and structural elucidation of castanospermine 1, it has been th
subject of numerous total synthesis attempts, expedited by the discovery of its antiH I V activity. M a n y reviews7'116-118 have been written on the subject and only a brief
summary (table 1.2) together with an overview of the most recent synthesis119 not
present in these reviews (scheme 1.3) will be presented here. The triple reductive
amination approach by Mootoo (scheme 1.2),120 although reported in the more recent
reviews, will also be presented here as it demonstrates a particularly elegant approach to
the formation of the ring system.
Table 1.2: Total syntheses of castanospermine 1.
STARTING MATERIAL

K E Y STEPS

YIELD

NO.

REFERENCE

STEPS
HO..OH

HO^X^I
HO^v°
OMe

methyl a-D-glucopyranoside
81

"^o

oV
OH

H

S>H#

OH

o o
MeO'VS
'BOC 84

reductive ringopening/ reductive
amination, Sakurai
allylation

10.5%

15

Ganem, 19845.
121-123

double cyclisation

0.4%
16
#
(0.35%) (17)#

Hashimoto,
1985 1 2 4

reductive amination

12.3%
10
(9.8%)@ (11)@

Anzeveno,
1990125

82

83
9.5%
stereoselective
biocatalytic oxidation,
acyloin condensation

8

Sih, 1990126

25

BnO u OH

BnO^Y°
0

6

tandem oxidation5.6%
reduction of a ketene (2.4%)&
dithioacetal

(9)&

use of 9phenylfluoren-9-yl Nprotecting group

11.8%

18

Rappoport,
1991128, 129

Wagner-Meerwein
rearrangement

15.0%

Vogel, 1991130

(3.5%)"

14
(17)"

Sharpless asymmetric
epoxidation

2.2%

22

Kibayashi,
1991131-133

Reformatsky reaction

30.2%
(22%)@

7
(9)@

Sttttz, 1993134

Chamberlin,
1990127

85

HOuOH

HO^ST 0
o

86

0
POBn

OBn

* 87

H

-v°7^ OH
A)-k.OH
H
88
Jr-O H
H 6TBDMS89
TIPSO

9
Sharpless asymmetric 4.0%
epoxidation and
dihydroxylation,
double cyclisation
13
5.3%
ring-closing
metathesis
(2.8%)*! (15)*

o 90

HO

BnO u OBn

BnO^0

o

139

91
triple reductive
amination

BnO^V0

OMe
0

Pandit, 1996138>

36, 137

BnO H
BnO^^CHO

93

Cha, 1993135

°

40

92
OR*

94

9
Mootoo, 1996120
22%
(20%)*» (13)*

95

asymmetric tandem
[4+2]/[3+2]
cycloaddition, use of
a chiral auxiliary

18%

8

Denmark, 1999119

* from 2,3:5,6-di-0-wopropylidene-D-mannose 96 1 4 1
® from D-glucurono-6,3-lactone l 4 2 "! 4 4
* from methyl a-D-glucopyranose 81
&
from 2,3,4-tri-O-benzyl-D-glucopyranose 145 ' 146
* from furan and 1-cyanovinyl (lj?>camphanate 97147-150

The first total synthesis of castanospermine b y G a n e m in 1984 elucidated its absolute
configuration.5 This was a long, 15 step synthesis starting with methyl a-Dglucopyranoside 81 where the correct stereochemistry was already established. Ganem

later refined this synthesis.121"123 Six of the subsequent 12 syntheses also utilized t

D-glucose stereochemistry. Interestingly, although no improvement on the initial route,
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Hashimoto presented a total synthesis of castanospermine from D-mannose.124 A total

of five syntheses are now available using non-sugar starting materials and wh
heavily on Sharpless asymmetric epoxidation and dihydroxylation methodology,
together with stereoselective cycloaddition reactions.

4 steps
methyl cc-Dglucopyranose

1. Whitesides
allylation
(75%)

BnO

BnO

BnCL>^.CHO
2. benzylation

Bn00"S^°

81

OBn

OMe

92

OMe

1. iodinium
dicollidine
perchlorate
2. reductive
elimination''

BnO
BnO

0

CHO

Bn0

bHO
100
NH4HCO3
NaCNBH3
1f

OBn

-^1. S w e m oxidation
2. ozonolysis
3. acetal hydrolysis
(90%)

. OMe
MeO
99

(53%)

BnO

Bn0

(74%)

OBn

BnO^A^J*.
J

98

OBn

v/V^(

Pd/C

BnO* \ ^
101
Scheme 1.2: Synthesis of castanospermine 1 using a triple reductive amination key
step.120

The total synthesis by Mootoo (scheme 1.2)120 represents a highly efficient app

in which the key step combines the reduction of two aldehydes and a ketone wi

amination and double ring closure (100 to 101). The sequence of events propos
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begins with the reductive amination of the left aldehydic group of 100 followed by
formation of the six-membered ring, reduction of the intermediate iminium ion, and
formation of the five-membered ring.

feu
LnBuLi

6

*Bu

CI
KO

\

2. tBu2Si(Cl)OTf
•
(73%)

r

93

/%^N02
94

102

W
Sharpless
asymmetric
dihydroxylation

^ o

tandem [4+2]/[3+2]
cycloaddition

feu^ /Bu

HO^S \ T J.
I

O

OH

°

105
(63%)

(86%)

V r ''n
°

Ph

1. TsCl, pyr.
2. H 2 , Ra-Ni
3. desilylation

104

Ph

(40% for 2 steps)

Scheme 1.3: Synthesis of castanospermine 1 using an asymmetric tandem [4+2]/[3+2]
cycloaddition key step.119

Denmark and coworkers have recently reported a total synthesis of castanospermine 1

(scheme 1.3) from non-carbohydrate starting materials.119 The synthesis began with the

stereoselective cycloelimination of 2,5-dihydrofuran 93 followed by silylation of th
resultant alkoxide to give a stable chlorosilane 102. Displacement of this chlorine

nitroethenoxide 94 led to an unstable nitroalkene 103 which was used immediately in t
tandem Diels-Alder cycloaddition with the chiral dienophile 95 and 1,3-dipolar
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intramolecular cyloaddition. The cycloadduct 104 was thus prepared in 4 0 % yield over
two steps, and with diastereomeric purity.

Sharpless asymmetric dihydroxylation

followed by N-alkylation and deprotection resulted in an overall yield of 1 8 % of
castanospermine 1 in 8 steps. The chiral auxiliary could be recovered in 9 8 % yield.

Many other syntheses have been devised which produce the unnatural enantiomer of
castanospermine

1, (-)-castanospermine,

castanospermine

epimers

and

deoxy

analogues.7 However, the primary focus of our work was to be ring-expanded and ringmodified analogues using castanospermine 1 as starting material, and thus previous
chemistry directed towards these aspects will be discussed.

Stutz prepared the quinolizidine homologue of castanospermine 106 (figure 1.17),
containing the correct stereochemistry, from the idohexodialdose 89 which was in turn
prepared from a readily available sugar starting material. This homologue 106 was found
to exhibit p-glucosidase inhibitory activity, but not oc-glucosidase inhibition.151
Herczegh has produced quinolizidine analogues of castanospermine epimers, 107, 108
and 109 (figure 1.17), using sugar starting materials to produce the A ring, and a DielsAlder cycloaddition of an intermediate imine to prepare the B ring.152 Pearson has also
prepared quinolizidine analogue epimers, 110, 111, 112 and 113 (figure 1.17).153>154

To date, no ring-expanded analogues have been prepared which increase the number of
hydroxyl groups in the B ring. Such compounds would be of interest in terms of
potential glucosidase inhibitory activity.

Furneaux has produced a series of publications on the chemistry of castanospermine 1
which provide an invaluable starting point for any synthesis beginning with this
alkaloid. Part I in the series deals with synthetic modifications at the C-6 position,155
part II with the synthesis of deoxyfluoro analogues of castanospermine.156 The third
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paper looks at the chemistry of castanospermine-6-phosphate.157 Part IV explores

synthetic modifications at C-8158 and finally part V describes synthetic m
C-l and C-7.159

HO

OH

? H

OH

HO,
HO v

106

107

108

HO
OH
: H

HO

OH

HO^-O
110
HO
OH
= H

111
HO
HO.

z H

OH
T

HO^-O
112 113

Figure 1.17: Quinolizidine analogues of castanospermine and epimer

1.4 OUTLINE OF PROJECT AIMS
The aim of this project essentially was to produce ring-expanded and ring-modified

analogues of castanospermine 1, with a longer term goal of assessing selec
glycosidase inhibitory activity. Castanospermine 1 was available in large

starting material through a research collaboration with Dr. R. Smith of Ph

Sydney. Initially it was envisaged to use a 1,3-dipolar cycloaddition rea

6) to achieve this. However, we did not intend to limit ourselves in our a

further ring-forming reactions, such as ring-closing metathesis (chapter 4

radical cyclisation (chapter 5), were also investigated. In addition to th
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hoped to provide a synthesis of casuarine 114 (figure 1.18) from castanospermine 1,
beginning with elimination across C1-C2. Unfortunately all attempts with this first
reaction proved unsuccessful and are presented in the following chapter.

1.5 OUTLINE OF THESIS

Chapter two outlines the retrosynthetic plan for the synthesis of casuarine 1
1.18) from castanospermine 1 together with a discussion of the work carried out in an
attempt to instigate thefirstsynthetic step.

CH 2 OH
Figure 1.18: Casuarine 114.

Chapter three describes the route taken to acquire the key intermediate 115 u
subsequent studies, together with a discussion of the choice and synthesis of the model
intermediate 116 (figure 1.19).

MeO

OH

MeO.

^NH
MeO ^ ^

k ^NH
\^

115
116
Figure 1.19: Key and model intermediates.

Chapter four presents the results on the investigation of ring closing metath
to prepare ring-expanded homologues of castanospermine, such as 117 (figure 1.20),
which allow for increased hydroxylation in the B ring.
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MeO
MeO* '

OTBDMS

117
Figure 1.20: Ring-expanded homologue of castanospermine.

Chapter five describes the use of a free-radical cyclisation reaction to produce
tropane 118 and benz-fused tropane 119 alkaloids (figure 1.21).

MeO
= H
MeO
MeO4*'

118 ' 119
Figure 1.21: Free-radical cyclisation products.

Chapter six is concerned with the preparation of 1,3-dipoles from the model

intermediate 116, together with their attempted intramolecular 1,3-dipolar cycloa

Chapter seven deals with a ring-expansion reaction of B-ring carbamates, derived
castanospermine 1, using a thioglycolate ester.

Each discussion chapter begins with a series of schematic overviews whose purpose

to summarize the chemistry undertaken in that area. The introductory and explanat
section follows and describes the aims and methods of each particular chapter.
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CHAPTER 2

PROTECTING GROUP STUDIES
2.1 SCHEMATIC OVERVIEWS

LG.

-X-

-•

HO*
LG.
120

CH3C02
02N
C02

121

Scheme 2.1: Attempts at making a leaving group at the 1-position of castanospermine 1
for projected elimination studies (see section 2.2).
MeO
7 H ?"
MeO

O
MeOx%

0
124

MeO
MeO

^r
MeO
125

Scheme 2.2: Attempted Pd catalyzed decarboxylation/7V-allylation.
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1-0-silylation

H

acetylation

?

H

OTBDMS

N-protection
0-methylation

126
\

Af-deprotection
Ac

9

H

M e 0

OTBDMS

AcO

H

OTBDMS

MeO
127

AcO
/<

MeO

129

1-0-desilylation

AcO
AcO
AcO

128

Scheme 2.3: Protecting/deprotecting studies with castanospermine 1.

2.2 PROPOSED SYNTHESIS OF CASUARINE 114 FROM CASTANOSPERMINE 1

O n e of the aims of this project w a s the total synthesis of casuarine 114 from

castanospermine 1. Currently there is only one total synthesis of casuarine 114 repo
in the literature.160-161 Castanospermine 1 would be a unique starting material which
already contains most of the stereochemistry present in casuarine 114. The first two

steps in the proposed synthesis (scheme 2.4) was the enzymatic selective 1-O-acylati
of castanospermine to 120 followed by elimination of acetic acid to give a novel 1,2-
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unsaturated castanospermine analogue. Dihydroxylation of this intermediate would also
lead to novel castanospermine analogues.

OAc

120

RO
HQ

H

R

OH

9 H

R0
"-CD-™^""— D^^/^A
~\JL>
CH2OH
114

RO

XX>

^

CH2OBn
132

•

•

131

Scheme 2.4: Proposed synthesis of casuarine 114 from castanospermine 1.

Margolin et al. has reported the successful 1-O-acylation of castanospermine using
subtilisin Carlsberg (scheme 2.5) and a variety of acylation agents.162

HO

H

OH

AcOCH=CH2
Subtilisin Carlsberg
pyridine

HO

H

QAc

45°C, 84h
shaken

120
(91%)

Scheme 2.5: 1-O-Acylation of castanospermine 1.

Perrone similarly reported the use of this enzyme to selectively 2-0-acylate
swainsonine, but reported only a moderate yield of 22%.163

The next stage in the proposed synthesis was the preparation of a necessarily excelle

leaving group at the 6 postion, together with protection of the remaining two hydroxy
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to give 130. It was hoped that the strongly nucleophilic nitrogen would then attack the

6-carbon with displacement of the leaving group to give a highly strained tricyc

aziridinium intermediate 131. Such a reaction has been observed by Furneaux where

the leaving group was a DAST ester 133 (scheme 2.6).155 Here fluoride was used to

open the aziridine 134 to yield the fluorinated indolizidine 135 and pyrrolizidin

alkaloids. Attack of our aziridinium intermediate 131 by benzyl alcohol at C-5 co

open the aziridine ring to afford the pyrrolizidine 132. Finally hydroxylation an
deprotection would give casuarine 114.

AcO

H

QAc

AcO
Ac

9

H

Ac

OAc

AcO.

AcO

Q

u
n

OAc
•

135 (49%)

F

+

^N^^

Et 2 NF 2 SO

©

133

HO

H

OH

134

-N.
FHaC
136 (19%)
Scheme 2.6: Furneaux' aziridinium reaction.155

2.3

TOWARDS ELIMINATION ACROSS THE C1-C2

BOND

OF

CASTANOSPERMINE 1

Our attempts to repeat the work of Margolin162 resulted in a 4 5 % recovery of
castanospermine starting material 1 together with an 11% yield of a mixture of
monoacylated products (scheme 2.7). The major component of this mixture appeared

be the desired 1-O-acylated derivative due to the downfield shift of the H-l trip

proton to 5.22ppm in the proton NMR. This is even slightly downfield to that repo
by Margolin, but our sample was run in CDC13, whereas Margolin used d6-DMSO. It

was decided that our differing yield was possibly a result of the fact that we us
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different source of subtilisin, namely Bacillus licheniformis, whereas the literature
report followed used B. subtilis.

HO

H

AcOCH=CH 2
Subtilisin Carlsberg
pyridine

OH

HO

QAc

H

~^-

37to45°C,144h
shaken at 160-180rpm

MU

120
(11% of a mixture
of 1-O-acyl: 120 as
the major component)

(45%)

Scheme 2.7: Attempted selective 1-O-acylation of castanospermine 1.

Unfortunately these results were not positive enough to allow for proceeding to the n

step in the synthesis and other avenues towards selectively forming a leaving group at
the 1-position were investigated. Initial work was based on the discovery by Furneaux

that using bis(tributyltin)oxide as base, castanospermine could be selectively silyla
with TBDMSC1 at the 1-hydroxyl (scheme 2.8).159 This was in direct contrast to
acylation which occurred selectively at the 6-hydroxyl under the same conditions.155
H?

H

OH

(Bu3Sn)20
Bu^NBr
TBDMSC1
toluene
A
(77%)

HO

H

OTBDMS

126

Scheme 2.8: 1-O-Silylation of castanospermine 1.

A repeat of Furneaux' 1-O-silylation was undertaken to ensure the reproducibility of this
reaction. Thus addition of TBDMSC1 to a refluxing solution of castanospermine and

bis(tributyltin)oxide in toluene, further refluxing and work-up gave a 44% yield of t
desired product 126 following purification by silica gel column chromatography.
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It was thought that perhaps the difference in selectivity of the T B D M S group compared
to the benzoyl group may have been a function of the steric bulk of the T B D M S group.
As such, the introduction of bulky potential leaving groups was trialled in the Furneaux
reaction with bis(tributyltin)oxide as base and the corresponding acyl halides.
However, attempts to prepare either 121 or 122 (figure 2.1) were not successful, leaving
residues from which only tetrabutylammonium salts and the acids, 3,5-dinitrobenzoic
and 2,4-dinitrosulphonic respectively, could be isolated. Attention was then turned to
the use of 7Y-(phenylseleno)phthalimide to replace the hydroxy group with a
phenylselenenyl group 164 (sheme 2.9) which could be oxidised with subsequent
selenoxide elimination to give an alkene.165 Selenylation was tried on castanospermine
1 using the above reagent with tributyl phosphine in dry tetrahydrofuran. Again, none
of the desired alkaloid product 123 (figure 2.1) could be isolated.
0

O

N02
HO

N02

H

SePh

H0 *

121

+

Bu3P
PhSePBu3 J

+

RCH2OH

-• RCH2OPBU3 PhSe

+

HN

PhSePBu3

RCH 2 OPBu 3 +

PhSe

->- RCH2SePh

+

Bu 3 P=0

Scheme 2.9: Rationalization for selenation of a primary alcohol.166
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It was then thought that perhaps the 1-0-TBDMS-castanospermine 126 could be used
directly to afford a leaving group in the 1-position. T B D M S protected alcohols have
been converted directly into acetates by the use of ferric chloride and acetic
anhydride.167,168 However, this reagent system was unsuccessful in this instance.
Indirect use of the 1 -O-TBDMS-castanospermine 126 was then explored. This
compound has a unique protection problem as methyl or benzyl protection of the
remaining hydroxyl groups would concurrently lead to alkylation of the tertiary amine.
There are several possible solutions to this problem, namely the use of non-alkyl
protecting groups, alkylation followed by selective de-N-alkylation, and lastly Nprotection/O-alkylation/iV-deprotection. At this point the only groups proven to protect
all three of the remaining hydroxyls were acetate, methyl, and methoxymethyl. As the
use of M O M reagents, such as bromomethyl methyl ether used extensively by
Furneaux, is precluded at our university by their classification as class I carcinogens,
only two protecting groups remained.
Tri-O-acetyl protection of 126 was carried out successfully by Furneaux,159 and
repeated here to give 127 in 6 5 % yield after purification by recrystallisation (scheme
2.10). It was then hoped that the T B D M S group could be selectively cleaved to give a
free hydroxyl at the 1-position 128 (figure 2.2) which could in turn be converted into a
suitable leaving group, or selenyl group.
HO
:

HO

'

*• '

HO>

AC

OTBDMS
H

.
-

"^127

9

H

Ac20,DMAP

OTBDMS
'

pyridine

65

*

AC

°'"

127

Scheme 2.10: Triacetylation of 1-O-TBDMS-castanospermine 126.
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AcO
AcO
A c O * " ^ , W 128
Figure 2.2.

De-silylation attempts included the use of zinc tetrafluoroborate,169 a recent mild
reagent which unfortunately proved too mild for our purposes giving an 8 4 % mass
recovery of starting material 127. Stronger agents were deemed necessary and due to
the base lability of the acetate groups, acidic conditions were then explored. The use of
8 0 % acetic acid 170 resulted in a 6 2 % mass recovery of starting material 127, and
hydrofluoric acid in acetonitrile171 gave a similar result. Lastly the most reliable
desilylating agent, tetrabutylammonium fluoride, was tried. T B A F however proved too
efficient with cleavage of the acetate groups together with the T B D M S group observed
in the proton N M R . This avenue was finally abandoned.

Few protecting groups exist for tertiary amines during alkylation reactions. Of thes
borane complexes have been used mostly as activating groups towards a-lithiation and
alkylation,172-174 but also as protecting groups. 175 TV-oxides are by far the most
c o m m o n protecting group for tertiary amines as well as having a multitude of other
uses.176 In a similar vein to our proposal, both Rapoport 177 and Koniuszy 178 have
successfully protected tertiary amines as A^-oxides for the methylation of hydroxyl
groups, followed by reduction of the JV-oxide. It was decided to try this sequence
beginning with oxidation using hydrogen peroxide in refluxing acetone (scheme 2.11).

40

H

9

H

OTBDMS

H

H202/acetone
(97%)

9

H

OTBDMS

HO.
HO*
O

126

137

Mel/Ag 2 0
acetonitrile
A
Me

9

H

OTBDMS NaHP02/Na2C03
C

tIT}

V

Me

9

H

OTBDMS

MeO.

tetrahydrofuran
MeO

129
138
Scheme 2.11: #-protection/(9-alkylatioii/JV-deprotection approach.

N-Oxidation proceeded smoothly to give 1-O-TBDMS-castanospermine N-oxide 137 in
97%o yield (scheme 2.11). It was found that the addition of a small piece of platinum, to
destroy the peroxide at the end of the reaction and before work-up, was necessary to
prevent de-silylation. Methylation of the iV-oxide product using the proven
MeI/Ag20/MeCN reagent system (see chapter 3) provided a complex inseparable
mixture. However, mass spectral analysis (CI) revealed that although castanospermine
1 is the major product (m/z 190 and 172), some of the desired trimethylated product 138
(m/z 362 and 330) was present. Such promising indications of methylation from the
mass and the proton N M R spectra supported continued perseverance with this approach,
but unfortunately time did not allow for it in this instance. Although Rapoport used
sulphur dioxide in order to reduce the JV-oxide in situ following methylation, this
reagent is highly toxic and noxious and as such it is suggested that sodium
hypophosphite may be a safer alternative.179 Koniuszy used zinc dust and hydrochloric
acid for this transformation.
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Thefinalapproach investigated towards the desired elimination across the C1-C2 bond
of castanospermine utilised the protected alkene carbamate 124, which was an
intermediate (see chapter 3) in our synthesis of other ring modified analogues of
castanospermine. W e envisaged that reaction with a suitable palladium complex would
lead to an allyl-palladium intermediate 139 with concurrent loss of carbon dioxide and
that this would be followed by intramolecular attack by the amide anion to give 125
(scheme 2.10).

MeO

MeO

H .-'
Pd(0)L„

M e 0

MeO

-CO2

MeO

MeO

124

139
Scheme 2.10: Palladium-assisted route to 125.

Tsuji and coworkers carried out m u c h work in the late 1980's on the use of allyl
carbonates to afford allyl-palladium complexes.180"182 These studies then rely on the
basicity of the alkoxide intermediate to generate a carbonucleophile in situ. This
carbonucleophile then attacks the allyl-palladium complex. Carbamates can also be
used in these reaction types, and are in fact considered superior to the carbonates.183
Although the use of cyclic carbamates was not reported in this work, it was predicted
that these would readily undergo decarboxylation and that the intermediate cyclic
complex 139 would favour N-allylation more than previous acyclic complexes. Even
here Tsuji reported that N-allylation was competitive with C-allylation and this
provided a significant problem w h e n using allyl morpholine carbamate 140 to allylate
141. It w a s reported that N-allylmorpholine 142 was in fact the major product, and not
the desired adduct 143 (scheme 2.11).183
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O

C02Me

o
O

0
141

140

N-

Pd2(dba)3»CHCl3
PPh 3
»
tetrahydrofuran
20-25°C, lh

142 (60%)

C02Me

143 (40%)

Scheme 2.11: N-Allylation vs. C-allylation.183

Several attempts were m a d e to prepare 125 in this manner using a range of conditions
(table 2.1). Both tetrakis(triphenyl)palladium (0) and tris(dibenzylideneacetone)-

dipalladium (0) palladium catalysts were trialled together with the phosphine ligand
triphenylphosphine and l,2-bis(diphenylphosphino)ethane (dppe or DIPHOS). Both
room temperature and reflux conditions were investigated. All attempts resulted in

recovery of starting material only, with none of the desired product able to be isol
on work-up. Also, proton NMR spectral monitoring indicated no product formation in
the crude reaction mixtures.

Iable 2.1: Range of condilions used for attempted transformation of 124 to 125.*
TRIAL

124:PD:P

P D CATALYST

P LlGAND

TEMPERATURE

TIME

1

1:0.05:0.1

Pd(PPh3)4

PPh3

r.t.

llh

2

1:0.1:0.2

Pd2(dba)3

PPh3

r.t.

19h

3

1:0.05:0.2

Pd2(dba)3

dppe

reflux

24h

|

* tetrahydrofuran was the solvent in each case

This palladium catalysed route w a s the last avenue to be investigated, and discarded.
However, there remains the proven l,6-acylation/6-deacylation approach159 which was

initially not investigated as it was not a novel route to a desired 1-acylcastanospe
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Although, in light of the fact that none of the other methods tried proved successful, this
final approach is deemed to be the most profitable for any future work in this area.

CHAPTER 3

PREPARATION OF THE K E Y AND MODEL
INTERMEDIATES
3.1 SCHEMATIC OVERVIEWS

'N
i

'Boc

'Boc

145

(i) lithiation
(ii) electrophilic attack
piperidine

Scheme 3.1: Attempted preparation of piperidine model compounds.

NH
1,2,3,4-tetrahydoisoquinoline
oxidation

N
3,4-dihydroisoquinoline 1 4 7
1-allylation
\'

key functional groups

116
Scheme 3.2: Preparation of the tetrahydroisoquinoline model compound.
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MeO
MeO'
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Scheme 3.3: Schematic overview of the preparation of the key intermediate 115.
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3.2 PREPARATION OF THE MODEL SYSTEM

The allylpiperidine castanospermine derivative 115 was the key intermediate for
preparation of B ring modified analogues of castanospermine. A s a plethora of reactions
were to be undertaken with this alkaloid 115 (see chapters 4-6), and due to difficulties
experienced in its preparation (see section 3.3), it w a s decided to optimize all
subsequent reactions firstly on a more easily prepared model compound. Initially, both
piperidine and tetrahydroisoquinoline model systems were investigated (schemes 3.1
and 3.2).

2-Allylpiperidine 159 and 2-(l-hydroxyallyl)piperidine 160 (figure 3.1) were first
selected as models of our key intermediate, the protected piperidine 115.

Several

methods were available to prepare 159, including a 5-step asymmetric procedure from 5hexenyl azide,184 a 6-step asymmetric procedure from Af-methylamino piperidine,185
dehydration of 2-(3-hydroxypropyl)piperidine, dehydrohalogenation of //-benzoyl-2(3-chloropropyl)piperidine, nucleophilic addition to 3,4,5,6-tetrahydropyridine,186 and
lastly b y an JV-activation - a-lithiation - electrophilic attack sequence from
piperidine.187

O f these general synthetic approaches, the last w a s chosen due to

problems with length of synthesis, unavailability of starting materials or low overall
yields in the first four methods.

H

159

H

OH

i60

Figure 3.1

Meyers had used formamidines to activate the a-position of pyrrolidines and
piperidines towards lithiation.
alkylating agents, such

It was found that in the piperidine series, m a n y

as allyl bromide, gave unsatisfactory

yields

unless
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pentynylcopper was used in the reaction mixture (scheme 3.4).187 O n e major drawback
of this method is the use of highly toxic dimethyl sulphate (class I carcinogen) in the
synthesis of the formamidine intermediates.

sec- or tert-BuLi

allyl bromide

•

N
feu
KOH
(85%)

CuC=C-Pr
*

159

Scheme 3.4: Meyers 1 8 7 synthesis of 2-allylpiperidine 159

More recently, Beak reported the use of the tert-butoxycarbonyl group as an activati
agent towards

ot-lithiation.188

It was

therefore

preferred

to

formamidine

protection/activation on the basis of health and safety considerations. Specifically,
benzaldehyde and propanal189 were the only aldehydic electrophiles utilized on the NBoc-piperidine and the use of allyl bromide was only reported on 4-substituted
piperidines which were found to be more reactive. For example, the 4-phenyl derivative
was found to be more reactive towards lithiation than the unsubstituted N-Bocpiperidine in a competition experiment.190

Thus protection of the piperidine nitrogen with the terf-butoxycarbonyl group,
following the method of Beak and Lee, 190 gave JV-BOCpiperidine 144 in an almost
quantitative yield (scheme 3.5). Unfortunately, lithiation, and electrophilic trapping of
the dipole-stabilised carbanion with either allyl bromide or acrolein, gave a mixture of a
large number of inseparable compounds.

The crude product mixture from the allyl

bromide reaction showed no evidence of a terminal C-C double bond in the *H N M R

48

spectra. It was thought that these problems were due to the side-reactions mentioned

by Meyers and thus may be overcome by the use of pentynylcopper. However, before

this reagent could be accessed, focus was shifted to the 1,2,3,4-tetrahydroisoqu

me

system.

'Boc

i) T M E D A , 'BuLi (1.7M in pentane)
diethylether, -78°C to -25°C

CBoc) 2 0
Et 3 N, chloroform

N"
H
piperidine

R.T., 3h
(97%)

145

(ii) allyl bromide, -78°C to r.t.
"N

feoc
N-*Boc-piperidine

144

(i) H M P A , 'BuLi (1.7M in pentane)
diethylether, -78°C to -25°C
(ii) acrolein, -78°C to r.t.

Scheme 3.5: Attempted synthesis of the piperidine model compounds

As the piperidine compounds proved more difficult to synthesize, and with the eas

formation and detection by TLC of the tetrahydroisoquinoline compounds, reactions
the latter model system were seen as more attractive.

1-Allyl-1,2,3,4-tetrahydroisoquinoline 116 had been prepared successfully by Kesser
using the anionic rearrangement of the boron trifluoride-complexed JV-allyl
compound.191 The use of either formamidine192 or phosphoric amide193-194 activating

groups, followed by oc-lithiation, was also reported to be effective in the synthe

alkyl-l,2,3,4-tetrahydroisoquinolines. However, with the ease of formation of the

dihydroisoquinoline imine, the latter imine formation - alkylmetal addition was t
of choice.
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Several methods have been reported for the oxidation of 1,2,3,4-tetrahydroisoquinolines
to 3,4-tetrahydroisoquinolines, including mercuric acetate,195 sodium hypochlorite196
and AM>romosuccinimide.197 Due to the unavailability of the hypochlorite experimental
procedure, and the toxicity of mercuric compounds, N-bromosuccinimide was the
reagent used. Thus 3,4-tetrahydroisoquinoline was obtained as a colourless oil in 86%
yield, after Kugelrohr distillation, from the commercially available 1,2,3,4tetrahydroxyisoquinoline by oxidation with a slight excess of A^bromosuccinimide in
dichloromethane (scheme 3.6).
NBS
dichloromethane
1.2h

•

NH

allylation

-•

N

(86%)
1,2,3,4-tetrahydoisoquinoline

3,4-dihydroisoquinoline

116

147
Allylation Reagent Conditions

(i) BF3-OEt2, dichloromethane, -78°C to 10°C
(ii) allylBu3Sn, -78°C to r.t., 18h
allyl bromide, Zn, tetrahydrofuran
0°C to r.t., 42h

Yield
Starting
Product
Material
116
80%
(2.3:1 SM:Product)
—

59%

Scheme 3.6: Preparation of 1 -allyl-1,2,3,4-tetrahydroisoquinoline 116.

Three key classes of reagents have been reported for the allylation of imines. These
were the use of allyl magnesium,198 barium199 or zinc reagents,198' 20°
allylboronates,201 and allyltrialkyl tin202 or germanium203 reagents in the presence of a
Lewis acid. As most of the literature reports appeared to be on the use of

allylstannanes this method was attempted first. Boron trifluoride was used as it was the
most common Lewis acid reported in the literature for this procedure,202- 204> 205
although titanium tetrachloride,206 lanthanum triflate,207 and tin(II) chloride208 have all
been used successfully.
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Accordingly, boron trifluoride etherate was first allowed to react with the imine
followed by the addition of allyltributyltin. This resulted in a 2.3:1 mixture, by *H
NMR,194 of starting material 147 to product 116 which ran as one spot on TLC.

Exclusive C-allylation is clear from the downfield shift of the H-l proton to 4.05ppm i
116, from 3.85ppm in 1,2,3,4-tetrahydroisoquinoline, together with the presence of
only one terminal C-C double bond by *H NMR.

The use of zinc/allyl bromide was also tried at this time and gave the superior result
an 8:1 mixture of product 116 to starting material 147 initially, which was later
optimized to give product only (scheme 3.6). This last point was important as the two
compounds could not be separated satisfactorily by either column chromatography or
Kugelrohr distillation. Thus racemic l-allyl-l,2,3,4-tetrahydroisoquinoline 116 was
prepared from 1,2,3,4-tetrahydroisoquinoline in two steps and a 51% overall yield

(scheme 3.6). It should also be noted that this last allylation reaction could easily b
converted into an enantioselective synthesis, and indeed has been carried out in the

presence of the chiral lithiated bisoxazoline ligand to give, in 95% e.e. and 72% yield
(iS)-1 -allyl-1,2,3,4-tetrahydroisoquinoline.200

3.3 PREPARATION OF THE TRIHYDROXYCARBAMATE 151

Synthesis of the trihydroxycarbamate 151 from castanospermine 1 had been developed
previously by Tarrant and Bremner.209 The key reaction in this synthesis was the
opening of the pyrrolidine ring using a chloroformate ester.

Castanospermine 1 was taken through in three steps to give the trihydroxycarbamate
151 in 76% overall yield (scheme 3.7). Previously Tarrant209 had reported a yield of
44%. Incomplete silylation of all hydroxy groups in castanospermine 1 always resulted
using standard TBDMSCl/imidazole/DMF conditions. Mean silylation of the carbamate
51

intermediate 150 was determined by comparison of the integration of the H-3' triplet at
2.05ppm with theter/-butylgroups at 0.90-0.96ppm. This was found to be in the range
of 2 to 3 T B D M S groups per molecule on repeated trials.

H

?H

OH

R'O

TBDMSC1
imidazole

DMF
r.t., 72h

HO'
castanospermine

OTBDMS

TBDMSCf

148

R,R' = TBDMS,H

ClC02Me chloroform
K2CQ3 reflux, 13h

CI

(85%)

151

R'O
OTBDMS
= H

1 M T B A F in T H F
r.t., 2.2h
.<

CI
TBDMSO*

N

R,R' = TBDMS,H

OMe
O

150

(89% from castanospermine)
Scheme 3.7: Protection,ring-openingand desilylation: 1 to 151.

Mechanistically the ring opening of the castanospermine system 148 occurs in two
steps; attack on the formate carbonyl carbon by the castanospermine tertiary amine,
with chloride ion as the leaving group, followed by attack of the a-C-3-carbon by the
chloride ion producing ring opening of the five-membered ring (scheme 3.8). It was
envisaged that with sequestering of this chloride and introduction into the system of a
non-nucleophilic base, ring opening might then occur with concomitant elimination to
give the already highly protected alkene 149 (scheme 3.9). Carbamate cleavage would
then lead directly to a synthetically useful key intermediate in two steps from the
protected castanospermine 148, compared to our finally establishedfivesteps.
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Scheme 3.8: Ring-opening mechanism (P=TBDMS).
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Scheme 3.9: Mechanism of the proposed eliminative ring-opening.

Silver (I) was selected as the chloride sequestering agent. Both the nitrate and oxide
were

trialled

together

with

either

potassium fert-butoxide or

1,8-

diazabicyclo[5.4.0]undec-7-ene as base or no other base present at all. Other conditions
trialled included the use of chloroform, acetonitrile and tetrahydrofuran solvents, and
both room temperature, to form the saltfirst,and reflux conditions. In all the product
mixtures, no carbon-carbon terminal double bond was detected in the proton N M R .
Generally, only starting material 148, was recovered except in the two cases of silver (I)
oxide/acetonitrile and silver (I) nitrate/acetonitrile/potassiumtert-butoxidewhere a
formate-derived product was isolated in low yield (10%). From the proton N M R of
this product and the CI-MS, several structural possibilities were entertained, including
the rearranged carbamate 161 (figure 3.2), which was thought to be a mechanistic
possibility by attack and ring opening at the C-5 carbon of the castanospermine
carbamate intermediate by a deprotonated C-8 hydroxy group. However, after close
analysis of the C O S Y spectrum the compound was identified unequivocally to be the

53

carbonate 162 (figure 3.2) with the H-8 proton moving downfield from 3.64ppm in the
starting material to 4.90ppm in the carbonate product as would be expected.
Me

TBDMSO
^O
TBDMSO*

QTBDMS

602Me

161

H /—\

9 w OTBDMS
TBDMSO.
TBDMSO'
162

Figure3.2

3.4 ELIMINATION, CARBAMATE CLEAVAGE AND PROTECTION

Repetition of the one-pot carbamate cleavage and dehydrohalogenation reaction on
trihydroxycarbamate 151 to give 154 proved more troublesome. Results were

inconsistent and ranged from 40% to an 84% yield of the hydrochloride salt 154»HC

This was, for the most part, due to the difficulties involved in the purification
compound. Dehydrohalogenation, without the carbamate cleavage step, occurred

without incident to give the alkene 152 in 85% yield (scheme 3.10). The products,
154-HC1 and 152, were identified by comparison of their *H NMR spectra to those
reported by Tarrant.209

It was decided that it would be wise to protect the three hydroxyl groups of the

trihydroxycarbamate 151 while the amine was protected as an oxazolidinone. Due to
the wide range of subsequent reactions the key intermediate 155 was expected to
undergo, a quite robust protecting group was deemed necessary. Additionally,

protection of all three hydroxyl groups on similar compounds had proved difficul
but the smallest of protecting groups. Thus the methyl group was chosen.
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KO*Bu, T H F
reflux, 2h

(i) KO'Bu, T H F
reflux, 2h
(ii) aq. N a O H
(40%
reflux, lh

(85%)

to 84%)

HO
OH
= H
,NH2CI
154-HC1
Scheme 3.10: Dehydrohalogenation and carbamate cleavage of the trihydroxycarbamate
151.

Initially sodium hydride was used as the base in tetrahydrofuran for methylation of the
hydroxyl groups with iodomethane, but only starting material was recovered. Silver(I)
oxide has been used extensively as a reagent for the methylation of hydroxy groups,
particularly in carbohydrate chemistry. Following the method of Finch,210 methylation
proceeded to give the trimethoxy carbamate 153 in 9 0 % yield using a slight excess of
silver (I) oxide per hydroxyl group (scheme 3.11). This reaction was later found to be
extremely sensitive to the source and batch of silver (I) oxide and was often required to
be returned for a second, and occasionally even a third, reaction cycle to allow for
complete hydroxyl group protection. Furthermore, due to the expense of the silver (I)
oxide reagent, other bases were investigated, including potassium hydroxide in
dimethylsulphoxide,211 but to no avail. Dimethyl sulphate (class 1 carcinogen) was not
tried due to health and safety requirements.

The three methoxy groups were clearly visible in the *H N M R spectra of 153 as singlets
at 3.49, 3.627 and 3.629ppm, each with an integration value of 3H. This occured with
the concurrent downfield shift of the H-6,7 and 8 proton resonances from 3.0-3.2ppm in
the unprotected starting material 151 to 3.2-3.5ppm in 153. Finally, the molecular
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formula of 153 was confirmed by high resolution electrospray mass spectrometry which
measured the M H

+

ion at m/z 294.1111 compared to the calculated value for

C i 2 H 2 i N 0 5 3 5 C l of 294.1108.

Mel, Ag?0
acetonitrile

MeO
z H

reflux
8h,N 2
(90%)

Scheme 3.11: Protection of the trihydroxy carbamate 151.

Dehydrohalogenation and dehydrohalogenation - carbamate cleavage reactions on the
trimethoxy-protected chlorocarbamate 153 consistently gave low yields w h e n the same
conditions were used as for the unprotected system 151. A s earlier conditions for the
dehydrohalogenation of the unprotected compound 151 had included the use of as little
as 2 equivalents of potassiumtert-butoxidewhich resulted in a 5 3 % mass recovery of
mostly starting material (by *H N M R of the crude product mixture), such low molar
equivalents of this reagent were initially not included in the various reaction conditions
trialled. The use of l,8-diazabicyclo[5.4.0]undec-7-ene as the base was tried, but again
only low product yields were obtained.

D u e to the high yield from the dehydrohalogenation of the unprotected compound 151,
it was thought that methyl protection of the resulting trihydroxy alkene 152 could
circumvent this problem. Surprisingly though, on repeated attempts to trimethylate
152, only mixtures of a large number of products were obtained, even after returning the
mixture into further reaction cycles. D u e to the low mass recoveries obtained in the
dehydrohalogenation and dehydrohalogenation - carbamate cleavage reaction of 153, it
was speculated that this m a y be caused by the creation of a charged species, such as a
quaternary indolizidinium salt, which would remain in the aqueous phase on work-up.
Such a salt was thought to be the result of excess base inducing further elimination

56

reactions around the ring. It was reasoned then that the use of 1.1 equivalents of
potassiumtert-butoxidewould prevent this undesirable reaction. In addition to this,
according to Fuchs, problems have been found with this reagent if it was not freshly
prepared.212 Purification by sublimation (200°C/2mm H g ) was deemed adequate and
allowed for known molar amounts to be weighed.

Thus use of 1.1 molar equivalents of freshly sublimed potassium tert-butoxide in
refluxing tetrahydrofuran resulted in an 8 6 % yield of the alkene 124 from the trimethoxy
chlorocarbamate 153 (scheme 3.11). The terminal alkene was clearly visible in the
proton N M R spectra with the H - T proton appearing as a ddd at 5.90ppm and the
protons cis and trans to this appearing at 5.32ppm and 5.46ppm respectively. Loss of
H C 1 was confirmed by chemical ionisation mass spectrometry where the high resolution
spectra gave a measured ion M H + at m/z 258.1343, compared to the calculated value for
C12H20NO5 of 258.1341.

Subsequently, the one-pot dehydrohalogenation - carbamate cleavage reaction afforded
the product 115 in 7 6 % yield (scheme 3.12). The carbamate cleavage was evidenced in
the proton N M R by the concurrent downfield shifts of the H-l, 5a, 5b and 8a
resonances at 4.72, 2.62, 4.10 and 3.14-3.22ppm respectively in the alkene 124 to the
resonances at 4.41, 2.37, 3.10 and 2.45ppm of the equivalently assigned protons H-2,
6a, 6b and 1' respectively in the cleaved product 115. Supporting this, the carbonyl
resonance at 156.26ppm in the 1 3 C N M R spectra of 124 was no longer present in that
of 115. High resolution mass spectrometry further supported the structure for 115 with
the measured M H

+

peak at m/z 232.1542 compared with a calculated value for

CnH22N04of232.1549.
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(i) KO*Bu, T H F
reflux, 2h
(ii) aq. N a O H
reflux, lh

MeO

OH
z H

KO'Bu, THF
reflux, 2h
(86%)

124
Scheme 3.12: Dehydrohalogenation and carbamate cleavage of the trimethoxy
chlorocarbamate 153.

Finally, our attention was directed towards the protection of the last hydroxyl group,
unmasked in the carbamate cleavage. Now we had the added complication of alcohol
protection in the presence of a secondary amine. A robust silyl protecting group was
thus preferred. Although some procedures for their introduction report concurrent

silylation of amines,213-214 these are generally unstable to aqueous conditons. A furthe
complication could be predicted from the work by Djuric who reported N-formylation
in the presence of the tert-butyldimethylsilyl chloride/AyVdimethylformamide/triethylamine/4-dimethylaminopyridine reagent system.215

Initial T B D M S protection using the standard TBDMSCl/imidazole/DMF conditions
resulted in only very poor yields of product. More recently, the use of silyl triflates
has gained widespread use. Although TBDMS triflate can be prepared from the silyl

chloride and triflic anhydride, both of which we had available, it was decided to try th
TES triflate and await the purchase of the TBDMS reagent. Use of the TES triflate
with triethylamine as base and dichloromethane as solvent appeared to proceed
smoothly by tl.c. but upon work-up and purification a second product of unknown
structure was isolated with the desired product, 157, in a 1:2 ratio (scheme 3.13).
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Proton N M R

and mass spectral analysis were inconsistent and the structure of this

second product could not be established.

MeO
OH
z H

TESOTf
Et3N

MeO
OTES
r H

dryDCM
0°C

+ unknown

(39%)
2 : 1
Scheme 3.13: T E S protection of 115.

TMS protection was also carried out employing standard conditions
(TMSC1/TEA/THF) to provide 156 in 88% isolated yield (scheme 3.14). The TMS
product 156 was clearly shown in the proton NMR by the emergence of the TMS
singlet at 0.13ppm corresponding to an integral of 9 protons.

13

C NMR also showed

the TMS methyl peak at 0.60ppm. Further evidence was from the H-l' proton coupling

to H-2' with a constant of 6.3Hz for the product 156, whereas this same proton co

with a constant of only 3.8Hz in the starting material 115. The high resolution m
spectrum confirmed the molecular formula of Ci4H29N04Si with an MH+ peak at m/z
304.1944 compared to the calculated value of 304.1944.

MeO
OH
= H
NH

TMSC1
Et3N
dry THF
r,y,2.5h

MeO
OTMS
= H

M

e O ' ^

N H

115 (88%) 156
Scheme 3.14: TMS protection of 115.

Finally, T B D M S protection was carried out successfully using T B D M S triflate, with

2,6-lutidine as base and dry dichloromethane as solvent.216-217 These conditions ga

94% isolated yield of 155 (scheme 3.15). No secondary product was detected in eith
the NMR or mass spectra. In fact, the proton NMR spectrum of the product was very
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clean making further purification unnecessary. The T B D M S protecting group appeared
as two methyl singlets at 0.05 and 0.09ppm, and a tert-butyl singlet with an integral of 9
hydrogens at 0.90ppm. A single quaternary carbon was present at 18.14ppm in the

13

C

N M R spectrum. Again the coupling constant between the H-l' proton signal and H-2'
in the proton N M R spectra was increased from 3.8Hz for the starting material 115 to
7.6Hz for the product 155. High resolution mass spectral analysis confirmed the
molecular formula of 155 to be Ci7H 3 5N0 4 Si with the M H

+

ion at m/z 346.2414

compared to the calculated value of 346.2413.
MeO
OH
= H

TBDMSOTf
2,6-lutidine

MeO

OTBDMS

T H

dryDCM
0°C - r.t.
3.5h
(94%)

Scheme 3.15: T B D M S protection of 115

The two key intermediates, 155 and 156, were thus able to be produced in 4 9 % and
46%> overall yield respectively in 6 steps from castanospermine 1. Furthermore, the
only purification steps deemed necessary in this sequence were the ion-exchange column
chromatography of 151 and silica column chromatography of 153. It should again be
noted that the trimethylation of 151 can be quite problematic depending on the quality
of silver (I) oxide used. However, this is the only troublesome reaction encountered in
the sequence and could easily be overcome by using the cheaper, but more toxic,
dimethyl sulphate methylating reagent with careful control measures in place.

3.5 ATTEMPTED OXIDATION OF CARBAMATE 153

In the early stages of the synthetic approaches to the n e w tropane alkaloid analogue
166, Tarrant had attempted to oxidise alpha to the nitrogen of both the acetate protected
163 and T B D M S

protected 164 carbamates but to no avail (scheme 3.16).218
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Ruthenium tetroxide w a s found to b e the only reagent capable of performing such
transformations. T h e reagent w a s successfully used to oxidise the model methyl Npiperidinecarboxylate to 1 6 7 (scheme 3.17).218 It w a s concluded in the case of the
acetate protected carbamate that perhaps the electron withdrawing effects were the
problem, and in the case of the T B D M S

protected carbamate, that the bulk of the

protecting groups w a s preventing the desired reaction.

AcO
AcO
AcO*^N>(
163 O
...«OH

166
164
S c h e m e 3.16: Proposed synthesis of the tropane alkaloid 166.

RuCl3«H20/NaI04
H20/MeCN/CCl4

X.

O " ^OMe

167

1ST ^ O
y(71%)
Mn,/

'

O

X.

OMe

168

S c h e m e 3.17: Ruthenium oxidation of the model carbamate 167.

T h u s with the newly available methyl protected carbamate 153, it w a s decided to try
the ruthenium oxidation again. Unfortunately, none of the desired product 169 w a s
isolated (scheme 3.18). In fact, a mixture of starting material and an unidentified product
which b y m a s s spectral analysis appeared at first to b e the desired product, w a s
obtained. H o w e v e r , analysis of the proton N M R spectrum of this product showed
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both the H-5 protons to be still present, and that a demethylation had occurred. Further
oxidation work on 153 was thus discontinued.

Cl

Ru02/NaI04
H20/MeCN/CCl4

MeO
MeO
MeO

6
153
169
Scheme 3.18: Attempted alpha-oxidation of the carbamate 153.

CHAPTER 4

RING CLOSING METATHESIS
4.1 SCHEMATIC OVERVIEWS
amide
formation

ring closing
metathesis

N

Y ^

K—•
n=l 172
n=2 173

n=l 170
n=2 171

116

Scheme 4.1: R C M attempts for, and preparation of, the model amides.

N-alkylation

(i) HC1

i^^
v

116

n=l 174
n=2 175
n=3 176

'n

*(n)metathesis
nng closing
n=l 177
n=2 178
n=3 179 (no reaction)

Scheme 4.2: R C M , and preparation, of the model amines.

63

MeO
OTMS
• H
MeO
MeO°'

156
Af-alkylation

MeO
MeO.

MeO
OTBDMS
-- H
MeO

OH

r H

MeO x

^

^

MeO^

180

155
TBDMS

Af-alkylation

protection

MeO
OTBDMS
: H
MeO

181

MeO
(i) H C 1

MeO
r

OH
H

(ii) ring closing
metathesis

MeO
OTBDMS
• H
MeO
MeO°

182

117

Scheme 4.3: R C M , and preparation of, the key amine 181.

4.2 BACKGROUND

Carbon-carbon bond forming reactions play a central role in organic synthesis. Of

these, alkene metathesis has received increasing acknowledgement due to a

catalyst development which allow for greater functional group compatibili

conditions.219 Ring closing metathesis is now being used extensively in al

synthesis,220 including the total synthesis of castanospermine l221 and the
australine 5.222
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In the overall generalised reaction, two C - C double bonds are broken and two new C - C
double bonds are formed (scheme 4.4).

R1 Ft3
R1 R3 [M]= catalyst
R R /^^X
R2

R4

Scheme 4.4: Generalised overall metathesis reaction.

Obviously this is a reversible reaction, but if for example terminal double bonds wer
employed, then ethene gas would be produced and released from the reaction mixture.

In the special case of a diene, the reaction is termed ring-closing metathesis (RCM).
This reaction is now used extensively in organic synthesis,223 particularly for the
formation of macrocycles,224 and other ring sizes.

The generally accepted mechanism of the reaction was first proposed in 1970 by
Chauvin and involves [2+2] cycloaddition of the C-C double bond to the metal-carbene
complex, followed by cycloreversion (scheme4.5). Although this mechanism may hold

true for some catalysts, it has recently been found through kinetic studies that it m
only be a minor pathway. The major pathway for RCM for diethyl malonate and
(Cy3P)2Cl2Ru=CH2 involves loss of a phosphine ligand before cycloaddition of the
complexed amine (although not shown, in both mechanisms the alkene first forms a
n complex with the metal centre), and regain of this ligand later in the mechanism.

Of the catalysts available for RCM, the molybdenum-based Schrock catalyst 183225 and
the ruthenium-based Grubbs* catalysts, 184226 and 185,227 have been the most
extensively studied (figure 4.1).
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Scheme 4.5: The Chauvin mechanistic model for ring-closing metathesis.

A s w e were intending on usingring-closingmetathesis on tertiary amines and amides,
these catalysts were reviewed for their usefulness in this area. Although the
molybdenum Schrock catalyst 183 has showed particular success in the RCM of tertiary

amines,228 and with many amides,229 it has proven to be quite unsuccessful with certain
amides, purportedly due to complexation of the carbonyl oxygen to the metal centre
(figure 4.2).230

66

Cy 3 P
CI i... J

^Ph

PCy 3
184

185

Figure 4.1: Catalysts forring-closingmetathesis.

R
Figure 4.2: Complexation of 183 to amides. 230

Furthermore, the Schrock catalyst 183 is more air and water sensitive than its ruthenium
counterparts. Whilst the ruthenium catalysts effectively metathesise most amides,
amines can complex with the metal centre and inhibit the reaction. Grubbs has
overcome this problem by using the hydrochloride salt of the amine. 226 F e w studies
have been carried out to compare the effectiveness of the two Grubbs catalysts 184 and
185.

N a k a g a w a has shown that 185 m a y induce faster cyclisation with some

amides.231 Thus, together with availability, 185 was our selected catalyst.

One of the current problems when using these catalysts is the separation from the fina
product mixture of darkly coloured ruthenium and phosphine by-products. Several
methods have been developed to combat the problem. The first arrived with the
development of the highly water soluble /ra(hydroxymethyl)phosphine232 which would
complex with the ruthenium allowing the by-products to be washed into the aqueous
phase.233 However, this reagent is extremely expensive, difficult to prepare and only
moderately stable. Its use has not been successful in our laboratories.
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Most recently, lead tetraacetate has been used to oxidise the ruthenium by-products to
species which are strongly absorbed onto silica and can thus be removed by simple
filtration through a plug of silica.234 It has been noted, however, that this method has
not been very successful in the presence of the amine functionality.235

Recently Hoveyda and co-workers have developed a stable ruthenium based catalyst
186 which is stable to, and easily separated by, silica chromatography. This n e w
development not only offers the advantage of allowing purification of the metathesis
products, but also provides the possibility of recycling the expensive catalyst, especially
significant w h e n working on larger scale reactions. T h e catalyst is prepared by
sequential treatment of RuCl 2 (PPh3)3 236 with (2-isopropoxyphenyl)diazomethane and
P C y 3 (scheme 4.6). 237

OH
JL

Kj

CHO

(i) Na, EtOH
(") 2-iodopropane
(iii) p-tosylhydrazide

O'Pr

J^XHNNHS^Ar

u

Me2N

NMe2

Y
NH
RuCI 3 »3H 2 0
A

PPh3
MeOH

RuCI2(PPh3)3

O'Pr

(1)

r^V CHN2

a ci
PrO-*~Ru-PCy 3

(ii) PCy 3

S c h e m e 4.6: Synthesis of the stable ruthenium catalyst 186.

4.3 SYNTHESIS AND RING CLOSING METATHESIS OF THE MODEL DIENES

In order to examine ring-closing metathesis reactionsto form seven and eight membered
rings, the model diene amides 170 and 171 were prepared.
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Dicyclohexylcarbodiimide coupling of 3-butenoic acid and 4-pentenoic acid to the 1allyl- 1,2,3,4-tetrahydroisoquinoline 116 gave the amides 170 and 171 in 8 6 % and 8 2 %
yields respectively (scheme 4.7).

HO

Y^
0

DCC
dichloromethane

n=ll70(86%)
n=2 171 (82%)

11|5
110

Scheme 4.7: Preparation of the amides 170 and 171.

Each amide appeared as a mixture of two rotamers (majonminor, 1.3:1) in the proton
and

C N M R spectra. B y analysis of the chemical shifts in the proton N M R spectrum

of 170 it could be ascertained that H-l was syn to the carbonyl group in the major
rotamer as it appeared downfield at 5.69ppm, whereas it was anti to the carbonyl group
in the minor rotamer, appearing at 4.88ppm. O n e needs to be cautious, however, using
this method for rotamer assignment.238-240 B y this method, one would expect the H-3
protons of the minor rotamer to both appear downfield from their counterparts in the
major rotamer. Spectral analysis reveals that this is not the case since, although the H3b proton of the minor rotamer appears downfield at 4.69ppm (from 3.83ppm in the
major rotamer), the H-3 a signal appears upfield, at 3.1 lppm, relative to the equivalent
proton of the major rotamer which appears at 3.56ppm. The amide carbonyl group is
evidenced by a signal at 169.66ppm in the 1 3 C N M R spectrum, and a strong amide
carbonyl stretch at 1649cm -1 in the IR spectrum.

Variable temperature proton NMR analysis was carried out on the pentenamide 171 in
order to prove the doubling of signals was due to slowly interconverting rotamers.
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Although w e were unable to reach a high enough temperature for full coalescence, peak
flattening and merging over a range of temperatures from 25 to 130°C was observed.

Ring-closing metathesis of 170 and 171 was hoped to produced the fused sevenmembered and eight-membered rings, although from a study of the literature it was not

expected that the cyclisation to give the eight-membered ring would be successful, su

rings being notoriously difficult to prepare. Several attempts at ring-closing metath
were carried out for each of these amide starting materials. A nitrogen or argon

atmosphere were used (using a balloon or a continuous supply), as well prior drying of
the inert gas by passing through a column of self-indicating silica and anhydrous
calcium chloride were all tried. Refluxing dichloromethane or benzene at room

temperature were tried as solvents, together with increasing the quantity of the cata
from 4% up to 10%o, but all to no avail. Only starting material was recovered in each
case. It was thought that perhaps the amide was preventing the two alkene moieties
from coming in close enough proximity at the metal centre for reaction to occur. This
anomaly seems to be specific to the tetrahydroisoquinoline system as Nakagawa has
formed the six- and seven-membered fused rings (191 and 192) from pyrrole amides
(187 and 188) with the carbonyl in the newly forming ring (scheme 4.8). Also

noteworthy is that the eight and nine membered rings (193 and 194) were not able to be
formed by this procedure.241 However, due to our lack of success in this area, it was
thought that the amines may provide the necessary flexibility to undergo reaction.

70

184 or 185
benzene, r.t.

n=0l87
n=l 188
n=2 189
n=3 190

n=0 191
n=l 192
n=2 193
n=3 194

(66-93%)
(29-91%)
no reaction
no reaction

Scheme 4.8: Metathesis of amides.241

The required amines could be accessed, potentially, by either JV-alkylation of 116 wi
an appropriate alkenyl halide, or by reduction of the amides 170 and 171.

While awaiting the arrival of the alkenyl halides, 4-bromo-l-butene and 5-bromo-l-

pentene, it was decided to reduce the amides, 170 and 171, directly to the amines, 175
and 176. Pakrashi had successfully used sodium borohydride to reduce the amide in a
similar system.242 Unfortunately for us, though, sodium borohydride reduction of the

butenamide 170 resulted in a mixture with only a small amount of starting material and
products able to be recovered from the reaction mixture. Borane reduction moreover
reduced the alkene double bonds.243 Diisobutylaluminium hydride (DIBAH) reduction

of the butenamide 170 proved successful giving the amine 175 in 21%> yield on the firs

trial of the reaction (scheme 4.9). Reduction of the amide was evident by the loss o
carbonyl resonance in the 13C NMR spectrum, together with the appearance of a new
CH2 resonance in the DEPT spectrum at 51.90ppm. High resolution mass spectral
analysis confirmed the loss of oxygen and the gain of two hydrogens. Furthermore, the
1-2

alkene groups remained unchanged as could readily be seen in the proton and

C NMR

spectra.
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I
1

DIBAH (8equiv.)
toluene

v / N ^

| (21%)
170
Scheme 4.9: DIBAH reduction of 170.

Before optimisation of this reaction was performed, the bromoalkenes became
available. Thus the new alkenes 174,175 and 176 were prepared from the model amine

116 in 62-67% yield (scheme 4.10). All products exhibited an upfield shift of their H
protons from 4.05ppm to 3.77, 3.75 and 3.70ppm respectively. Proton NMR spectra
also showed doubling of the integrals for the alkene resonances. 13C NMR spectra
revealed the extra alkene CH and CH2 peaks as well as n extra CH2 resonances from
DEPT analysis. The molecular formulae of all compounds were confirmed by high
resolution mass spectrometry.

KsCOg
acetonitrile

A
116

II

n=l 174 (62%)
n=2 175 (64%)
n=3 176 (67%)

Scheme 4.10: N-Alkylation of 116: Preparation of the dienes 174-176.

A s previously noted it was necessary to protect the amines as their hydrochloride salts
to prevent coordination to the ruthenium catalyst 185. This was achieved by bubbling

freshly prepared hydrogen chloride gas244 through a solution of the amine in dry diet
ether, followed by evaporation of the solvent under reduced pressure. Ring closing
metathesis was undertaken using Grubbs' catalyst 185, in refluxing degassed

dichloromethane under an argon atmosphere. Only amine 176 failed to react to give the
fused eight membered ring 179 (scheme 4.11). The cyclisation of the

72

diallyltetrahydroisoquinoline 174 was most successful, although the yield of 178 was
low (28%) and some starting material 174 was also recovered (13%) in this case
(scheme 4.11). Proof that cyclisation had occurred was easily found in the NMR

spectra by the disappearance of the terminal alkene CH2 groups. The H-l resonance (

1 lb in the product) moved upfield slightly from 3.77ppm to 3.53ppm. Low resolution

mass spectral analysis no longer exhibited an (MH+ - propene) peak, but instead ha
base peak corresponding to (MH+ - 4H) which presumably derives from the stable
aromatic cation 195 (figure 4.3). High resolution mass spectrometry was used to
confirm the molecular formula of the benz-fused quinolizine product 177.

(i) HC1, diethyl ether
(ii) 185
dichloromethane

III ]li

n=l 177 (28%)

n=3 176

n=2l78(8.4%)
n=3 179 (no reaction)

Scheme 4.11: Ring closing metathesis of the model amines 174-176

195

196

Figure 4.3: Cations in the CI-MS of 177 and 178 corresponding to MH+ - 2H2.

Ring closing metathesis of the butenyl amine 175 allowed isolation of only a small

quantity of product 178 (8.4%) and starting material (5.5%) (scheme 4.11) although
reaction was performed on a much smaller scale (0.48mmol). Nakagawa also found
that larger scale reactions performed better with a 93% yield of 191 (scheme 4.8)

obtained on a 2.9mmol scale, but under the same conditions and with a similar reac
time only a 68% yield of product 191 was isolated (together with 31% of starting
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material 187) when performing the reaction on a 0.3mmol scale.241 Proof that ring
closing metathesis had occurred in the case of 178 was from the lack of the terminal
C H 2 groups in the proton and

13

C N M R spectra. The H-l resonance (H-12b in the

product) experienced the opposite shift from the quinolizine product moving downfield
to 4.23ppm. In the CI mass spectrum, although not the base peak, there was again a
significant signal for ( M H + - 2 H 2 ) corresponding to the aromatised ion 196. High
resolution mass spectrometry confirmed the molecular formula of the M H

+

cation.

Due to the fact that ring closing metathesis of the diallyl compound 174 was the most
successful, the N-aHylation of the key intermediates 1 5 5 and 156 were then
investigated.

4.4 SYNTHESIS AND RING CLOSING METATHESIS OF THE DIENE 181

When the preparation of the piperidine diallyl compound 181 was first investigated, t
TBDMS-protected intermediate 155 was not as yet available on a large enough scale.
Hence, the first iV-allylation was undertaken with the T M S protected intermediate 156.
However, it was recognised that, even if the T M S group survived the JV-allylation
work-up, it was not likely to survive the hydrochloride salt formation and thus was not
the protecting group of choice.

JV-Allylation of the TMS-protected key intermediate 156 proceeded smoothly but with
concurrent desilylation to give the diallyl amine 180 in a modest 5 4 % yield after
purification (scheme 4.12). Proton and
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C N M R spectra of the purified product 180

both exhibited resonances from two terminal alkenes, as well as showing the loss of the
T M S group. C-V gave the extra C H 2 in the alkyl region of the D E P T spectra at
57.65ppm. The H-2 resonance in the proton N M R moved downfield from 2.3 lppm in
the starting material 156 to 2.55ppm for the product 180. In the CI mass spectrum there
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was a peak at m/z 254 corresponding to loss of H 2 0 from M H + , and another at m/z 240
which ( M H + - propene), indicative of the presence of the hydroxyl and allyl groups
respectively. High resolution mass spectrometry confirmed the molecular formula.
MeO
OTMS
z H

allyl bromide
K2C03

NH

acetonitrile
A, 18h

156

MeO
OH
= H

(54%)

Scheme 4.12: JV-Allylation of the TMS-protected key intermediate 156.

D u e to the use of hydrogen chloride in the following reaction it was deemed necessary
to use a quite robust protecting group for the remaining unprotected hydroxyl group.
Alkyl protecting groups such as benzyl (from a benzyl halide) would, however, give the
added problem of possible JV-alkylation. Thus the T B D M S group was chosen. The
hydroxy diallylamine 180 was silylated with T B D M S triflate to give the protected
diallylamine 181 in 7 7 % yield (scheme 4.13). Silylation was evidenced by the
appearance of a tert-butyl group at 0.89ppm in the proton N M R , together with two
diastereotopic methyl groups at 0.04 and 0.08ppm. The H-l" resonance moved
downfield from 3.47ppm in the starting material 180 to 4.20ppm in the protected
product 181.

MeO
OH
z H

TBDMSOTf
2,6-lutidine
dichloromethane
0°C, 2h
(77%)

MeO
OTBDMS
z
H
MeO
MeO

181

Scheme 4.13: T B D M S protection of the hydroxy diallylamine 180.
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Preparation of the TBDMS-protected diallylamine 181 was also prepared from the
TBDMS-protected key intermediate 155 once it became available. Interestingly this

reaction, following the same conditions as for the //-allylation of 156 (scheme 4.1

gave only a low purified yield of the desired product 181 (25%) together with some
recovered starting material (18%).

Ring closing metathesis of 181 was only tried on a very small scale (0.05mmol), bu

clear proton NMR evidence was obtained for some of the desired cyclised product 11
(scheme 4.14). In the proton NMR spectrum of 117, diagnostic signals for the

disubstituted double bond in the B ring were observed at 5.78 and 5.90ppm. The H-9

(2.00ppm) signal shifted upfield in the cyclized product 117 compared to the equiv

proton, H-2 (2.43ppm), in the starting material 181. Purification by preparative th
layer chromatography was not able to separate the product 117 from the monoallyl
compound 115. An earlier attempt at this cyclization reaction gave, what appeared
be, some desilylated product 182.

MeO

OTBDMS

r H

(i) HC1, Et 2 0
(ii) Grubbs' cat. 185
A, dichloromethane
Ar

MeO
OTBDMS
= H
MeO
MeO

117

Scheme 4.14: Ring closing metathesis of 181.
The alkene moiety of the quinolizine derivative 117 provides a useful handle for further

functionalisation of the of the B ring through epoxidation, dihydroxylation and 1,
dipolar cycloaddition reactions.
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CHAPTER 5

FREE-RADICAL CYCLISATION
5.1 SCHEMATIC OVERVIEWS

147
zinc-allylation/Af-acylation

free-radical cylisation

CCV

Me

of diastereomers
198 + 199 ^separation
/

198
de-benzoylation

200
Scheme 5.1: Free-radical cyclisation on the model tetrahydroisoquinoline system.
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Af-bromobenzoylation

MeO
OR
: H

R
H
TBDMS

201
202

TMS

203

210
free-radical cyclisation
demethylation

MeO
MeO
MeO

H
TBDMS

MeO
j

MeO'

i
H
TBDMS

204
206

205
207

debenzoylation/
desilylation
(forR=TBDMS)

MeO

204 + 205

MeO
MeO
MeO
208

209

Scheme 5.2: Free-radical cyclisation of the castanospermine derivatives.
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5.2 BACKGROUND

Free-radical reactions have become an increasingly useful tool for the synthetic organic
chemist. This is primarily due to the increased predictability of such reactions. W e
were interested in intramolecularfree-radicalcyclisation reactions in the context of
modifying castanospermine.

Baldwin made a significant contribution not only to

predicting the regio- and stereo-selectivity of polar, but also of radical, cyclisations.
These predictions are summarized into what are k n o w n as Baldwin's rules.

Taking the 5-hexenyl radical as a representative example, and also the simplest analogu
of the radical of interest in this work, it can be seen that there are three
thermodynamically significant transition states: the 5-exo-chair, the 5-exo-boat and the
6-endo-chak (figure 5.1).

2.34A

2.34A

-t-lkcalmol"
5-exo-chair

5-exo-boat

+3kcalmol -1
6-endo-chak

Figure 5.1: T h e three favoured 5-hexenyl radical transition states.

Energy calculations245 reveal the 5-ejco-chair transition state to be favoured over the 5exo-boat and this over the 6-endo-chak which is supported

by experimental

observations.

Our interest in this area w a s sparked by the work of Ikeda et al. w h o used a radical
translocation from o-halobenzamides to generate thefree-radicalinvolved in these cyclic
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transition states. O f particular interest w a s the cyclisation of a l-o-bromobenzoyl-2-

allylpiperidine 211 to give the tropane alkaloid bicyclic ring structure (scheme 5.3)
Thus 5-exo-trig cyclisation is the favoured pathway resulting in a 2:1 mixture of
diastereomers 212. This is in direct contrast to the equivalent cyclisation with the
pyrrolidine system where 6-endo-trig cyclisation is favoured (scheme 5.4).247 In this
system however, simple reduction of the radical intermediate is faster than its

cyclisation, resulting in an 81% yield of the reduction product 217. One disadvantage

the use of tributyltin hydride, however, is its neurotoxic effects but a suitable alt
may be hypophosphorus acid (H3P02).248

Bu3SnH, AIBN
toluene, A

NBz

+

. f•

'N-COAr ^ /"H^Me
Ar = o-bromobenzoyl 212

<75%)

211

I

>

Bz

214
(5%)

Scheme 5.3: Free-radical cyclisation of l-o-bromobenzoyl-2-allylpiperidine.

Bu3SnH, AIBN
toluene, A
COAr
Ar = o-bromobenzoyl
215

NBz
X\

Bz

216
(17%)

217
(81%)

Scheme 5.4: Free-radical cyclisation of l-o-iodobenzoyl-2-allylpyrrolidine

It w a s envisaged that such a reaction using our key intermediate 115 (or O-protected

derivatives), would lead to a novel polyhydroxylated tropane alkaloid which lacks the
bridgehead hydroxyl group present in the naturally occurring calystegine wortropane

alkaloids, but retaining the other hydroxyl groups necessary for glycosidase inhibito
activity. Thus, such a system would not be susceptible to ring-opening to the amino-
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ketone tautomer but would still retain the sugar-like features for glycosidase inhibition.
Furthermore, on biosynthetic grounds, systems of this type could conceivably occur
naturally.

5.3 PREPARATION OF THE MODEL CYCLISATION PRECURSOR

Prior to the investigation of the free-radical cyclisation in the o-bromobenzamide
from 115, it was decided to study the reaction in the more readily available model
system 197.

o-Bromobenzoylation of 1-allyl-1,2,3,4-tetrahydroisoquinoline 116 proceeded without
incident to give l-allyl-2-(o-bromobenzoyl)- 1,2,3,4-tetrahydroisoquinoline 197 in
yield (scheme 5.5).

NH

o-bromobenzoyl chloride
Et3N/DMAP
1
dichloromethane
r.t.

Scheme 5.5: o-Bromobenzoylation of the base model 116.

The proton and 13C NMR spectra of 197 showed a mixture of four rotamers. These
arise from hindered rotation about the amide N-CO bond238 together with hindered
rotation about the CO-Ar bond,249 the latter being due to the presence of the bulky
ortho-bromo constituent. Conformational molecular modeling calculations (Spartan
program) of the four possible rotamers gave strain energies of 76.0, 76.0, 76.4 and
77.2kcalmol_1 (figure 5.3.1). These appear to correspond to the observable rotamers
the NMR spectra, A, B, C and D respectively, whose integrals indicated a relative
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abundance of 5:4:3:1. In agreement with the molecular modeling calculations, the two
major rotamers, A and B, both have the carbonyl group syn to H-l.

rotamer A: 75.98kcalmol—1

rotamer B: 76.04kcalmol

rotamer C: 76.44kcalmol l

rotamer D: 77.22kcalmol ]

Figure 5.2: Conformational modeling calculations for 197.

The syn relationship of the H-l proton to the carbonyl group is evident in the pr

NMR by the downfield position of the H-l resonances at 5.75 and 5.83 for rotamers

and B, compared to its upfield positions at 4.41 and 4.52 for rotamers C and D. T
2' resonances are also slightly downfield for rotamers A and B, at 5.84-6.00ppm,

compared to the H-21 of rotamers C and D, at 5.50 and 5.54ppm. High resolution mas
spectral analysis confirmed the molecular formula of Ci9Hi879BrNO with an MH+
measured at m/z 356.0638 compared to a calculated value of 356.0650. The low

resolution mass spectrum showed the molecular ion as two peaks of equal intensity

m/z 356 and 358 for the bromine isotopes. Peaks at m/z 314/316 correspond to loss

propene, common for all these 1-allyl derivatives. A peak at m/z 132 supported th
presence of the core tetrahydroisoquinoline structure.

It was later discovered that a one-pot 1-allylation/JV-acylation procedure could

out to give the desired precursor 197 in 80% overall yield from 3,4-dihydroisoqui

(scheme 5.6), compared with 48% overall yield in the two isolable step process. T

one-pot reaction presumably proceeds by the direct acylation of the zinc intermed
218 (figure 5.3).

(i) allyl bromide
Zn, dry T H F
^

(ii) o-bromobenzoyl chloride

inn

147
Scheme 5.6: 1-Allylation/N-acylation of 3,4-dihydroisoquinoline 147.
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NZnBr

Figure 5.3: The zinc intermediate 218 in the 1-allylation of the imine 147.

5.4 PREPARATION OF THE TARGET CYCLISATION PRECURSORS

With conditions in place for the tetrahydroisoquinoline model system, attention was
turned to N-o-bromobenzoylation of the T B D M S protected key intermediate 155.
However, following the same procedure as for the model system, it gave only low to
moderate yields of the desired precursor 202 (scheme 5.7), with low overall mass
recoveries. This product 202 appeared as a mixture of four rotamers, with a ratio of
14:8:4:1, in the proton N M R spectra. The major rotamer exhibited a signal for the H-2
proton at 4.41ppm, significantly downfield from the H-2 signal in starting material 155
which appeared at 2.31ppm. Such a large downfield shift indicates that this proton is
syn to the carbonyl group in this rotamer. The H-6 protons also moved downfield, to
3.32-3.46ppm, but to a lesser extent. The benzoyl protons appeared in the aromatic
region as two doublets and two triplets. A quaternary carbon appeared at 169.22ppm
in the 1 3 C N M R spectra diagnostic of an amide carbonyl group. L o w resolution mass
spectral analysis (CI) showed the major peaks as pairs with N + : N + + 2 approximate
intensities of 1:1 indicating the presence of the bromine. Apart from the M H

+

base

peaks, the other two major peaks were consistant with losses of T B D M S O H and
T B D M S O C H 2 C H = C H 2 . High resolution mass spectrometry was used to confirm the
molecular formula of 202.
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MeO
OTBDMS
? H
MeO
OTBDMS
.. _
? H |
MeO,.

o-bromobenzoyl chloride
Et^N/DMAP

Me0

<

>

dichloromethane
r.t.
Scheme 5.7: N-Acylation of the T B D M S protected key intermediate 155.

Initially, due to the low yields obtained from the TBDMS protection of the key

intermediate 115, it was decided to try other silyl protecting groups together with d
TV-acylation in the presence of the free hydroxyl group, the N-acy\ product being

expected to be favoured thermodynamically. The latter acylation reaction proceeded but
gave only a low-22% yield of the desired JV-acylated product 201, together with 8% of
the diacylated product 219 (scheme 5.8), and two other compounds which ran with

slightly higher Rf values than the JV-acylated product 201 on TLC. Quantities of these
two unknown products were too small for an accurate and comprehensive analysis. The
/V-acylated product appeared as a mixture of four rotamers in the proton NMR spectra.
Again the H-2 resonance of the major rotamer was shifted significantly downfield from
the starting material, to 4.70ppm. A peak at 170.73ppm in the 13C NMR indicated the

presence of an amide carbonyl, while pairs of peaks of equal relative abundance in the
mass spectrum (CI), separated by two mass units, confirmed the presence of the
bromine. High resolution mass spectrometry was used to confirm the molecular
formulae of both the JV-acylated product 201 and the diacylated product 219.
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MeO
z

OH
H

(22%)

MeO
OH
= H
MeO

o-bromobenzoyl chloride
Et3N/DMAP
dichloromethane

MeO*

r.t.

115
MeO
O
= H

^O

(8%)

Scheme 5.8: Af-Acylation of the unprotected key intermediate 115.

As could be the expected, both major rotamers of 201 would have the carbonyl group

syn to H-l, whereas the minor isomers would have the ring in a chair conformation a
have the carbonyl group anti to H-l. Analysis of the NMR spectra does indeed

support four conformers with one major rotamer, A, and three minor rotamers, B, C a

D. Individual ratios could not be determined from the proton NMR. Integration of th
H-2" resonances gave a ratio for A+B : C+D of 5:1.

While Murahashi has reported the successful use of acyl cyanides as selective Nacylating agents in the presence of primary and secondary alcohols,250 however, the
required acyl cyanides were not readily available and this avenue was not explored
further as an alternative route to 201.

Reaction of the TMS-protected key intermediate 156 with o-bromobenzoyl chloride

proceeded initially on a small scale to give 25% of the desired product 203 togethe
31% of the desilylated/N-acylated product 201 (scheme 5.9). However, no O- or di-
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acylated products were observed which indicated that loss of the T M S group occurred
during work-up. This reaction on a larger scale gave, after purification, 7 0 % of the
desilylated/iV-acetylated product 201. The TMS-protected bromobenzoylpiperidine
203 again appeared as a mixture of four rotamers in the proton N M R with a ratio of
6:5:2:1. Rotamer A (the major rotamer) and C (the third most abundant rotamer) both
appeared to have the carbonyl group syn to H-2 as this proton resonates downfield at
4.59 and 4.73ppm respectively, whereas for rotamer B and D H-2 appeared at 3.56 and
3.65ppm respectively. The signals for the alkene C H protons also appeared further
downfield in rotamer A and C as ddd at 6.12 and 5.99ppm respectively. For rotamers B
and D this same proton appeared at 5.57 and 5.66ppm respectively. The carbonyl
peaks of the two major rotamers were observed in the
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C N M R at 169.27ppm for

rotamer A , and at 169.76ppm for rotamer B, consistent with an amide carbonyl. Three
methyl signals due to T M S could be observed in the 1 3 C N M R at 0.44, 0.51 and
0.58ppm. L o w resolution mass spectrometry (CI) revealed a series of peak pairs (in a
1:1 ratio and two mass units apart in each case), at m/z 486 (base peak), 396, 356 and
255, which corresponded to M H + , loss of T M S O H , loss of T M S O C H 2 C H = C H 2 and
loss of 100 from 356. High resolution mass spectrometry confirmed the molecular
formula of 203.

MeO
MeO^

OTMS

/N/NvO
MeO
J
MeO
OTMS
r H
MeO

o-bromobenzoyl chloride
Et3N/DMAP
i

dichloromethane
r.t.

MeO

156

Br
203

\A

u

MeO ,. OH
T H
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Scheme 5.9: JV-Acylation of the T M S protected key intermediate 156.

5.5 CYCLISATION OF THE MODEL PRECURSOR

Ikeda recently reported free-radical cyclisation in a similar tetrahydroisoquinoline
system 251 which prompted us to report our o w n work in this area.252 Cyclisation of
the model precursor 197 was performed by the slow addition of a solution of tributyltin
hydride and A I B Nfree-radicalinitiator in toluene to a solution of 2-(o-bromobenzoyl)l-(2-propenyl)-1,2,3,4-tetrahydroisoquinoline 197 in refluxing toluene. Further reflux,
work-up, and column chromatography resulted in a 6 4 % isolated yield of the cyclised
product,

7V-benzoyl-7-methyl-6,7,8,9-tetrahydro-5//-benzocyclohepten-5,8-imine

198/199, together with a 1 2 % yield of the debrominated reduction product, N-benzoyll-(2-propenyl-1,2,3,4-tetrahydroisoquinoline 220 (scheme 5.10).

A small amount

(0.5%) of what appeared to be stannylated product 221 w a s also isolated.

OCV

• Me

I

II

Bu3SnH, AIBN
toluene
-•
reflux

^

^

' I D , /"

\ y

221

Scheme 5.10: Cyclisation of 2-(o-bromobenzoyl)-l-(2-propenyl)-1,2,3,4tetrahydroisoquinoline 197.

Although cyclisation gave exclusively the 5-exo-trig product, a mixture of diastereome
in a 2:1 ratio, was obtained. These results are consistent with those from the analogous
piperidine system reported by Ikeda et al.246

Preference for hydrogen atom transfer

from the 3-position to the aryl radical initially generated from 197 can be explained in
terms of the likely preferred amide rotamer being as shown in scheme 5.5.1. Although
hydrogen atom transfer from the 1-position would lead to the more stable benzylic
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radical, this probably either did not occur due to steric considerations, or else did occur,
followed by B u 3 S n H reduction to give the reduction product 220. S o m e of the major
diastereomer 198 (figure 5.4) w a s isolated by multi-sweep preparative thin layer
chromatography. The exo cyclised structure was clearly evidenced in the proton N M R
of this diastereomer by the methyl doublets at 1.02ppm and 1.19ppm for the minor and
major rotamers respectively.

198
Figure 5.4

Mechanistically, this 5-exo major diastereomer is from the 5-exo chair transition state,
with the minor diastereomer due to cyclisation through the 5-exo boat transition state
(figure 5.6). Semi-empirical molecular modeling calculations reveal heats of formation of
24 and 26kcalmol —l for the chair and boat transition states respectively.

This is in

agreement with the experimental observations. Calculations for the third energetically
significant transition state, the 6-endo chair (figure 5.5), reveal a heat of formation of
79kcalmol — 'and explain w h y the product from this transition state is not observed for
this system.

5-exo-chair

5-exo-boat

A E f o r m = 23.94kcalmol _1

A E f o r m = 26.04kcalmol"
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6-endo-chak
AE f o m i = 79.04kcalmor1
Figure 5.5: Transition state energy calculations for cyclisation of 197.
Conversion of the amide 198 to the secondary amine 200 was then investigated. Base
hydrolysis

of the amide 198 was first tried with

lithium hydroxide

water/tetrahydrofuran biphasic mixture at room temperature.

in a

This method only

returned starting material 198 with a 9 2 % mass recovery. Reduction of the amide 198
was also attempted with D I B A H in cyclohexane at 0°C following the procedure of
Yoon, 253 but again only starting material 198 was recovered from the reaction mixture.
Presumably conditions were too mild for this bridged system.

More forcing conditions using refluxing 6M hydrochloric acid were then tried.254 Thus
debenzoylation of the major diastereomer 198 with aqueous hydrochloric acid gave the
free amine, 7-methyl-6,7,8,9-tetrahydro-5i/-benzocyclohepten-5,8-imine 200 after basic
work-up (scheme 5.5.2). 2 D N M R experiments ( H S Q C and H M B C ) were used to
assign the lH and

13

C resonances of this compound.

The relative stereochemistry

across the C 7 - C 8 bond has been assigned as cis due to the H-8 resonance at 3.39ppm
being a doublet (J8,9=4.9Hz), and the H-7
(^7,6=«^7,Me=6-8Hz) at 2.10ppm.

proton

a doublet of quartets

High resolution mass spectrometry (chemical

ionization) confirmed the molecular formula of C12H15N for 200.
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Me

(i) 6M aq. HC1
reflux
^

(ii) aq. N a O H
198

200

Scheme 5.11: Debenzoylation of the model cyclisation product 198.

Previous approaches to this ring system all involve 1,3-dipolar cycloadditions and
such the products are unsaturated in the 9 position and mostly have electron
withdrawing groups in the 6 or 7 positions or both (figure 5.6). 255 " 260

EWG.H
Figure 5.6: General structure of products from previous syntheses of the
benzocyclohepten-5,8-imine ring system.
The synthesis developed in our work to the reduced 5//-benzocyclohepten-5,8-imine
system is a short and convenient one, with scope for the introduction of other
substituent groups.

5.1 CYCLISATION OF THE TARGET CYCLISATION PRECURSORS

Cyclisation was first undertaken on the TBDMS-protected amide 202 (scheme 5.12).
This resulted in a mixture of products which were not able to be separated by
preparative thin layer chromatography. Although the proton N M R

of the product

mixture was very messy, the mass spectrum (CI) was very clean with a base peak at
m/z 450 corresponding to the M H

+

ion expected for the cyclisation products (206 and

207), and only one other significant peak at rn/z 214 whose mass w a s consistent with
loss of both the T B D M S group (as T B D M S O H ) and the benzoyl group. It was
decided to directly debenzoylate/desilylate to facilitate identification of the products by
N M R , and perhaps allow for their separation. The benzoyl functionality confused the
N M R by introducing rotamers, and the tert-butyl of the T B D M S

protecting group
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masked the position of the methyl doublets in the proton N M R .

The method

previously used on the model compound 198 to debenzoylate was selected as it was
hoped that such conditions ( 6 M

aq. HCl/reflux) would concurrently desilylate.

Unfortunately debenzoylation did not occur, but desilylation did, and the product
mixture was able to be separated. Purification of the products gave the 5-exo 7-epimeric
cyclisation products 204 and 222 (3.4% over 2 steps) as almost exclusively a single
diastereomer 204 (>90%), together with the 6-endo cyclisation product 205 (10.6% over
2 steps) (scheme 5.12). Thus cyclisation of the TBDMS-protected allylpiperidine was
6-endo selective.

This w a s in direct contrast to cyclisation of the hydroxy

allylpiperidine 201 which gave the 5-exo cyclisation product 204 in a 2 8 % yield
compared to the 6-endo cyclisation product 205 which was isolated in a 9.8% yield
(scheme 5.13). Additionally, more of the 5-exo-trig minor diastereomer (29%) was
isolated with the major diastereomer (71%).

Thus cyclisation of the unprotected

allylpiperidine is 5-exo selective but diastereomeric selectivity is lost.

MeO

MeO
OTBDMS

MeO
OTBDMS
:
H
MeO
^

MeO

Q

MeO
206 H
AIBN, Bu3SnH

204 + 222
(3.4%)

6MHC1

toluene
A

MeO
OTBDMS

202
MeO*
207

205

(10.6%)

not separated
Scheme 5.11: Cyclisation and desilylation of the TBDMS-protected allylpiperidine 202.

High resolution mass spectrometry confirmed the molecular formula of the isolated
cyclisation products 204 and 205. N M R spectra of all the products exhibited a mixture
of two rotamers. D E P T analysis of the 6-endo-trig product 205 showed the two
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identifying C H 2 groups at 30.47ppm and 28.62ppm for the C-8 signals of the major and
minor rotamers, and 30.47ppm and 28.62ppm for the C-7 signals. Only three methyl
groups and six non-aromatic C H groups were found by D E P T analysis. The bridgehead hydrogens were ascribed to signals at 3.94-4.90ppm in the proton N M R .
MeO OH

MeO.

A T X
I
^

Me

^
MeO
^o

MeO „

9H

V

AIBN,Bu3SnH^
toluene

Xl^
^

- "
Me0

'

M e 0 *-

204 + 222
(28%)

201

Scheme 5.12: Cyclisation of the unprotected allylpiperidine 201.

The methyl doublets were the most distinguishing and identifying features in the N M R
spectra of the 5-exo-trig cyclisation products 204 and 222. These appeared as pairs of
doublets due to hindered rotation about the amide bond. For the major diastereomer 204
these signal appeared at 1.13 and 1.28ppm, and for the minor diastereomer 222 at 0.95
and 1.04ppm. D E P T analysis revealed no C H 2 groups, four methyl groups and seven
non-aromatic C H groups. The presence of the benzoyl group was clear in the aromatic
region of the proton N M R (7.37-7.59ppm) and 13 C N M R (127-130ppm) spectra. The
stereochemistry at C-7 of the major diastereomer 204 was deduced from coupling
constants in the proton N M R . H-7 did not couple at all with H-l indicating a dihedral
angle close to 90 degrees, and thus an axial H-7 with the methyl group at C-7 must be
exo and equatorial (figure 5.7). This is compared to the H-6 equatorial proton which is
coupled to H-5 with a constant of 6.8Hz. Lack of coupling between H-5 and H-4
indicate H-4 is also in an axial position.
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Figure 5.7: Stereochemistry of the major diastereomer.

Finally, demethylation of the diastereomeric mixture 204/222 was attempted using
boron tribromide to give positive initial results. Aqueous work-up was expected to take
the desired product 224 into water. Evaporation of this phase and preparative thin
layer chromatography (silica, 9 5 % ethanol) did not allow isolation of the fully demethylated product. Further purification by ion exchange chromatography was also to
no avail. However, mass spectral analysis (CI) of the crude solid residue from the
organic phase revealed the presence of unreacted starting material 204/222 as a minor
component, together with mono-demethylated product and di-demethylated product,
the latter appearing as the major component. A mixture of all three possible didemethylated products were isolated from a single band from the P T L C plate. Proton
N M R exhibited three methoxy singlets at 2.92, 2.99 and 3.53ppm, whereas the mass
spectrum (CI) revealed a single M H

+

ion at m/z 308, corresponding to the mono-

methylated products, including 210. Unfortunately, quantities and time did not allow
for further investigation into this reaction and products.

These initial results are

extremely positive and are proof of concept that the methyl groups can be removed
under these conditions.

Figure 5.8: O n e of the mono-methylated products 210.
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CHAPTER 6

1,3-DIPOLAR CYCLOADDITIONS
6.1 SCHEMATIC OVERVIEWS

N ^

.CHO

225 ^ O
nitrone formation / \ oxime formation

"r^»4
1,3-dipolar
cycloaddition

'0-%e
Scheme 6.1: Preparation of model 1,3-dipoles and attempted cycloadditions.
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^^COoEX

Scheme 6.2: Attempted preparation of an amine 1,3-dipole precursor 232.

N-alkylation

NH

C02Me

*-

reduction

CHO

nitrone formation

1,3-dipolar
cycloaddition

O

N

Me

Scheme 6.3: Alternative route to an amine 1,3-dipole precursor 234.
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6.2 BACKGROUND

1,3-Dipolar cycloaddition reactions (scheme 6.4) have played a prominent role in
organic synthesis.261-263 The main attraction of these reactions is the formation of up

4 stereocentres in one step and in usually a highly regio- and stereo-selective manner

1,3-dipCe aj>

"i C h-J
dipolarophile

d =e

Scheme 6.4: Generalised 1,3-dipolar cycloaddition reaction.262

A review of the mechanistic evidence by Huisgen in 1963 led to the conclusion of a
single-step concerted mechanism.264 However, in 1968 Firestone proposed a multi-step
mechanism proceeding through a 1,5-diradical intermediate.265 These conclusions were
refuted by Huisgen266 and the ensuing debate267 lasted for almost two decades when in
1985 Firestone and Houk presented evidence which proved Firestone's own mechanism
to be incorrect.268 Thus the conflict ended and the mechanism was declared to be
unequivocally a concerted one. Interestingly, Huisgen has found examples of 1,3dipolar cycloadditions which proceed through a two-step mechanism, although the
intermediate was determined to be a 1,5-zwitterion and not a diradical.269

Frontier Molecular Orbital (FMO) theory was used to fully explain the mechanism and
the regioselectivity observed.270- 271 Three reaction types for cycloadditions are

observed (figure 6.1) depending on the nature Of both the dipole and the dipolarophile
and specifically the relative energies of their LUMOs (lowest unoccupied molecular
orbital) and HOMOs (highest occupied molecular orbital).272-273 When the LUMO of
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the dipole is closer in energy to the H O M O of the dipolarophile, than its H O M O is to
the LUMO of the dipolarophile, then the reaction is said to be dipole LU controlled.
When the HOMO of the dipole is closer in energy to the LUMO of the dipolarophile

then the reaction is dipole HO controlled. When energy differences are similar for bo
cases then neither control mechanism is dominant and the reaction is termed dipole
HO,LU controlled. Diels-Alder reactions are generally considered dipole HO
controlled, whereas [3+2] cycloadditions using nitrones are usually dipole LU
controlled.263
1,3-dipoles

dipolarophile

LUMO

41HOMO

41-

4141-

type I

type II

typem

dipole H O
controlled

dipole H O , L U
controlled

dipole L U
controlled

Figure 6.1: Illustration of the three cycloaddition reaction types.

W e decided to utilise nitrones and oximes as these lead to an internal N - 0 bond which

can be cleaved reductively to give an amine and an alcohol, desirable functional gro
for potential glucosidase inhibitors. These dipoles are both readily prepared by
condensation of an aldehyde with a hydroxylamine (scheme 6.5).
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R'NHOH

H

©
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R- -C—N- -o
H

I

I

R'

•CHO
NH2OH

R—C=N—OH

H
1,2-diprotic shift

©

ft

©

0

©

R—C—N—O
H H
H H
Scheme 6.5: General preparation of nitrones and oximes, and illustration of their 1,3R—C=N—O

dipolar nature.

It may not be immediately apparent that the oxime can indeed act as a 1,3-dipole.
Usually oximes are converted into nitrile oxides by oxidation with sodium
hypochlorite,274 however, thermolysis of oximes in the presence of a dipolarophile has

led to cyclisation also. It has been postulated that this is due to a 1,2-diprotic shif
give a nitrone intermediate (scheme 6.5).275

6.3

PREPARATION

OF

THE

1,3-DIPOLES

AND

ATTEMPTED

CYCLOADDITION REACTIONS ON THE MODEL SYSTEM

Initially, it was planned to study the possibility of intramolecular 1,3-dipolar
cycloadditions in the 1-allyl-1,2,3,4-tetrahydroisoquinoline system, and as a starting

point for this, the introduction of a suitable functionality on nitrogen for eventual 1,
dipole (specifically nitrone) formation was investigated.

Aminolysis of lactones promoted with triethylamine/aluminium chloride seemed an
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ideal starting point in the synthesis. The reaction wasfirsttrialled with the non-benzfused piperidine system to verify its effectiveness. Thus piperidine reacted with ybutyrolactone to produce piperidinyl 4-hydroxybutanamide 238 in 8 3 % yield (scheme
6.6). The product gave the correct molecular weight for the M H + ion in the high
resolution mass spectrum (CI). A n amide carbonyl stretch in the IR at 1626cm"1 and a
broad O H stretch at 3410cm -1 was consistent with a hydroxyamide. This was supported
in the proton N M R by the hydroxyl group appearing as a broad resonance at 3.78ppm,
together with the amide carbonyl carbon at 171.56ppm in the 1 3 C N M R . Both the
proton and

C N M R revealed the piperidinyl group as asymmetric due to amide

rotamers.

Q

+

JH

v7

AlCl3/NEt3
chloroform

83%

Scheme 6.6: Reaction of piperidine with y-butyrolactone.

Reaction of piperidine with 8-valerolactone afforded piperidinyl 5-hydroxypentanamid
239 in 7 7 % yield (scheme 6.7). Again, a correct M H

+

in the high resolution mass

spectrum was obtained together with the requisite hydroxy and amide carbonyl stretches
in the IR spectrum (at 3419 and 1608cm" 1 respectively). N M R spectrometry also
supported the product structure.

O^
NH

+

O^

-

AlCl3/NEt3
chloroform

77%

Scheme 6.7: Reaction of piperidine with 8-valerolactone.

Both these reactions were then carried out on the model tetrahydroisoquinoline
intermediate 116. Thus reaction of 1-allyl-1,2,3,4-tetrahydroisoquinoline 116 with y-
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butyrolactone again proved successful with a yield of 6 5 % of the desired hydroxyamide

product 224 (scheme 6.8). High resolution mass spectrometry confirmed the molecula
formula for the MH+ ion of this compound. A mixture of rotamers was apparent in the
proton and 13C NMR with two amide carbonyl peaks appearing at 172.30 and
172.43ppm. The H-l proton moved significantly downfield to 4.93ppm for the minor
rotamer, and to 5.69 for the major rotamer.

NH

O

+

AlCiyNEta
chloroform

o^Q

65%

Scheme 6.8: Reaction of 1-allylTHIQ 116 with y-butyrolactone.

Swern oxidation of this hydroxyamide 224 proceeded smoothly to give a 65% yield of

the purified aldehyde 225 (scheme 6.9). The aldehyde functionality was confirmed b

resonances at 9.85 and 9.86ppm for the two rotamers in the proton NMR, together wi
an aldehyde carbonyl peak at 201.21ppm in the 13C and DEPT experiments. High

resolution mass spectrometry was used to successfully confirm the molecular formul

(COCl) 2 /DMSO
dichloromethane
CHO

65%

Scheme 6.9: Swern oxidation of the hydroxyamide 224.

Reaction of the aldehyde 225 with hydroxylamine afforded the oxime 227 in 86% yield

(scheme 6.10). Other workers have directly used oximes in 1,3-dipolar cycloaddition
simply by heating. Attempts with this oxime 227 gave only starting material (12%
mass recovery) with no other products able to be isolated.
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'

NH^H-HCl
NaOAc

^

o
225

methanol
86%

Scheme 6.10: Oxime formation from the aldehyde 225.

Nitrone formation using N-methylhydroxylamine with the aldehyde and heating of the
reactive intermediate was hoped to yield the 1,3-dipolar cycloaddition product. Nitrone
formation (scheme 6.11) and attempted cyclisation gave the same result, but with the
isolation of a little of the nitrone intermediate 226. The proton N M R of this product
revealed the two methyl singlets at 3.6ppm (due to rotamers) and an imine C H at
6.95ppm. Mass spectrometry confirmed the formula. N o n e of the aldehyde starting
material 225 could be seen in the proton N M R of the product mixture, as noted by the
lack of the distinguishing C H O protons at 9.85 and 9.86ppm.

MeNHOH-HCl

v

•©,00

"*- , ^ T"Y 1L
ethanol

225
Sheme 6.11: Nitrone formation from the aldehyde 225 .

It was thought again that perhaps the amide carbonyl was preventing the 1,3-dipole and
dipolarophile from coming into close enough proximity to each other for a reaction.
Attention was thus again turned towards the amine equivalent.

N-Alkylation of 1-allyl-1,2,3,4-tetrahydroisoquinoline with 3-bromopropanol procee
smoothly to give the alcohol 230 in 5 6 % yield after purification by flash silica
chromatography (Scheme 6.12). The molecular formula w a s confirmed by high
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resolution mass spectrometry. In the proton N M R , the H-l resonance shifted slightly
upfield from that in the starting material 116 (4.05ppm) to 3.75-3.85ppm. The hydroxy
proton was clearly seen as a broad singlet at 4.61ppm.

13

C N M R showed the required

seven C H 2 groups in the D E P T analysis.

3-bromo-1 -propanol
K2C03
acetonitrile
56%

Scheme 6.12: Preparation of the aminoalcohol 230.

Swern oxidation of the alcohol was tried several times but none of the desired aldeh
could be isolated and only very low mass recoveries from the organic phase were
obtained after aqueous work-up. It was postulated that the majority of the product(s)
were water soluble and remained in the aqueous phase. O n e possible explanation for
this observation is that the amine m a y be oxidised to a resonance stabilised iminium ion
240 (figure 6.2). Oxidation was also attempted using pyridinium chlorochromate but to
not avail. Jones' reagent w a s also tried as it w a s thought that the acidic conditions
would protonate the amine protecting it from oxidation. Unfortunately, this was also
unsuccessful. It was thus decided to try and prepare the aldehydes by reduction of the
esters instead.

Figure 6.2: Possible product from Swern oxidation of the alcohol 230.

N-Alkylation of 1-allyl-1,2,3,4-tetrahydroisoquinoline with methyl 4-iodobutanoate
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proceeded to give the desired ester 231 in 3 9 % purified yield (scheme 6.13). The H-l
resonance was again moved upfield to 3.69ppm in the proton NMR spectrum. DEPT
analysis revealed a further three CH2 peaks and a methyl resonance at 51.40ppm. The
ester carbonyl appeared in the 13C NMR at 174.28ppm. High resolution mass
spectrometry confirmed a molecular formula of C17H24NO2 for the MH+ ion.

methyl 4-iodobutyrate (| j
K

2CQ3

acetonitrile

\J*AslNv^vv^C02Me
I

(39%) * | 233
Scheme 6.13: Preparation of the ester 233.

Selective reduction of esters to aldehydes is an important process in synthetic or
chemistry. This transformation is generally instigated by the use of 1 equivalent
wobutylaluminium hydride (DIBAH) at temperatures which must be carefully
maintained below -60°C to prevent over-reduction to the alcohol. Some esters have

proven difficult to selectively reduce to the aldehyde due to the ease of reductio
aldehyde intermediate to the alcohol.

Reduction of the methyl ester 233, even with careful temperature control, was not a

to produce exclusively the aldehyde reduction product 234, with the more polar alc
235 appearing early in the TLC of the reaction mixture (scheme 6.14). Work-up and
purification gave a 27% mass recovery of the ester starting material 233 and only
yield of the aldehyde 234. 13C NMR spectrometry of this aldehyde product 234 showed

the downfield shift of the carbonyl carbon to 202.4 lppm, together with its appear
in the DEPT spectrum. The aldehydic proton was also present in the proton NMR as a

triplet at 9.79ppm. High resolution mass spectrometry confirmed the molecular form
for the MH+ ion of the product 234.
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DIBAH
toluene

CHO

+

235

-78°C to -60°C

Scheme 6.14: D I B A H reduction of the methyl ester 233.

The nitrone was formed from the aldehyde in situ and then refluxed in ethanol in th
hope of initiating the desired 1,3-dipolar cycloaddition (scheme 6.15). The nitrone
formation proved successful with the disappearance of the aldehyde proton in the proton
N M R . Unfortunately though, none of the desired cycloaddition product 237 was in the
product mixture as shown by the presence of the allyl group in the proton and 13 C N M R
spactra. Further evidence for the nitrone 236 was obtained from the mass spectrum
(CI) where the M H + ion appreared at m/z 273 with a base peak at m/z 257
corresponding to loss of either the nitrone methyl group or oxygen. High resolution
mass spectrometry confirmed the molecular formula. The 13 C N M R spectrum exhibited
an extra C H peak at 140.64ppm, and the proton N M R a triplet at 6.75ppm, which
correspond to the C H of a nitrone.

CHO

NHMeOH-HCl
pyridine

•
ethanol

Scheme 6.15: Nitrone formation from the aldehyde 234.

As the eight membered ring was proving difficult to prepare from the amine, it was
proposed that cycloaddition to form the seven membered ring m a y be more likely. This
required preparation of the aldehyde 232 which, it was found, could not be prepared
from the alcohol 230. However, due to the success, albeit limited, of the selective
reduction of the ester 233 to the aldehyde 234, it was decided to take this route to the
desired aldehyde 232. N-Alkylation of the amine 116 with ethyl 3-bromopropanoate
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gave the pure ethyl ester 231 after silica gel chromatography (scheme 6.16). Alkylation
was shown to occur due to the upfield shift of the H-l resonance from 4.05ppm in the
amine starting material 166 to 3.69ppm in the product 231. Furthermore, an extra three
C H 2 groups and one C H 3 group appeared in the D E P T N M R . A quaternary carbon at
172.68ppm in the 1 3 C N M R was consistent with an ester carbonyl. High resolution
mass spectrometry confirmed the molecular formula.

ethyl 4-iodopropionate
K2C03
^.
acetonitrile

Scheme 6.16: Reaction of the three-carbon bromoester with 116.

The planned selective reduction of the ester 231 with DIBAH to give the aldehyde 232
did not proceed. Instead, the product mixture contained only ester starting material 231
and the fully reduced alcohol 230 (see scheme 6.2), even with careful monitoring by
T L C and temperature control to below -60°C. Obviously reduction from the aldehyde
232 to the alcohol 230 was more facile than that from the ester 231 to the aldehyde 232.

Finally, this investigation had to be terminated due to time constraints. It would be
advisable that any future work in this area be preceded by extensive molecular
modelling studies, which were not available at the beginning of this project.
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CHAPTER 7

CARBAMATE RING EXPANSION

Following the success of Ishibashi to ring expand the carbamate in the 2-oxazolidi

241276 (scheme 7.1) it was decided to try this reaction on the chlorocarbamate 15
direct route to a B-ring expanded castanospermine analogue.

U HSCH2C02Et H
/ 1^\
/
I O
\ ^ N^ /

1

PrONa
•
propanol

A

en

241 ° 242 °
Scheme 7.1: Ring expansion of the 2-oxazolidinone 241.

Exposure of the chlorocarbamate 153 to ethyl thioglycolate under strongly basic
conditions led to the isolation of the 1,4-thiazinone 243 (scheme 7.2), albeit in
yield. The mass spectrum (CI) of the product 243 exhibited a base peak at m/z 392
corresponding to MH+. High resolution mass spectral analysis reported this ion at

392.1744, compared to a calculated value of m/z 392.1743 for the molecular formula
C]7H3oN07S. DEPT analysis revealed five CH peaks, six CH2 peaks and four CH3

peaks. However, repetition of this work proved difficult and will be required to b

undertaken on a larger scale in order to provide enough of the product 243 for ful
characterisation by 2D NMR spectroscopy, and glycosidase inhibition testing.
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HSCH2C02Et
PrONa

9

OCH 2 C0 2 Et
H

MeO.

• Y
propanol

M e O [_

Jj

243

O

Scheme 7.2: Ring-expansion of the chlorocarbamate 153.

Mechanistically, formation of this product can be rationalised as shown below (s
7.3).
^--SCHgCOzEt

Me
-cr

? H\n

MeO*. X^ ? l^—o

MeO -^IJ/j^^CHsCOga
153

O

SCH 2 C0 2 Et

-COS

OCH 2 C0 2 Et
MeO

"OCH 2 C0 2 Et
H
-EtO"

MeO
= H
MeO
MeO

Scheme 7.3: Possible mechanism of formation of the product 243.

While this formation of 243 was of some interest, other synthetic priorities in the
project meant that it was not pursued further.

108

CHAPTER 8

CONCLUSIONS AND FUTURE W O R K
Although we were unable to find a novel route to the elimination product from
castanospermine 1 in order to synthesise casuarine 114, the synthetic work carried out has
provided useful information on the chemistry of castanospermine 1. It has also revealed a
limitation to the use of palladium chemistry to intramolecularly iV-alkylate an ethenyl
carbamate, specifically the castanospermine derivative 124 (figure 8.1).

O
124
Figure 8.1

We have successfully prepared several B-ring-modified analogues of castanospermine.
This work initially began with the preparation of the key protected intermediates 155 and
156 (figure 8.2) from castanospermine 1, achieved in 6 steps and with 4 9 % and 4 6 %
overall yields respectively. These compounds contain the amine and alkene functional
groups which have been used for further elaboration. A model intermediate 116 (figure
8.2), containing these principal functionalities but lacking the other spectator groups, was
used to investigate the subsequent reactions prior to their application on the key compounds
155 and 156.
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MeO H OTBDMS
MeO
eO^ X^ = X ^ MeO.
MeO

OTMS
principal
functional
groups

MeO
155

156
Figure 8.2

Ring closing metathesis with the model system allowed for the formation of both the fused

six- and seven- membered ring compounds, 177 and 178 respectively (figure 8.3). A fused
six membered ring was also formed from the castanospermine derivative 181 to give a

quinolizidine product 117 (figure 8.3). The alkene moiety of the B ring of this produc

forms a starting point for a series of reactions for future investigation. These react
include Sharpless asymmetric dihydroxylation and epoxidation, and 1,3-dipolar

cycloaddition reactions. Each of these potentially can lead to more hydroxyl groups and
amine groups which form the basis of glucosidase inhibition by castanospermine 1 and
analogues.

MeO
MeO.

OTBDMS

r H

MeO

177

117

178
Figure 8.3

Free-radical cyclisation was carried out on the model compound 197 as a novel route to

benzocyclohepten-5,8-imine ring system found in the product 200 (figure 8.4). Cyclisat
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with the castanospermine derivatives 201 and 202 gave mixtures of the 5-exo 204 and 6-

endo 205 products, with the 5-exo favoured for 201 and 6-endo favoured for 202 (sch

8.1). Initial demethylation of the desilylated 5-exo product gave positive, although
comprehensive, results. Future work in this area would involve complete deprotection

these products and biological testing. This reaction has provided a novel route to a

alkaloid derivative 204 lacking the bridgehead hydroxyl characteristic of the calyst
wortropane alkaloids.

.Me
200 ^/

Figure 8.4
MeO
OH
= H
MeO
MeO
major

MeO

204

OTBDMS
MeO

z H

MeO

Scheme 8.1

1,3-Dipolar cycloaddition investigations with the model system did not prove success

and so were not applied to the castanospermine system. However, several novel nitrone
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and oximes were able to be isolated together with the discovery of the possible oxidation of
the tetrahydroquinoline system under conditions used to oxidise alcohols. It is advised that
any future w o r k in this area begin with molecular modelling calculations of the
cycloaddition transition states.

Ring-expansion from the chlorocarbamate 151 has given the novel pyrido-fused 1,4thiazinone 243 (Figure 8.5). Loss of the alcohol substituent would lead to a structurally
interesting c o m p o u n d for glycosidase inhibitor activity testing.

HO f^^OCHgCOjpEt

V^ y^ s
N

HCAX
243

^
O

Figure 8.5
M a n y novel and functionally interesting compounds have been synthesised in the course of
this project. Initial synthetic problems were overcome to produce the key intermediates for
further elaboration into B-ring modified analogues of castanospermine 1. A s is often the
case, this project has also led to the synthesis of another compound 117 which could act as
a key intermediate in a future body of work. Although biological testing remains to be
carried out, these compounds provide a diverse range of possible glucosidase inhibitors. A s
such, their activity, or lack thereof, will lead to further conclusions on structure-activity
relationships of the glucosidase inhibitors.
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CHAPTER 9

EXPERIMENTAL
9.1 GENERAL

1. All new (i.e. unlisted in Chemical Abstracts) compounds have been written in ita
wherefirstreported with spectral data.
2. Infrared spectra (I.R.) were recorded on a Hartmann and Braun B o m e n FTIR
spectrometer ( M B series) as potassium bromide discs or as a thin film as specified.
3. UV-Vis values were recorded on a Shimadzu UV-265 Recording Spectrometer.
4. N M R spectra were obtained using a Varian Unity 300, operating at 300.1MHz for
l

H and 75.5MHz for 1 3 C nuclei, or a Varian Unity 400 spectrometer, operating at

3 9 9 . 9 M H z for *H and 100.1MHz for 1 3 C nuclei. ! H and 1 3 C spectra are reported as
parts per million downfield shift from tetramethyl silane as internal reference
(Oppm). The lU N M R is reported as chemical shift followed by relative integral,
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multuplet, br. =
broad), coupling constants, and assignment. Where two rotamers were observed
they are identified as major or minor. Where three or more rotamers were observed
they are identified as A , B, C etc. in descending order of abundance.
5. Chemical ionisation (CI) and electron impact (EI) low resolution mass spectra
( L R M S ) were recorded on a Shimadzu QP-5000 mass spectrometer using a direct
insertion probe. /so-Butane was used as the reactant gas for chemical ionisation
spectra. Electrospray (ES) low resolution mass spectra were recorded on a V G
Quattro mass spectrometer. Most high resolution mass spectra ( H R M S ) were
obtained using a Fisons/VG Autospec-TOF mass spectrometer. Polyethylene
glycol was used as the internal standard for E S - H R M S . Perfluorokerosene was used
as the internal standard for CI and E I - H R M S . The high resolution liquid S I M S data
( L S I M S ) was obtained on a Kratos Concept spectrometer (Cs ion source) using m-
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nitrobenzyl alcohol for the liquid matrix (Central Science Laboratory, University of
Tasmania)
6. Analytical thin layer chromatography (TLC) was carried out using aluminium
backed 0.3mm plates of Merck Silica gel 60 F254. U V light or iodine was used for
detection of spots. Preparative thin layer chromatography (PTLC) was carried out
on 1 m m plates of Merck Silica gel 60 F254. Flash silica column chromatography was
carried out using Merck Silica gel 60 0.040-0.063mm (230-400 mesh).
7. Reagents and solvents were purified with reference to Perrin and Amarego. 277
Dry solvents were prepared as follows:
•

Dichloromethane wasfreshlydistilled from calcium hydride.

•

Diethyl ether w a s distilled and then kept over calcium chloride for 24h and then
over calcium hydride. It was then usedfreshlydistilled from sodium
wire/benzphenone.

•

AyV-Dimethylformamide: Water was azeotropically distilled with benzene.
Benzene was then distilled off and the solvent left to stand over activated 4 A
molecular sieves for at least 24h.

•

Tetrahydrofuran wasfirsteither left over sodium wire or . It was then used
freshly distilled from sodium wire/benzophenone.

•

Methanol w a sfirstfractionallydistilled (b.p. 65°C) and then used freshly
distilled from calcium hydride.

•

Chloroform w a sfirstwashed with water to remove the ethanol, shaken and left
overnight over anhydrous calcium chloride and finally distilled from and stored
over activated 4 A molecular sieves.

•

Iodomethane w a s washed sequentially with 2 M sodium hydrogen sulphate,
water, sodium carbonate and water. It was dried with anhydrous calcium
chloride overnight, then distilled and stored in the dark over copper powder and
potassium carbonate.

Solvent compositions specified are mixed v/v.
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8. Reaction temperatures were controlled using ice/water (0°C), ice/water/calcium
chloride (-5°C to -30°C), dry ice/acetone (-65 to -78°C) or liquid nitrogen/acetone
slurry (-78 to -90°C).
9. "Drying" or "dried" refers to the use of anhydrous sodium sulphate.
10. Compound purity was confirmed by N M R , M S and T L C analysis.
11. Molecular modelling calculations were carried out on a Sun Workstation using the
Spartan modelling program. Ab initio calculation for the transition state modelling
used A M I calculations.

9.2 TOWARDS ELIMINATION ACROSS THE C1-C2 BOND OF
CASTANOSPERMINE 1

Enzyme-catalysed selective 1-O-acetylation of castanospermine 1

Subtilisin Carlsberg (46.6mg, EC 3.4.21.62, from Bacillus licheniformis) was diss
0.1M phosphate buffer (1ml, p H 7.8) and thenfreeze-driedover 4h.
A suspension of castanospermine 1 (11 l.lmg, 0.56mmol), Subtilisin Carlsberg (46.6mg
enzyme in buffer) and vinyl acetate (115uL, 1.2mmol) in pyridine (9.6mL) was shaken
at 160-180rpm and at 45°C for 6 days. The resulting slightly brown mixture was
filtered and solvent removed under reduced pressure. P T L C (silica, 9 5 % ethanol) gave
recovered castanospermine starting material 1 (47.5mg, 45%) and a mixture of monoacetylated castanospermine products (12.1mg, 11%) the major product in which is the
desired 1-0-acetylcastanospermine 120 (correct lU N M R and T L C behaviour).162

Selective 1-0-TBDMS protection of castanospermine 1
H
9 H OTBDMS
A suspension
of castanospermine 1 (497.6mg, 2.6mmol) and

bis(tributyltin)oxide (2.7mL, 5.3mmol) in toluene (24mL) was
refluxed with azeotropic removal of water for 2h under
115

nitrogen. Tetrabutylammoniu bromide (683.2mg, 2.1mmol) and tert-butyldimethylsilyl

chloride (738.0mg, 4.9mmol) was added and the colourless solution was refluxed for
The resulting brown solution was cooled, further ter/-butyldimethylsilyl chloride
(99.5mg, 0.66mmol) added and refluxing continued for lh. After removal of solvents
under reduced pressure, the brown solution appeared to solidify on standing with a

colourless surface layer. This was sonicated with 1% aqueous acetonitrile (30mL) a
washed with hexane (4x30mL). Aqueous solvents were removed under reduced

pressure. Purification by silica chromatography (ethyl acetate to ethylacetate + 5%
methanol) afforded l-0-(ferf-butyldimethylsilyloxy)castanospermine 126 (352.3mg,
44%yield) as a white crystaline solid (correct 'H NMR and TLC behaviour).159

Attempted iV-oxide formation with the 1-0-TBDMS-castanospermine 126

1-O-TBDMS-castanospermine 126 (49.7mg, 0.16mmol) was suspended in acetone
(3mL) by sonication. Aqueous hydrogen peroxide (30%w/v, 87uL, 0.77mmol) was

added and the white suspension was again sonicated and then refluxed for 15h. Remo

of solvents under reduced pressure gave a solid residue (32mg) which appeared to be
castanospermine TV-oxide by JH NMR spectral analysis.

N-oxide formation with the 1-0-TBDMS-castanospermine 126 and attempted
methylation of the product 137

1-O-TBDMS-castanospermine 126 (49.5mg, 0.16mmol) was dissolved in acetone (4mL)
by sonication. Aqueous hydrogen peroxide (35%w/v, 37uL, 0.4mmol) was added and

the resulting white suspension was refluxed for 12h. Upon cooling, Pt foil (18.2mg

added and the mixture stirred at room temperature for 2h. Removal of the foil and t
evaporation of solvents under reduced pressure gave 1-O-TBDMS-castanospermine N-

oxide 137 (51.2mg, 97%) as a white solid; This crude product was sonicated with dry

acetonitrile (3m). Silver oxide (126.3mg, 053mmol) and iodomethane (lOOmL, 1.6mmol
116

were added and the mixture refluxed under nitrogen for 38h. Solvent was removed under
reduced pressure and the residue was extracted with a mixture of methanol (30mL) and
dichloromethane (20mL) and filtered through celite. Solvents were again removed under
reduced pressure to give a white solid.
CI-MS: m/z 362 (16%, 138H+), 330 (15%, 138H + - M e O H ) , 262 (23%), 214 (19%),
190 (97%, 1H+), 172 (100%, (castanospermine 1 - H 2 0 ) + ) .

Triacetylation of 1-O-TBDMS-castanospermine
Ac

9H
Ac0

AcO

OTBDMS
vx^vL-(

White solid 1-O-TBDMS-castanospermine 126 (105.4mg,

X,.L

0.35mmol) and 4-(dimethylamino)pyridine (27.4mg,

N ^y
^^

0.22mmol) were dissolved in pyridine (4mL) and cooled to
0°C under nitrogen. Acetic anhydride (l.OmL, 10.6mmol) was slowly added and stirring
was continued for 15h at room temperature. Solvents were removed under reduced
pressure and the resulting orange oil was taken up in dichloromethane (15mL), washed
with saturated aqueous sodium hydrogen carbonate (15mL) and dried. After removal of
solvents under reduced pressure, the crude product was recrystallised from
ethanol/water to give 6,7,8-tri-O-acetyl-1-O-TBDMS-castanospermine 127 (97mg,
6 5 % ) as slightly off-white crystals (correct *H N M R and T L C behaviour).159

Attempted de-silylations

Using Zinc Tetrafluoroborate
Zinc tetrafluoroborate (39.6mg, 2.1mmol), 6,7,8-tri-O-acetyl-1-O-TBDMScastanospermine 127 (39.4mg, 0.093mmol), water (1.4mL) and acetonitrile (lmL) were
sonicated to give a cloudy suspension and then stirred at room temperature for 72h to
give a colourless solution. Solvents were removed under reduced pressure and the
resulting residue taken up in dichloromethane (6mL) and water (6mL). The organic
phase was separated and the aqueous layer was extracted with further dichloromethane
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(2x6mL). The combined organic extracts were dried and solvent was removed under
reduced pressure to give starting material 127 only (33.5mg, 8 4 % mass recovery).

Using 80% Acetic Acid
6,7,8-Tri-O-acetyl- 1-O-TBDMS-castanospermine 127 (33.5mg, 0.078mmol) was
stirred in 8 0 % aqueous acetic acid (lmL) for 3.3h. Saturated aqueous sodium hydroxide
(15mL) was added and the mixture extracted with dichloromethane (2xl2mL). The
combined organic extracts were dried and solvent was removed under reduced pressure
to give starting material 127 only (20.9mg, 6 2 % mass recovery).

Sample reaction of the ethenylcarbamate 124 with Pd (0)

A yellow solution of the ethenylcarbamate 124 (101.4mg, 0.39mmol),
tris(dibenzylideneacetone)dipalladium (0) (18.1mg, 0.02mmol) and 1,2bis(diphenylphosphino)ethane (54.4mg, 0.14mmol) in dry tetrahydrofuran (2mL) was
refluxed under nitrogen for 18h. After removal of solvents under reduced pressure the
residue was extracted with dichloromethane (5mL), washed with 2 % aqueous potassium
carbonate (lOmL), and extracted with 2 M hydrochloric acid (2x7mL). After drying,
solvents were removed under reduced pressure from the organic phase to give a yellow
solid (148.0mg) which appeared to be mostly starting material 124 by *H N M R spectral
analysis. N o evidence for an internal double bond was present in the N M R spectrum.
The acidic extracts were basified with 1 0 M sodium hydroxide (2.5mL) and backextgracted with dichloromethane (7mL) and then with ethyl acetate (7mL). The
combined organic extracts were dried and solvents were removed under reduced pressure
to give starting material (1.2mg) (correct 'H N M R and T L C behaviour).
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9.3 S Y N T H E S I S O F T H E K E Y I N T E R M E D I A T E

Preparation of the ring cleaved castanospermine 150
R'O
OTBDMS
R O . X^ - JL ^-v.
A white suspension of castanospermine 1 (6.05g,
CI
N
OMe
32mmol), imidazole (8.27g, 122mmol) and tertvV
TBDMSO
^-^
Y
R R" - TBDMS H O butyldimethylsilyl chloride (18.56g, 123mmol) in dry
A^/V-dimethylformamide (75mL) were sonicated and then
stirred at room temperature for 3 days under nitrogen. Solvent was removed under
reduced pressure (a little water was added to prevent excessive frothing during this
evaporation step). The resulting slurry was taken up in dichloromethane (200mL). The

resulting white imidazole precipitate was filtered off and the filtrate washed with w
(2xl00mL). The combined aqueous phases were re-extracted with dichloromethane
(30mL). The combined organic extracts were washed with brine, dried and then the
solvent removed under reduced pressure to give a colourless oil 148(14.49g).
This protected castanospermine 148 (14.43g, 32mmol), methyl chloroformate (140mL,
181mmol), anhydrous potassium carbonate (13.01g, 94mmol) and chloroform (70mL)
were refluxed under nitrogen for 13h to give a deep blue mixture. This mixture was
cooled and filtered through a plug of silica (washing the inorganic salts with
dichloromethane). The pale blue-green filtrate was washed with saturated aqueous
sodium bicarbonate, dried and solvents removed under reduced pressure to yield the
ring-cleaved castanospermine 150 as a pale blue oil (15.47g, 89%) (correct !H NMR)209
with a mean silylation of 2.3 TBDMS groups per molecule (by integration of the H-2'
triplet at 2.05ppm).
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Deprotection of the ring cleaved castanospermine 150

CI A dark green solution of the protected ring cleaved
N^/
0

castanospermine 150 (10.41g, assuming 2.6 T B D M S groups,
18mmol) and tetrabutylammoniumfluoridein tetrahydrofuran

(1M, 4 5 m L , 45mmol, 2.5equiv.) was stirred at room temperature under nitrogen for
2.2h. Solvent was removed under reduced pressure and the resulting oil dissolved in
dichloromethane (80mL) and extracted with water (lOOmL, 50mL). Solvent was
removed under reduced pressure from the combined aqueous extracts. Ion-exchange
chromatography (Dowex® 5 0 W - X 8 , cation exchange resin, 100-200 mesh, hydrogen
form) gave, in thefirst3fractions,the hexahydrotrihydroxy-oxazolopyridinone 151 as a
white-pale yellow semi-solid (3.84g, 8 5 % ) (correct ! H N M R ) . 2 0 9

Dehydrohalogenation to give the alkene carbamate 152

The hexahydrotrihydroxy-oxazolopyridinone 151 (540,4mg,
2.1mmol) and potassiumtert-butoxide(0.67g, 6.0mmol) in dry
O

tetrahydrofuran (15mL) and dry AyV-dimethylformamide (0.5mL)

were heated under reflux for 3h. After the solvents were removed under reduced
pressure, the residue was taken up in 1 M hydrochloric acid (14mL). The resulting
solution was basified with concentrated aqueous ammonia solution and the solvent was
again removed under reduced pressure to give a solid residue. Ion-exchange
chromatography (Dowex 5 0 W - X 8 , H + form) gave (l^,6,S',7i?,8/?,8ai?)-l-ethenyll,5,6,7,8,8a-hexahydro-6,7,8-trihydroxy-3//-oxazolo[3,4-a]pyridin-3-one 152 as a
crystalline solid (387. lmg, 8 4 % ) (correct 'H N M R and T L C behaviour).209

Carbamate cleavage and dehydrohalogenation of 151 to give the unprotected
double bond compound 154
HO
OH
HO^ ^ \ ? > V ^

Tne

hexahydrotrihydroxy-oxazolopyridinone 151 (198.3mg,

0.79mmol) was sonicated with a little dry NJVdimethylformamide to give afinesuspension. Dry
tetrahydrofuran (lOmL) and potassiumtert-butoxide(441.0mg, 3.9mmol) was added and
the mixture refluxed for 14h under nitrogen to give a brown mixture. Aqueous
potassium hydroxide (10%w/v, 3 m L ) was added and refluxing continued for a further
2h. After cooling, the brown aqueous phase was separted from the upper pale yellow
organic layer. The aqueous phase was acidified to p H 6 with aqueous acetic acid (1.7M,
2.5mL) and then basified to p H 8 with aqueous ammonia (28%w/w, 0.8mL).
Purification was carried out on tandem ion exchange columns. Thefirstwas the Yt form
of the D o w e x 5 0 W - X 8 . Aqueous hydrochloric acid (1M) was used to elute the sample.
The second used the N H / form of the column and the product was eluted with distilled
water. Evaporation of thefractionsgave (2R,3R,4R,5S)-2-(l'-hydroxy-2'-propenyl>
piperidine-2,3,4-triol as the hydrochloride salt 154«HC1 (140.6mg, 8 4 % ) (correct ! H
N M R and T L C behaviour).209

Methyl protection of the trihydroxy chlorocarbamate 151
2'

f^r»

The trihydroxy chloro-carbamate 151 was sonicated with dry

O 2

acetonitrile (4mL) to give afinesuspension. Silver (I) oxide
(2.45g, 10.6mmol) and methyl iodide (2mL, 32mmol) were
added and the mixture refluxed under nitrogen for 8h. The

mixture was thenfilteredthrough celite, and solvents removed under reduced pressure to
give a pale orange-brown oil. This was purified byflashsilica chromatography
(dichloromethane/ethyl acetate 9:1) to give l-(2-chloroethyl)-(lS,6S,7R,8R,8aR)1 5 6,7,8,8a-hexahydro-6,7,8-trimethoxy-3H-oxazolo[3,4aJpyridin-3-one 153 (0.8424g,

90%) as a pale yellow oil (measured M H + 294.1 111, calculated for C 1 2 H 2 iClN0 5
294.1108);
*H N M R (400MHz, CDC1 3 ): 5 2.10 (1H, dddd, Jla., 4.3Hz, J^^Jwav

8.0Hz, Jla. lb.

14.7Hz, H-l a'), 2.23 (1H, dddd, JWt2a.=Jlb.2b. 5.2Hz,Jlb., 8.8Hz, Jlb. la. 14.1Hz, H-lb*),
2.62 (1H, dd, 75a>6 10.3Hz, J5a,5b 13.2Hz, H-5a), 3.02 (1H, dd, J%>1~\u 9.0Hz, H-8),
3.09 (1H, dd, Jlte=Jn,% 8.8Hz, H-7), 3.12 (1H, dd, J8a>1 4.6Hz, J8a,8 9.3Hz, H-8a), 3.18
(1H, ddd, J6(5b 5.6Hz, J6J 8.8Hz, J6>5a 10.3Hz, H-6), 3.49 (3H, s, M e O ) , 3.627 (3H, s,
M e O ) , 3.629 (3H, s, M e O ) , 3.70 (2H, dd and dd, ^a'.ib^b'.ib1 5.3Hz, J2*M< 6.4Hz, J2V,la.
8.2Hz, H-2a' and 2b'), 4.09 (1H, dd, J5b;6 5.8Hz, J5b;5a 13.1Hz, H-5b), 4.54 (1H, ddd,
Ji,i^Ji.w 4.5Hz, y u b . 8.8Hz, H-l);
13

C N M R (75MHz, CDC1 3 ): 8 37.8 (C-T), 39.7 (C-2'), 42.2 (C-5), 58.6 (MeO), 60.8

(MeO), 61.1 (MeO), 61.2 (C-8a), 75.1 (C-l), 78.8 (C-6), 82.6 (C-8), 87.3 (C-7), 155.5
(C-3);
EI-MS: m/z 296/294 (35/100, M H + ) , 60 (41).

Dehydrohalogenation of the methyl protected intermediate 153
2'
Me

°fi H

TT
Me0

1

**s*

^
5

4

O 2
\

The oxazolopyridinone 153 (668.8mg, 2.3mmol), freshly
sublimed potassiumterf-butoxide(300.2mg, 2.7mmol) and dry
tetrahydrofuran (30mL) were refluxed under argon for 50min.
Solvent was removed under reduced pressure and the residue

taken up in dichloromethane (40mL). The solution was washed with water
(30mL,15mL) then saturated aqueous sodium hydrogen carbonate (12mL) and dried.
Solvent was removed under reduced pressure to give (IS, 6S, 7R,8R,8aR)-l-ethenyl-

1,5,6,7,8,8a-hexahydro-6,7,8-trimethoxy-3H-oxazolo[3,4a]pyridin-3-one 124 (501.4
86%) as a pale yellow oil (measured M H + 258.1343, calculated for C 1 2 H 2 0 N O 5
258.1341);
»H N M R (300MHz, CDC1 3 ): 5 2.62 (1H, dd, J5a,6 10.1Hz, J5a,5b 13.3Hz, H-5a), 3.03
(1H, dd, Js,7~Jm 8.9Hz, H-8), 3.10 (1H, dd, J7>6« J7,8 8.5Hz, H-7), 3.14-3.22 (2H, m,

H-6 and 8a), 3.49 (3H, s, MeO-6), 3.62 (3H, s, MeO-8), 3.63 (3H, s, MeO-7), 4.11

(1H, dd, y5b,6 5.5Hz, J5b>5a 13.2Hz, H-5b), 4.72 (1H, dd, J1;8a 4.3Hz, Jl>v 5.5Hz, H
5.32 (1H, d, JXcis,v 10.7Hz, H-2' cis to H-l'), 5.46 (1H, d, J2tram>
H-l') 5.90 (1H, ddd, JVtl 5.7Hz, Jv?cis 10.6Hz, Jr,

2W

v

17.2Hz, H-2'

17.2Hz, H-l');
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C NMR (75MHz, CDC13): 8 42.47 (C-5), 58.74 (MeO), 61.04 (MeO), 61.17 (MeO),

61.86 (C-6), 77.97 (C-l), 79.00 (C-8a), 82.59 (C-8), 87.48 (C-7), 118.02 (C-2'), 134.
(C-T), 156.03 (C-3 carbonyl);
CI-MS: m/z 258 (100%, MET).

Carbamate cleavage and dehydrohalogenation of the methyl protected
intermediate 153

MeO OH
MeO
al?Jl ^

, A pale orange-brown mixture oftheoxazolopyridinone 153

4| 2| ^ <v

L
NH
MeO^'s^ i

(0.41 g, 1.4mmol) andfreshlysublimed potassium tert-butoxide
(179.4mg, 1.5mmol) in dry tetrahydrofuran (17mL) were

refluxed for 2h under argon. The mixture was cooled and aqueous sodium hydroxide

(0.5M, 5.6mL, 2.8mmol) was added to give a biphasic mixture. Refluxing was conti

for a further lh. Solvent was removed under reduced pressure and the remaining s
were taken up in water and extracted with ethyl acetate (3x25mL). The combined
organic extracts were dried and solvent was removed under reduced pressure. NMR

the crude product revealed a 2:1 mixture of uncleaved to cleaved product. Furthe
aqueous sodium hydroxide (1M, 6mL) was added. Reflux for 2h and work-up gave

(2R,3R,4R,5S)y2-(l '-hydroxy-2'-propenyl)-3,4,5-trimethoxypiperidine 115 (243.9m
76%) as a pale yellow oil (measured MH+ 232.1543, calculated for CnH22N04
232.1549);
l

H NMR (300MHz, CDC13): 8 1.97 (2H, br., NH and OH), 2.37 (1H, dd, J6a,6b 9.8Hz,

J6^5 11.5Hz, H-6a), 2.45 (1H, dd, J2,v2.2Hz, J2,3 9.3Hz, H-2), 3.07 (1H, d, J4,3 8.8H

H-4), 3.10 (1H, dd, J6h>5 4.4Hz, J6bM 10.1Hz, H-6b), 3.19 (1H, dd, J3t2=J3A 9.2Hz

3), 3.24 (1H, dd, J5,6b 4.6Hz, J5M 11.5Hz, H-5), 3.47 (3H, s, MeO-5), 3.61 (3H, s,

MeO-3), 3.64 (3H, s, MeO-4), 4.41(1H, dddd, 4 W i y v W i y w 1.9Hz, Jv,2 3.8Hz, H-

1'), 5.26 (1H, ddd, Jycis>v~JyciStytrans 1.7Hz, Jycis?10.5Hz, H-3' cis to H-2'), 5.41 (1
ddd, Jytrans,v~ Jytransjds L8Hz, J3W>2.17.1Hz, H-3' trans to H-2'), 5.90 (1H, ddd, J?yV
3.9Hz, JT>ycis 10.5Hz, J2%ytrans 17.1Hz, H-2');
13

C NMR (75MHz, CDC13): 8 47.18 (C-6), 58.29 (MeO), 60.69 (MeO), 60.83 (MeO),

62.39 (C-2), 69.64 (C-l1), 80.89 (C-5), 81.18 (C-3), 88.72 (C-4), 115.52 (C-3'), 138
(C-2');
ES-MS: m/z 232 (100%, MH+), 200 (27%, MH+-MeOH), 182 (55%), 69 (70%).

TES protection of (2R,3R,4R,5S)-2-(l'-hydroxy-2'-propenyl)-3,4,5trimethoxypiperidine 115 to give 157
MeO OTES
=

H •
MeO 3>L = JL ^.
To a solution of the hydroxypiperidine 115 (55.0mg,
,.L NH 0.24mmol) in dry dichloromethane (2mL) under nitrogen at
MeO* 5^-^ l
0°C, was added consecutively triethylamine (1 lOuL,

triethylsilyl trifluoromethanesulphonate (0.65uL, 0.29mmol). After 25min, the re

mixture was poured into a mixture of brine (8mL) and aqueous potassium carbonat
(5%, 2mL). The organic phase was separated and dried. Removal of solvent under

reduced pressure gave a crude oil (57.5mg) which appeared as a mixture of start

material 115 and the desired product 157 in a ratio of 1.5:1 from the 'H NMR. S

column chromatography (ethyl acetate) gave a mixture of the desired product 157
(measured MH+ 346.2411 (LSIMS), calculated for C17H36N04Si 346.2413);
CI-MS: m/z 346 (100%, MH+), 314 (42%, MH+ - MeOH), 174 (MH+ TESOCH2CHCH2);
and another species of indeterminate structure (in a 2:1 ratio from the lH NMR)
colourless oil (31.7mg, 39%);
'H NMR (CDC13, 300MHz): 8 0.62 (6H, two overlapping q, /CH2>CH3 7.6Hz, 8.3Hz,

SiCH2CH3), 0.96 (9H, t, JCH3,CH2 7.8HZ, SiCH2CH2), 1.70-1.81 (0.5H, m), 2.05 (0.5H, t,

J 10.1Hz), 2.29 (1H, dd, J6a,6b 13.2Hz, J6a,5 10.3Hz, H-6a), 2.30 (1H, dd, J2>v 7.

2.0Hz, H-2), 2.43 (0.5H, t, J 8.4Hz), 2.99-3.12 (3H + 1.5H, m , H-3, 4 and 5), 3.25 (1H
+ 0.5H, dd, 76b>6a 13.2Hz, J6b>5 4.9Hz, H-6b), 3.46 (3H, s, MeO-5), 3.49 (1.5H, s), 3.50
(1.5H, s), 3.59 (3H, s, MeO-3), 3.63 (1.5H, s), 3.64 (3H, s, MeO-4), 4.21 (0.5H, dd, J
8.1Hz, J 6.6Hz), 4.42 (1H, dd, Jr>2 7.3Hz, H-l1), 5.12 (1H, ddd, Jyebj 10.3Hz,

Jyasytrans^JycisA' l-2Hz, H-3' cis to H-2'), 5.18 (0.5H, ddd, J 10.3Hz, J 1.7Hz, J0.98Hz)

5.21 (1H, ddd, J 3 W > 2 . 17.1Hz, Jytnuay = J 3 W j 3 W j 1.3Hz, H-3' trans to H-2'), 5.37 (0.5H,
dt, J 17.1Hz, J 1.5Hz), 5.90 (0.5H, ddd, J 17.1Hz, J 10.3Hz, /6.6Hz), 6.03 (1H, ddd,
Ji\ytram 17.3Hz, J2^ycis 10.3Hz, J2.tl. 7.3Hz, H-2');
13

C N M R (75MHz, CDC1 3 ): 8 5.12 (SiCH 2 CH 3 ), 6.92 (SiCH,CHA 21.09,26.82,

46.80, 47.05 (C-6), 58.27 (MeO-5), 58.42, 60.19 (MeO-3), 60.62 (MeO-4), 64.61 (C2), 67.05, 72.22 (C-l'), 81.36 (C-5), 81.42, 82.82 (C-3), 84.02, 88.87, 89.15 (C-4),
93.45, 115.22 (C-3*), 116.41, 137.08, 140.19 (C-2');

TMS protection of (2/?3^,4/?,55)-2-(l'-hydroxy-2'-propenyl)-3,4,5trimethoxypiperidine 115 to give 156
MeO

OTMS

"Hi

MeO

3 l r JL ^

Thehydroxypiperidine 115 (576.7mg, 2.5mmol),
chlorotrimethylsilane (0.35mL, 2.7mmol) and triethylamine
(0.42mL, 3.0mmol) in dry tetrahydrofuran (12mL) was stirred

under nitrogen for 2.5h at room temperature to give a white suspension. The precipitate
was filtered off and washed with further dry tetrahydrofuran, but appeared to dissolve
again at this point. Solvent was removed from thefiltrateunder reduced pressure to give
a residue which was taken up in dichloromethane (25mL), washed with water (15mL)
and dried. Removal of solvent under reduced pressure afforded (l'S,2R,3R,4R,5S)-2-(ltrimethylsilyloxy-2-propenyl)-3,4,5-trimethoxypiperidine 156 (669.6mg, 88%) as a
colourless oil (measured M H + 304.1944 (LSIMS), calculated for C 1 4 H 3 0 NO 4 Si
304.1944);
*H N M R (300MHz, CDC1 3 ): 8 0.13 (9H, s, Me 3 Si), 1.60 (1H, br., N H ) , 2.29 (1H, dd,
/6a>6b 14.2Hz,/6a,5 10.1Hz,H-6a),2.31 (1H, dd,/2>3 8.8Hz,/2>1.2.1Hz, H-2), 3.04-3.10
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(3H, m , H-3, 4 and 5), 3.25 (1H, dd, J6b,6a 12.7Hz, J6b,5 4.9Hz, H-6b), 3.46 (3H, s,
MeO-5), 3.59 (3H, s, MeO-3), 3.64 (3H, s, MeO-4), 4.46 (1H, dd, JVt2- 6.3Hz, Jva
0.7Hz, H-l'), 5.16 (1H, ddd, J3W

10.3Hz, J3w,rans~ Jycis,v 1.3Hz, H-3' <& to H-2'),

5.24 (1H, ddd, ./3W)2. 17.3Hz, J 3 W > 2 , J 3W>3 . C * 1.5Hz, H-3' trans to H-2'), 5.96 (1H,
ddd, J2;ytrans 17.3Hz, J2.3.c„ 10.5Hz, J2.,. 6.3Hz, H-2');
13

C N M R (75MHz, CDC1 3 ): 8 0.57 (Me3Si), 47.20 (C-6), 58.23 (MeO-5), 60.30

(MeO-3), 60.61 (MeO-4), 64.01 (C-2), 71.85 (C-l'), 81.18 (C-5), 82.54 (C-3), 89.20
(C-4), 115.30 (C-3'), 139.83 (C-2');
CI-MS: m/z 304 (100%, M H + ) , 272 (50%, M H + - M e O H ) , 232 (48%), 174 (56%, M H +

- TMSOCH 2 CHCH 2 ), 149 (74%).

T B D M S protection of (2R3R,4R,5S)-2-(l'-hydroxy-2,-propenyl)-3,4,5trimethoxypiperidine 115 to give 155

MeO
MeO*.

OTBDMS
r1 I ^,

The hydroxypiperidine 115 (77.0mg, 0.33mmol) was
dissolved in dry dichloromethane (2mL) and cooled to 0°C
with stirring under argon. 2,6-Lutidine (77uL, 0.66mmol) and

tert-butyldimethylsilyl trifluoromethanesulphonate (115uL, 0.50mmol) were added
consecutively and stirring was continued for 3.5h as the solution was allowed to warm
to room temperature. The reaction was quenched by the addition of water (5mL) and
saturated aqueous sodium hydrogen carbonate (lmL). Extraction with dichloromethane,
drying and removal of solvent under reduced pressure gave (1 'S,2R,3R,4R,5S)-2-(l-tert-

butyldimethylsilyloxy-2-propenyl)-3,4,5-trimethoxypiperidine 155 (109.0mg, 95%) a
colourless oil (measured M H + 346.24136, calculated for C, 7 H 3 5N0 4 Si 346.24134);
*H N M R (300MHz, CDC1 3 ): 8 0.046 and 0.088 (3H each, s, Me 2 Si), 0.90 (9H, s,
r

BuSi), 1.74 (1H, br. s, N H ) , 2.29 (1H, dd, J6a,6b 13.2Hz, J6a,5 10.7Hz, H-6a), 2.31 (1H,

dd, J2,3 9.3Hz, J2yV 2.0Hz, H-2), 2.97 (1H, ddd, J5)6a 10.5Hz, J5A 9.0Hz, J5,6b 5.2Hz, H
126

5), 3.02 (1H, dd, J3,2=J3A 8.7Hz, H-3), 3.09 (1H, dd, J4,3~J4,5 8.7Hz, H-4), 3.24 (1H,
dd, J6bM 13.6Hz, J6b>5 5.0Hz, H-6b), 3.47 (3H, s, MeO-5), 3.59 (3H, s, MeO-3), 3.64
(3H, s, MeO-4), 4.39 (1H, ddd, Jva. 7.6Hz, JY,2~Jv,ycis 0.7Hz, H-l'), 5.11 (1H, ddd,
Jycis,T 10.3Hz, J3Wtrans 1.5Hz, Jycis>Y 0.98Hz, H-3' cis to H-2'), 5.19 (1H, ddd, Jytrans^

17.3Hz, Jytram,2~ Jytrans,ycis l-3Hz, H-3' trans to H-2'), 6.03 (1H, ddd, J2>ytrans 17.6Hz
J2.ycis 10.3Hz, JTtV 7.6Hz, H-2');
13

C N M R (75MHz, CDC1 3 ): 8 -4.89 (MeSi), -3.46 (MeSi), 18.14 (Me 3 CSi), 25.99

(M&CSi), 46.95 (C-6), 58.33 (MeO-5), 60.23 (MeO-3), 60.65 (MeO-4), 64.68 (C-2),
72.21 (C-l'), 81.40 (C-5), 82.95 (C-3), 89.10 (C-4), 115.27 (C-3'), 140.27 (C-2');
ES-MS: m/z 346 (100%, MlT").

t room temperature for 24h, dichloromethane (25mL) and water (lOmL) were added.
The organic phase was separated and the aqueous layer was further extracted with
dichloromethane (25mL, 15mL). The combined organic extracts were dried and filtered
through celite to give the crude product (74.8mg). Flash silica column chromatography
was unable to separate the two main products visible by tic.

CI-MS: m/z 296/294 (30%/100%, M H + o f starting material 153), 282/280 (25%/70%,
product from starting material with loss of CH 2 ).

9.4 SYNTHESIS OF T H E M O D E L INTERMEDIATE

Oxidation of 1,2,3,4-tetrahydroisoquinoline with NBS

CO

Yellow N-bromosuccinimide (29.44g, 0.17mol) was added portion-wise
over a period of 30min to a stirred yellow solution of 1,2,3,4-

tetrahydroisoquinoline (20.02g, 0.15mol) in dichloromethane (300mL) under nitrogen.
After the addition the orange mixture was stirred for a further lh lOmin. Aqueous
sodium hydroxide (30%, lOOmL) was added and the biphasic mixture was stirred for a
further lh. Water (60mL) was added and the organic layer was separated, washed with
water (140mL) then extracted with dilute aqueous hydrochloric acid (2M, 200mL,
lOOmL). The combined aqueous extracts were washed with dichloromethane (lOOmL)
then basified with concentrated aqueous ammonia solution (80mL). The resulting
cloudy mixture was then back-extracted with dichloromethane (lOOmL, 2x75mL). The
combined organic extracts were dried and then solvent was removed under reduced
pressure to give a pale brown oil. Kugelrohr distillation (l.OTorr, 135°C) afforded 3,4dihydroisoquinoline 147 (16.98g, 8 6 % ) as a colourless oil (correct *H N M R and T L C
behaviour).197

The BF3/alryltributyltin approach to l-allyl-l,2,3,4-tetrahydroisoquinoline 116

Boron trifluoride etherate (l.lmL, 8.4mmol) was added to a stirred solution of 3,4dihydroisoquinoline 147 (1.02g, 7.6mmol) in dry dichloromethane (40mL) at-78°C
under nitrogen. The solution was warmed to 10°C over a period of lOmin then recooled to -78°C whereupon allyltributyltin (2.7mL, 8.4mmol) was added and the
mixture allowed to w a r m to room temperature and stirred for a futher 18h. The resulting
mixture was poured onto a solution of saturated aqueous a m m o n i u m chloride (60mL).
Diethyl ether (25mL) was added. The aqueous layer was separated, basified with

aqueous sodium hydroxide (6M, 4 m L ) and then extracted with dichloromethane (50mL,
25mL). After drying, solvent was removed under reduced pressure to give crude
product (0.1 lg). The first organic phase was re-extracted with hydrochloric acid
2x25mL). The aqueous extracts were basified with aqueous sodium hydroxide (6M) and

extracted with dichloromethane. After drying and removal of solvent en vacuo, furt
crude product (0.7 lg) was obtained to give a final yield of 82% of crude product
by *H NMR, was determined to be a 2.3:1 mixture of starting material 147197 to
product 116.191-194.

The Zn/allyl bromide approach to l-allyl-l,2,3,4-tetrahydroisoquinoline 116
S 4

Allyl bromide (13.4mL, 0.16mol) was added to a stirred suspension
of zinc powder (12.65g, 0.19mol) in dry tetrahydrofuran (220mL)
under nitrogen. The mixture was cooled to 0°C where 3,4-

dihydroisoquinoline 147 (16.98g, O.Bmmol) in dry tetrahydrofuran (80mL) was slowly
added. Stirring was continued for 2 days. Saturated aqueous sodium bicarbonate
(200mL) was added and mixture was filtered through celite. The organic solvent was
removed under reduced pressure. The resulting aquous mixture was extracted with
dichloromethane (150mL, 50mL). The combined organic phases were then extracted
with aqueous hydrochloric acid (2M, 4xl00mL). These combined acidic aqueous

extracts were then washed with a little dichloromethane (60mL), basified with aqueo
sodium hydroxide (lOOmL), cooled in an ice-water bath and then back-extracted into
dichloromethane (2xl00mL, 50mL). The combined organic phases were dried. Solvent

was removed under reduced pressure to give a 1-allyl-1,2,3,4-tetrahydroisoquinolin
(13.28g, 59%) as a colourless oil (correct JH NMR and TLC behaviour).191-194
l

H NMR (CDC13, 300MHz): 8 2.51 (1H, ddd, yla.,lb. 14.2Hz, Jw**Jw 8.4Hz, H-la'),

2.68 (1H, dm, JlVM 14.2Hz, H-lb'), 2.75-2.89 (2H, m, H-4), 2.98 (1H, ddd, y3a,3b
12.2Hz, /3M 7.6Hz, J3aA 5.1Hz, H-3a), 3.24 (1H, dt, J3bM 12.2Hz, J3bA 5.3Hz, H-3b),

4.05 (1H, dd, y1>ra 9.0Hz, Jhrb 3.4Hz, H-l), 5.14 (1H, dd, Jycis,T 9.3Hz, Jycis>Vb 0.9
129

H-3' cis to H-3'), 5.18 (1H, dd, J 3 W > 2 , 15.4Hz, Jytrans,vb 1.5Hz, H-3' trans to H-2'), 5.84
(1H, dddd, J 2 \ 3 W 17.1Hz, J2>?cb 10.0Hz, J2, ra 7.8Hz, J2. rb 6.6Hz, H-2'), 7.07-7.18
(4H, m , H-5, 6, 7 and 8);
13

C N M R (CDC13, 75MHz): 8 30.01 (C-l'), 40.61 (C-4), 41.03 (C-3), 55.07 (C-l),

117.86 (C-3*), 125.75, 125.97 (two carbons) and 129.76 (C-5, 6, 7 and 8), 135.41 (C4a), 135.62 (C-2'), 138.69 (C-8a);

9.5 RING CLOSING METATHESIS INVESTIGATIONS

Preparation of l,23>4-tetrahydro-2-(l-oxo-3-butenyl)-l-(2-propenyl)-isoquin
170
5

4

6 ir^^V^^3

1,3-Dicyclohexylcarbodiimide (1.1862g, 5.7mmol) was
2

N 1" "

4

"

7 \*^sLx Y ^ f ^
1

added to a yellow solution of 1-allyl-1,2,3,4-

N | 2-

tetrahydroisoquinoline 116 (1.0001 g, 5 Jmmol) and

3

vinylacetic acid (0.49mL, 5.7mmol) in dry dichloromethane

'

(6mL) at 0°C under nitrogen. After the addition the mixture was allowed to warm to
room temperature and stirred for 9h. The resulting white precipitate was filtered off and
washed with dichloromethane. Evaporation of solvent under reduced pressure gave the
crude product. Purification by silica chromatography (dichloromethane:hexane, 80:20)
gave l,2,3,4-tetrahydro-2-(l-oxo-3-butenyl)-l-(2-propenyl)-isoquinoline 170
fractions 5-20, 1.19g, 86%) as a pale yellow oil (measured M H + 242.1546, calculated
for Ci6H 2 0 NO 242.1545);
*H N M R (300MHz, CDC1 3 ): 8 2.56-2.64 (2H, m, H-l" major and minor), 2.79-3.01

(2H, m , H-4 major and minor), 3.11 (1H minor, ddd, J3di,3b~ J3a,412.5Hz, J3a>4 4.4Hz, H3a minor), 3.20-3.25 (2H, m, H-2" major and minor), 3.56 (1H major, ddd, J3a>3b 13.4Hz,
J3a>4 10.4Hz, J3a,4 4.8Hz, H-3a major), 3.83 (1H major, ddd, J3b;3a 13.4Hz, J3b)4=^3b(4
4.5Hz, H-3b major), 4.69 (1H minor, dddd, J3b)3a 13.1Hz, J3bA 6.0Hz, J3bA 2.9Hz, J
1.2Hz H-3b minor), 4.88 (1H minor, dd, JhV 9.3Hz, JhV 5.1Hz, H-l minor), 4.98-5.22

(4H, m , H-4" and 3", major and minor), 5.69 (1H major, t, JltV 7.1Hz, H-l major), 5.775.88 (1H, m , H-2' major and minor), 5.91-6.04 (1H, m , H-3" major and minor), 7.107.22 (4H, m , H-5,6,7 and 8);
13

C N M R (75MHz, CDC1 3 ): 8 28.00 (C-4 minor), 29.06 (C-4 major), 35.26 (C-3

minor), 38.81 (C-2" minor), 39.28 (C-2" major), 40.14 (C-3 major), 41.09 (C-l' major),
41.37 (C-T minor), 51.93 (C-l major), 56.58 (C-l minor), 117.18 (C-3* major), 117.60
(C-4" minor), 117.76 (C-4" major), 118.75 (C-3'minor), 126.03, 126.27, 126.55, 126.75,
127.01, 127.36, 128.53, 129.25 (aromatic CH's), 131.54 (C-3" major), 131.62 (C-3"
minor), 133.85 (C-2' minor), 134.88 (C-2' major), 133.31, 134.32, 136.34, 136.88
(aromatic 4°C*s), 169.66 (C-l" carbonyl);
CI-MS: m/z 242 (88%, M H + ) , 200 (100%, M H + - propene), 132 (42%, (3,4dihydroisoquinoline + H) + );
IR (thinfilm):v 915 (str., C H = C H 2 out of plane deformation), 1446 (str., aliphatic C H
deformation), 1649 (str., amide C = 0 stretch), 2933 (med., saturated C-H stretch), 3018
and 3077 (med., = C H stretch).

Preparation of l,2,3,4-tetrahydro-2-(l-oxo-3-pentenyl)-l-(2-propenyl)isoquinoline 171
5 4

6 (i^*!S!i>r/Xv>|3

1,3-Dicyclohexylcarbodiimide (1.2074, 5.9mmol) was
2
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added to a yellow solution of 1-ally 1-1,2,3,4tetrahydroisoquinoline 116 (1.0041g, 5.8mmol) and 4pentenoic acid (0.59mL, 5.7mmol) in dichloromethane

(6mL) at 0°C under nitrogen. After the addition the mixture was allowed to warm to
room temperature and stirred for 9h. The resulting white precipitate wasfilteredand
washed with a little dichloromethane. Solvent was removed under reduced pressure
from thefiltrate.Purification by flash silica chromatography (dichloromethane:hexane,
80:20) afforded the amide l,2,3,4-tetrahydro-2-(l-oxo-3-pentenyl)-l-(2-propenyl)-

131

isoquinoline 171 (fractions 6-17, 1.21g, 82%) as a colourless oil (measured M H +
256.1702, calculated for C i 7 H 2 2 N O 256.1701);
l

R N M R (300MHz, CDC1 3 ): 8 2.36-2.73 (6H, m , H-l', 2" and 3"), 2.87 (1H minor, dd

J4a,3a 9.1Hz, JAa<3b 4.9Hz, H-4a minor), 2.88 (1H minor, dd, J4b;3a 6.8Hz, J4b;3b 4.3Hz, H4b minor), 2.95 (1H major, ddd, J4a>4b 16.4Hz, J4a>3a = J4a>3b 4.1Hz, H-4a major), 3.20
(1H minor, ddd, J3a>3b 13.2Hz, J3a>4a9.3Hz, J3a>4b 6.7Hz, H-3a minor), 3.63 (1H major,
ddd, J3a>3b 13.7Hz, J3a>4b 10.4Hz, J3a4a 4.7Hz, H-3a major), 4.02 (1H major, ddd, J3b)3a
13.7Hz, J3bAa 5.2Hz, J3bAb 3.9Hz, H-3b major), 4.60 (1H minor, ddd, J3b)3a 13.2Hz, J3b)4a
- J3bAb 4.2Hz, H-3b minor), 5.05 (1H minor, ddt, JhV 10.3Hz, J1.7Hz, /0.97Hz, H-l
minor), 5.09-5.37 (4H, m, H-4" and 3'), 5.71 (1H major, t, Jhr 7.2Hz, H-l major), 5.88
(1H major, ddt, J ^ w 17.0Hz, J2.3W, 10.3Hz, JXtV 7.1Hz, H-2' major), 5.92-6.06 (2H
minor + 1 H major, m , H-2' minor, 4" minor and major), 7.26-7.42 (4H, m , H-5,6,7 and
8);
l3

C N M R - D E P T experiment (75MHz, CDC1 3 ): 8 28.22 (C-4 minor), 29.27 (C-4

major), 29.41 (C-3" major), 29.47 (C-3" minor), 32.98 (C-2" minor), 33.08 (C-2" major),
35.30 (C-3 minor), 40.13 (C-3 major), 41.26 (C-l' major), 41.53 (C-l' minor), 52.09 (C1 major), 56.53 (C-l minor), 115.26 (C-5" major and minor), 117.20 (C-3' major),
118.84 (C-3' minor), 126.17,126.43, 126.68, 126.89,127.14,127.56,128.66,129.43
(aromatic CH's), 134.02 (C-2' minor), 135.14 (C-2' major), 137.70 (C-5");
CI-MS: m/z 256 ( M H + ) ;
IR (thinfilm):v 1641 (str., amide C = 0 stretch).

Attempted ring closing metathesis of the amide 170

1-Allyl-1,2,3,4-tetrahydroisoquinolyl but-2-enamide 170 (503.8mg, 2.1mmol) and
bis(tricyclohexylphosphine)benzylidene ruthenium(IV) dichloride 185 (68.7mg,
0.08mmol) were refluxed in dry dichloromethane (20mL) under argon for 16h. T L C
showed starting material still present so further bis(tricyclohexylphosphine)benzylidene
ruthenium(TV) dichloride (35mg, 0.04mmol) was added and refluxing continued for 17h.

After cooling to room temperature, the mixture was opened to the air and stirred for 6h.
Washing with saturated aqueous sodium hydrogen carbonate (2x30mL) gave a green-

brown organic phase. The organic phase was dried and solvent removed under reduced

pressure. Silica chromatography (dichloromethane:hexane, 80:20) yielded only start
material 170 (342.6mg, 68%).

Attempted ring closing metathesis of the amide 171

The diene 171 (503.5mg, 2.0mmol) and bis(tricyclohexylphosphine)benzylidene

ruthenium(TV) dichloride 185 (67.2mg, 0.08mmol) were refluxed in dry dichlorometh
(20mL) under argon for 16h. TLC showed starting material still present so further

bis(tricyclohexylphosphine)benzylidene ruthenium(IV) dichloride (39.3mg, 0.04mmol
was added and refluxing continued for 17h. After cooling to room temperature, the
mixture was opened to the air and stirred for 6h. Washing with saturated aqueous
sodium hydrogen carbonate (2x3 OmL) gave a green-brown organic phase. The organic

phase was dried and solvent removed under reduced pressure to give a crude residue

(541.4mg). Filtration through a short silica column (dichloromethane) gave startin
material only 171 (0.07g) by NMR analysis.

Carbonyl reduction of the butenamide 170 using DIBAH
5 4

6 t j ^ ^ V ^ ^ N3

Di-wo-butylaluminium hydride (1M in cyclohexane, 8 m L ,

I
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8.0mmol) was slowly added to a solution of the

3-

^j| 2- butenamide 170 (240mg, 1 .Ommol) in toluene (5mL) at 0°C

3

' under nitrogen. The solution was allowed to warm to room

temperature and stirred for 20min. A mixture of methanol (lOmL) and water (0.5mL)

were very slowly added, drop-wise at first, giving a vigorous evolution of gas and
white precipitate. The white precipitate was filtered and washed with methanol

(3x18mL). Solvent was removed under reduced pressure from thefiltrate.The resulting
residue was taken up in hydrochloric acid (2M, 2 0 m L ) and extracted with
dichloromethane (25mL, 5mL). The combined organic phases were dried and solvent
was removed under reduced pressure to give starting material 170 (171.6mg, 7 1 % mass
recovery) (correct *H N M R ) . The aqueous phase was basified with aqueous sodium
hydroxide (10M, lOmL) and back-extracted with dichloromethane (2x20mL). The
combined organic extracts were dried and solvent was removed under reduced pressure

to give l,2,3,4-tetrahydro-2-(3-butenyl)-l-(2-propenyl)isoquinoline 175 (48.4mg, 21
as a colourless oil ((measured M H + 228.1749, calculated for C 1 6 H 2 2 N 228.1752);
*H N M R (CDC1 3 , 300MHz): 8 2.30 (2H, dt, JTX « Ji«,y> 7.2Hz, H-2"), 2.38-2.70 (5H,
m , H-4a, 4b, 1' and la"), 2.82-2.96 (2H, m , H-3a and lb"), 3.21 and 3.23 (1H, two sets
of dd due to inversion isomers about N ,firstisomer: J 12.5Hz, J 9.3Hz, second isomer:
J 14.9Hz, J11.7Hz, H-3b), 3.75 (1H, t, J u - 6.3Hz, H-l), 4.97-5.09 (4H, m , H-3' and
4"), 5.83 (1H, ddt, JrArtrans 17.3Hz, JrA«cis 10.3Hz, Jra* 6.8Hz, H-3"), 5.89 (1H, ddt,
Jwtnms 17.1Hz, J2;ycis 10.5Hz, J2fl. 7.0Hz, H-2'), 7.05-7.14 (4H, m , H-5, 6, 7 and 8);
13

C N M R (CDC1 3 , 7 5 M H z ) : 8 23.47 (C-l'), 30.37 (C-2"), 39.37 (C-4), 42.74 (C-3),

51.90 (C-l"), 61.12 (C-l), 116.73 (C-4"), 117.70 (C-3'), 125.99, 127.07,128.22, 128.91
(C-5, 6, 7 and 8), 132.10 (C-4a), 134.34 (C-8a), 134.62 (C-3"), 134.80 (C-2');
CI-MS: m/z 228 (100%, M H + ) , 186 (38%, M H + - propene);

Preparation of l,2^,4-tetrahydro-2-(3-butenyl)-l-(2-propenyl)isoquinoline 175
from 116

1-Allyl-1,2,3,4-tetrahydroisoquinoline 116 (505.7mg, 2.9mmol), potassium carbonat
(936.5mg, 6.8mmol) and 4-bromo-l-butene (0.32mL, 3.2mmol) were refluxed in dry
acetonitrile (18mL) under nitrogen for 16h. Solvent was removed under reduced
pressure to give a pink residue which was taken up in ethyl acetate (38mL) and washed
with water (45mL). The aqueous layer was re-extracted with ethyl acetate (8mL). The
combined organic phases were extracted with 2 M hydrochloric acid (2x3 O m L , 15mL).

These combined aqueous extracts were basified with concentrated aqueous ammonia and
then back-extracted with ethyl acetate (65mL, 18mL). After drying of the combined
organic extracts, the solvent was removed under reduced pressure to give a crude oil
(526.9mg). Silica column chromatography gave l,2,3,4-tetrahydro-2-(3-butenyl)-l-(2propenyl)isoquinoline 175 (422.7mg, 6 4 % ) as a colourless oil (correct 5 H N M R and
T L C behaviour).

Preparation of l,23,4-tetrahydro-2-(4-pentenyl)-l-(2-propenyl)isoquinoline 176
from 116

1-Allyl-1,2,3,4-tetrahydroisoquinoline 116 (1.0105g,
4"
5

" 5.8mmol), potassium carbonate (2.0094g, 14.5mmol)
and 5-bromo-l-pentene (0.75mL,6.3mmol) were
refluxed in dry acetonitrile (40mL) under nitrogen for

17h. Solvent was removed under reduced pressure to give a pink residue which was
taken up in dichloromethane (20mL) and washed with water (50mL). The aqueous layer
was re-extracted with dichloromethane (2xl0mL). The combined organic phases were
extracted with 2 M hydrochloric acid (20mL, 2x15mL). These combined aqueous
extracts were basified with concentrated aqueous ammonia (ca. 6 m L ) and then backextracted with dichloromethane (4x15mL). After drying of the combined organic
extracts, the solvent was removed under reduced pressure to give a crude oil (197.4mg).
D u e to the low mass recovery, thefirstorganic phases were washed with saturated
aqueous sodium hydrogen carbonate, dried and solvents were removed under reduced
pressure to yield further crude brown oil (1.2069g). Silica column chromatography of
the combined crude oils gave l,2,3,4-tetrahydro-2-(4-pentenyl)-l-(2propenyl)isoquinoline 176 (948mg, 6 7 % ) as a colourless oil (measured M H + 242.1911,
calculated for C 1 7 H 2 4 N 242.1909);
l

H N M R (CDC1 3 , 3 0 0 M H z ) : 8 1.62 (2H, tt, Jr,p * Jr,y 7.4Hz, H-2"), 2.09 (2H, dt,

J3«,r~JyA» 7.2Hz, H-3"), 2.37-2.46 (1H, m , H-la'), 2.50-2.63 (4H, m , H-4a*, lb' and
135

1"), 2.77-2.95 (2H, m , H-3a and 4b), 3.17 and 3.21 (lH,two dd due to inversion isomers
about N , J 12.8Hz, J9.6Hz; J 11.2Hz, J8.1Hz, H-3b), 3.70 (1H, t, JltV 6.3Hz, H-l),
4.92-5.05 (4H, m , H-5" and 3"), 5.83 (1H, ddt, J4-.5 . w 16.8Hz, J4^as 10.1Hz, J4",3..
6.6Hz, H-4"), 5.89 (1H, ddt, JT,ytram 17.1Hz, J2.3.c/s 10.5Hz, J2. r 6.8Hz, H-2'), 7.04-7.13
(4H, m , H-5, 6, 7 and 8);
13

C N M R (CDC1 3 , 75MHz): 8 25.04 (C-4), 27.20 (C-2"), 31.52 (C-3"), 40.08 (C-l*),

43.95 (C-3), 53.00 (C-l"), 61.15 (C-l), 114.46 (C-5"), 115.73 (C-31), 125.44, 125.85,
127.86, 128.81 (C-5, 6, 7 and 8), 134.68 (C-8a), 136.89 (C-2"), 138.25 (C-4a), 138.73
(C-4");
CI-MS: m/z 242 (100%, M H + ) , 216 (15%, M H + - ethene), 200 (38%, M H + propene), 172 (43%, M H + - pentene);

Preparation of l,2-Dialfyl-l,2,3,4-tetrahydroisoquinoline 174

2N

2

"
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l-Allyl-l,2,3,4-tetrahydroisoquinolinell6(1.00g,4.9mmol),

3'

potassium carbonate (1.57g, 1 lmmol) and allyl bromide
(0.5 lmL, 5.9mmol) were refluxed in dry acetonitrile (75mL) for 18h under nitrogen.
Solvent was removed under reduced pressure and the resulting residue was taken up in
ethyl acetate (50mL) and washed with water (50mL). The combined aqueous phases
were then re-extracted with ethyl acetate (30mL). The combined organic extracts were
washed again with water (lOmL) and then extracted with aqueous hydrochloric acid
(2M, 2x40mL). The combined aqueous layers were basified with aqueous sodium
hydroxide (10M, 2 0 m L ) and then back-extracted with ethyl acetate (2x50mL). These
extracts were dried and solvent was removed under reduced pressure to give a brown oil.
Flash silica column chromatography of this oil (70% dichloromethane: 3 0 % ethyl
acetate) afforded 1,2-diallyl- 1,2,3,4-tetrahydroisoquinoline 174 (combinedfractions4-6,
0.65g, 6 2 % ) as a pale yellow oil.
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l

H N M R (CDC1 3 , 300MHz): 8 240-267 (3H, m , H-4a and 1'), 2.82-2.95 (3H, m, H-3a

and 4b), 3.20 (1H, ddd, J3b>3a 14.4Hz, J3b>4a 9.0Hz, J3b;4b 3.2Hz, H-3b), 3.26 (2H, ddd,
Jr.r 6.3Hz, Jr,yaS=Jr,ytrans 1.2Hz, H-l"), 3.77 (1H, dd, Jhy^Jlrb 6.4Hz, H-l), 5.005.20 (4H, m , H-3' and 3"), 5.87 (1H, ddt, J 2 . 3 W 17.1Hz, y2-3.c,, 10.7Hz, J2iV 7.1Hz, H2'), 5.92 (1H, ddt, Jr,yirans 17.1Hz, J2^Tcis 10.3Hz, JT>r 6.5Hz, H-2"), 7.04-7.15 (4H,
m, H-5, 6, 7 and 8);
,3

C N M R (CDC1 3 , 75MHz): 8 25.15 (C-l'), 39.97 (C-4), 43.91 (C-3), 56.84 (C-l),

60.36 (C-l"), 115.84 (C-3"), 117.10 (C-3'), 125.49, 125.91, 127.84 and 128.83 (C-5, 6,
7 and 8), 134.54 (C-4a), 136.32 (C-2*), 136.65 (C-2"), 138.01 (C-8a).

Preparation of the hydrochloride salt of l,2,3,4-tetrahydro-l,2-di-(2propenyDisoquinoline 174»HC1

Dry hydrogen chloride gas244 was bubbled through a solution of 1,2-diallyl-1,2,3,
tetrahydroisoquinoline (651.1mg, 3.0mmol) until a definate cloudy appearance remained.
Solvent was removed under reduced pressure to give a quantitative yeild of the 1,2,3,4tetrahydro-l,2-di-(2-propenyl)isoquinoline hydrochloride 174»HC1 (761.9mg, 100%).
*H N M R (dg-acetone, 300MHz): 8 2.71 (1H, ddd, Jl'a,l'b 13.7Hz, Jl'a,l=Jl'a,2'
8.4Hz, H-l'a), 3.15-3.20 (2H, m, H-4a and l'b), 3.39-3.44 (2H, m , H-3a and 4b), 3.713.80 (3H, m , H-3b and 1"), 4.51 (1H, dd, Ju.a 8.3Hz, J]yVb 4.2Hz, H-l), 5.07 (1H, d,
J3'trans,2' 17.6Hz, H-3' trans to H-2'), 5.09 (1H, d, J3*cis,2' 9.8Hz, H-3' cis to H-2'),
5.48 (1H, d, J3"trans,2" 18.1Hz, H-3" trans to H-2"), 5.47 (1H, d, J3"cis,2" 10.3Hz, H3" cis to H2"), 5.93 (1H, ddt, h,ytram 16.6Hz, JVtycis 10.5Hz, J2%v 8.5Hz, JXtV 5.9Hz, H2'), 6.43 (1H, ddt,Jr>Ttrans 17.1Hz, Jr,rcis 10.3Hz, Jrr 6.5Hz, H-2"), 7.04-7.15 (4H,
m, H-5, 6, 7 and 8);
13

C N M R (oVacetone, 75MHz): 8 22.4 (C-l'), 40.0 (C-4), 43.2 (C-3), 56.0 (C-l), 61.8

(C-l"), 119.7 (C-3"), 124.6 (C-3*), 127.3, 128.9 and 129.1 (two carbons) (C-5, 6, 7 and
8), 130.0 (C-2*), 134.3 (C-2").
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Metathesis reaction of the l,2,3,4-tetrahydro-l,2-di-(2-propenyI)isoquinoline
hydrochloride 174-HCI

1,2-Diallyl-1,2,3,4-tetrahydroisoquinoline hydrochloride 174-HCI
4 (0.76g, 3.0mmol) and bis(tricyclohexylphosphine)benzylidene
3

ruthenium(IV) dichloride 185 (99.4mg, 0.12mmol) were refluxed in
dry dichloromethane (20mL) under argon for 18.5h. After cooling
the mixture was exposed to the air and stirred for a further 5h, however the mixture
remained orange-brown. Subsequent washing with saturated aqueous sodium
bicarbonate (2x30mL) gave the organic phase as a green-black mixture. This was
extracted with aqueous hydrochloric acid (2M, 2x30mL). The combined aqueous
extracts were washed with dichloromethane (20mL), basified with aqueous sodium
hydroxide (10M, 15mL) and back-extracted with dichloromethane (3x20mL). The
organic extracts were dried and solvent was removed under reduced pressure to give a
crude brown oil (295mg). Flash silica column chromatography afforded 1,2-diallyl1,2,3,4-tetrahydroisoquinoline starting material (combinedfractions20-22, 85.1mg,
13%) and l,4,6,7-tetrahydrobenzo[a]quinolizine\ll (combinedfractions23-27,
155.3mg, 2 8 % ) as a colourless oil (measured M H * 186.1281, calculated for C 1 3 H 1 6 N
186.1283);
'H N M R (300MHz, CDC1 3 ): 8 2.21 (1H, ddm, Jlax,leq = Jlax>llb 12.7Hz, H-lax), 2.55
(1H, ddd, J7ax,7eq = J7tKt6ax 11.5Hz, J7ax, 6eq 3.4Hz, H-7ax), 2.65-2.75 (2H, m , H-leq and
H-6eq), 3.00-3.10 (2H, m , H-4eq and H-7eq), 3.20 (1H, ddd, J6ax> 6eq 17.1Hz, J6ax,7ax
12.0Hz, y6ax,7eq 5.5Hz, H-6ax), 3.40 (1H, dm, J4aX)4eq 16.4Hz, H-4ax), 3.53 (1H, dd,
Jnht lax 10.5Hz, JUb> leq 3.7Hz, H-l lb), 5.77 (1H, m , H-3), 5.85 (1H, m , H-2), 7.08-7.18
(4H,m,H-8,9,10andll);
13

C N M R (75MHz, CDC1 3 ): 8 29.39 (C-6), 33.34 (C-l), 51.20 (C-7), 55.35 (C-4),

59.02 (C-l lb), 125.31 (C-2), 125.45 (C-3), 125.25, 124.86, 125.89 (C-8,9 and 10),
128.74 (C-ll), 134.44 (C-7a), 138.20 (C-l la);
CI-MS: m/z 186 (68%, M H + ) , 182 (100%, M H + -2H 2 ).

Ring-closing metathesis of 2-(3-butenyl)-l-(2-propenyl)THIQ 175

7

2-(3-Butenyl)-l-(2-propenyl)THIQ 175 (0.1 lg, 0.48mmol) was
6

^b >?
/

dissolved in diethyl ether (1 OmL). Hydrogen chloride gas was

4

\ = /
2

passed through this solution until a cloudy appearance remained.

^

Solvent was removed under reduced pressure and the resulting
residue was dissolved in dry dichloromethane (20mL) and degassed.
Bis(tricyclohexylphosphine)benzylidene ruthenium(IV) dichloride 185 (14.5mg,

0.02mmol) was added and the resulting orange-brown solution was refluxed under a

for 96h whereupon it was opened up to the air and stirred for a further lOh. Furt

dichloromethane (20mL) was added and the brown solution was washed with saturated

sodium hydrogen carbonate (20mL). The organic phase at this stage appeared a dark
green-brown colour which was extracted with 2M hydrochloric acid (3x15mL). The

combined aqueous extracts were washed with dichloromethane (lOmL) and basified wi

concentrated aqueous ammonia (28%w/w, 8mL). After cooling to room temperature the

cloudy solution was back-extracted into dichloromethane (3x15mL), dried and solve

was removed under reduced pressure to give a crude oil (28.5mg). Preparative thin
chromatography (silica, dichloromethane:hexane 80:20) gave starting material 175
(6.0mg, 5.5%) and l,4,5,7,8,12b-hexahydroazepino[2,l-a]isoquinoline 178 (8.1mg,

8.4%) as a colourless oil (measured MH+ 200.1430, calculated for C14H18N 200.1439);
*H NMR (300MHz, CDC13): 8 2.23 (1H, dd, Jla>lb 17.2Hz, Jla>2 7.2Hz, H-la), 2.41

(2H, m, H-4), 2.74-3.05 (7H, m, H-lb, 5, 7 and 8), 4.23 (1H, d, 712b)lb 10.3Hz, H-1
5.82-5.87 (2H, m, H-2 and 3), 7.09-7.15 (4H, m, H-9, 10, 11 and 12);
13

C NMR (75MHz, CDC13): 8 27.44 (C-4), 29.49 (C-8), 34.43 (C-l), 47.03 (C-7),

55.97 (C-5), 61.24 (C-12b), 125.62 and 125.92 (C-10 and 11), 127.61 (C-12), 128.56
(C-9), 130.40 (C-3), 131.45 (C-2), 134.36 (C-8a), 139.49 (C-12a);
CI-MS: m/z 200 (100%, MH+), 198 (36%, MH+ - H2), 91.

Preparation of the diallyl alcohol 180
MeO

OH

"Hi
M e 0 ^ 3 ^ ? l ^, 3" The TMS-protected piperidine 156 (50.7mg, 0.16mmol),
4[ 2 f 1" 2"
potassium carbonate (54.6mg, 0.40mmol) and allyl bromide
f V o - ^ ^ N ^ ^ ^
6
1'
3'
(17uL, 0.20mmol) in dry acetonitrile (5mL) were refluxed
under nitrogen for 18h. After solvent was removed under reduced pressure, the residue
was taken up into ethyl acetate (8mL) and washed with water (8mL). The aqueous
phase was re-extracted with ethyl acetate (8mL) and the combined extracts were dried.
Solvent was removed under reduced pressure to give a crude oil (43.8mg). Silica
preparative thin layer chromatography (50:50 dichloromethane/ethyl acetate) gave

(1 "S,2R, 3R, 4R, 5S)-2-(l-hydroxy-2-propenyl)-l-(2-propenyl)-3,4,5-trimethoxypip
180 (24.7mg, 54%) as a colourless oil (measured M H + 272.1870 (LSIMS), calculated for
C 1 4 H 2 6 N 0 4 272.1861);
*H N M R (300MHz, CDC1 3 ): 8 1.75 (1H, br., O H ) , 2.28 (1H, dd, J6a,6b 12.0Hz, J6a>5
8.5Hz, H-6a), 2.55 (1H, dd, J2,3 7.1Hz, J2X 4.6Hz, H-2), 3.04 (1H, dd, J6b,6a 12.0Hz,
J6b)5 3.9Hz, H-6b), 3.16 (1H, dd, J4)3-J4)5 7.3Hz, H-4), 3.18-3.27 (3H, m , H-3,5 and la'),
3.43-3.45 (4H, m and s, M e O and H-lb'), 3.52 (3H, s, M e O ) , 3.55 (3H, s, M e O ) , 4.37
(1H, dddd, Ji-,2^1-,2" 4.4Hz, Jr,ycis~Jv\y trans l-7Hz, H-l"), 5.19 (1H, d, y

3 W

10.3Hz,

H-3' cis to H-2'), 5.20 (1H, d, Jytnm? 17.8Hz, H-3' trans to H-2'), 5.25 (1H, ddd, JVcis<T
10.7Hz, Jy^ytrans^Jycisr 1.8Hz, H - 3 V w to H-2"), 5.44 (1H, ddd, Jytram,T 17.3Hz,

J3°trans,ycis~Jytrans,r l-8Hz, H-3" trans to H-2"), 5.84 (1H, dddd, J2<,ytrans 16.6Hz, J

10.7Hz, JTtV 7.1Hz, J7tV 6.1Hz, H-2*), 5.95 (1H, ddd, J 2 .. >2W 17.3Hz, JT,ycis 10.5Hz,
J^M-4.4Hz, H-2");
13

C N M R (75MHz, CDC1 3 ): 8 51.14 (C-6), 57.65 (C-l'), 57.89, 59.45, 59.50 (MeO),

65.32 (C-2), 69.85 (C-l"), 79.38 (C-3), 80.59 (C-5), 86.46 (C-4), 115.70 (C-3"), 118.46
(C-3'), 134.00 (C-2*), 139.05 (C-2**);
CI-MS: m/z 272 (100%, M H + ) , 254 (32%, M H + - H 2 0 ) , 240 (28%, M H + - propene).

T B D M S protection of the diallyl alcohol 180
MeO

OTBDMS

"Hi

M e 0 ^ 3 x = JL ^ 3" To a stirred solution of the diallyl alcohol 180 (19.4mg,
4f 2fi" r
.N. ^ .
0.07mmol) in dry dichloromethane (0.5mL) at 0°C under
xX.L

MeO 5 ^ i y ^ N

argon was added, consecutively 2,6-lutidine (17uL, 0.14mmol)
and terf-butyldimethylsilyl trifluoromethanesulphonate (25 uL, O.lOmmol). Stirr
continued for 2h when the reaction was quenched with water (5mL) and extracted

dichloromethane (2x7.5mL). The combined organic extracts were dried and solven
removed under reduced pressure to give (1 "S,2R,3R,4R,5S)-2-(l-tert-

butyldimethylsilyloxy-2-propenyl)-l-(2-propenyl)-3,4,5-trimethoxypiperidine 18
(21.2mg, 77%) as a colourless oil;
'H NMR (300MHz, CDC13): 8 0.04 (3H, s, MeSi), 0.08 (3H, s, MeSi), 0.89 (9H, s,

Me3CSi), 2.16 (1H, dd, J6a,6b 12.8Hz, J6a>5 10.1Hz, H-6a), 2.43 (1H, dd, J2>3 9.2

3.3Hz, H-2), 3.11 (1H, dd, J4)3=J4,5 8.2Hz, H-4), 3.12 (1H, dd, J6bM 12.9Hz, J6

H-6b), 3.23-3.39 (3H, m, H-3,5 and la*), 3.40 (3H, s, MeO), 3.43-3.54 (1H, m, H-l

3.56 (3H, s, MeO), 3.60 (3H, s, MeO), 4.20 (1H, dd, Jv%2« 7.1Hz, Jr>2 3.4Hz, H-

5.09 (1H, d, J3W 10.1Hz, H-3' cis to H-2'), 5.12 (1H, d, JyW. 10.5Hz, R-3"cis to H-

2"), 5.15 (1H, dd, Jytrans? 17.1Hz, J 1.7Hz, H-3' trans to H-2'), 5.19 (1H, ddd, Jytrans

H.3UZ, Jytrans,ycis~Jytrans,v l-5Hz, H-3" trans to H-2"), 5.81 (1H, dddd, Jx>ytrans 17.1Hz

J??™ 10.0Hz, J2tV 6.8Hz, J2.

r

5.9Hz, H-2'), 6.00 (1H, ddd, Jr,rtrans 17.1Hz, Jr<y

10.5Hz, JTr73Uz, H-2");
13

C NMR (75MHz, CDC13): 8 ^.92 (MeSi), -3.60 (MeSi), 18.16 (Me3CSi), 25.99

(M&CSi), 51.01(C-6), 55.23 (C-l*), 57.86, 59.59 and 59.96 (MeO), 68.36 (C-2), 73.0

(C-l"), 78.48 (C-3), 78.95 (C-5), 89.13 (C-4), 115.19 (C-3*), 116.49 (C-3"), 136.55
2*), 140.80 (C-2");
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Preparation of the TBDMS-protected diallyl alcohol from 155

The TBDMSO-allylpiperidine 155 (104mg, 0.32mmol), allyl bromide (33uL, 0.38mmo

and potassium carbonate (114.0mg, 0.82mmol) and dry acetonitrile (lOmL) were h

to 60°C for 14h then refluxed for a further lh. The residue was extracted with

acetate (15mL) and washed with water (15mL). The aqueous phase was re-extracted

with ethyl acetate (15mL) and the combined organic extracts were dried and sol

removed under reduced pressure to give a brown residue (100.9mg). PTLC (silica,
dichloromethane:ethyl acetate 75:25) gave starting material 155 (18.7mg, 18%)

colourless oil (correct !H NMR and TLC behaviour), and the diallylpiperidine pr
181 (29.8mg, 25%) as a colourless oil (correct *H NMR and TLC behaviour).

Ring closing metathesis of the TBDMS protected diallyl compound 181
MeO OTBDMS

MeO

Hydrogen chloride (1.0M in diethyl ether, 90uL, 0.09mmol)
2

was added to the TBDMS-protected diallyl piperidine 181
n*«rv i

3

Solvent was removed under reduced pressure and the residue
further dried under high vacuum to give the 181»HC1 salt (34.6mg). Dry
dichloromethane (5mL) was added and the resulting solution sonicated to degas

solvent and placed under argon. Bis(tricyclohexylphosphine)benzylidene rutheni
dichloride 185 (12.0mg, O.Olmmol) was added and the orange-brown solution was

refluxed for 3 days. After cooling, more dichloromethane (5mL) was added and th

solution was washed with saturated aqueous sodium hydrogen carbonate (5mL). Aft

drying, solvent was removed under reduced pressure to give a crude product mix
(46.7mg). PTLC gave recovered starting material 181 (6.2mg) and a second band

appeared to be a 1:1 mixture of the monoallyl material 155 and (15,7,S,8i?,9i?

(ferr-butyldimethylsilyloxy)-7,8,9-trimethoxy-l,6,7,8,9,9a-hexahydro-4H-quinol
117(3.5mg).

H N M R (300MHz, CDC1 3 ): 8 0.10 (3H, s, MeSi), 0.11 (3H, s, MeSi), 0.92 (9H, s,
Me 3 CSi), 1.86 (1H, dd, J6a>6b = J^ 10.7Hz, H-6a), 2.00 (1H, dd, J9a,9 9.3Hz, J9aA
2.4Hz, H-9a), 2.66 (1H, d, J4a,4b 15.9Hz, H-4a), 3.00-3.40 (5H, m , H-4b, 6b, 7, 8 and 9),
3.48 (3H, M e O - 7 ) , 3.60 (3H, MeO-9), 3.64 (3H, MeO-8), 4.31 (1H, m , H-l), 5.78 (1H,
ddd, J3>2 9.9Hz, J3A 3.9Hz, J3A 1.5Hz, H-3), 5.86-5.94 (1H, m , H-4).

9.6 INVESTIGATIONS INTO THE FREE-RADICAL CYCLISATION
REACTION

DMAP coupling of o-bromobenzoyl chloride with the model compo
To a stirred solution of 1-allyl-1,2,3,4-tetrahydroisoquinoline 116 (1.0016g, 5.7mmol) in
dry dichloromethane (12mL), at room temperature under nitrogen, was added
consecutively, triethylamine (4.0mL, 29mmol), 4-dimethylaminopyridine (78.6mg,
0.64mmol) and o-bromobenzoyl chloride (0.98mL, 7.5mmol) in dry dichloromethane
(12mL). The resulting yellow solution was stirred for 4.5h
when T L C showed complete reaction. Water (11.5mL) was
added and the organic layer separated, washed with aqueous
hydrochloric acid (1M, 12mL) then saturated aqueous
sodium hydrogen carbonate (12mL). After drying the
solvent was removed under reduced pressure to give a crude oil. Purification by flash
silica chromatography (dichloromethane:hexane, 80:20) gave 2-(2-bromobenzoyl)-l-

(prop-2-enyl)-l,2,3,4-tetrahydroisoquinoline 197 (1.65g, 81%)as a pale tan oil (measur
M H + 356.0638, calculated for C 1 9 H 1 9 7 9 BrNO 356.0650);
'H N M R (CDC1 3 , 300MHz): (note: appears as a mixture of 4 rotamers A, B, C and D in
a ratio of 5:4:3:1) 8 2.30-2.77 (3.5H, m , H-l' and H-4), 3.01-3.52 (2.2, m , H-3 and H-4),
4.41 (1HC, dd, J u . 9.3Hz, JhV 4.9Hz, H-l C), 4.52 (1HD, t, J1>r 6.6Hz, H-l D ) , 4.77
(1HC, m , H-3b C), 4.90-5.07 (2H, m , H-3'cis and trans), 5.50 (1HC, dddd, J^y^ns
17.1Hz, J2,ycis 10.0Hz, JTtV 8.1Hz, J2r 6.7Hz, H-2' C), 5.54 (1HD, m , H=2' D ) , 5.75
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(1HA, t, J1>r6.6Hz, H-l A ) , 5.83 (1HB, dd, Jlir9.8Hz, JhV 4.9Hz, H-l B), 5.84-6.00
(1HA + 1HB, H-2' A and B), 6.48-7.51 (8H, m , aromatic CHs);
13

C N M R (CDC1 3 , 7 5 M H z ) : 8 27.99 (C-4 C), 29.02 (C-4 A ) , 29.37 (C-4 B), 30.88 (C-

4 C), 35.81 (C-3 C), 40.79 (C-l' A), 41.09 (C-3 A), 41.22 (C-3 B), 41.68 (C-l' B), 41.75
(C-l' C), 50.94 (C-l B), 52.37.(C-l A ) , 57.52 (C-l C), 117.43 (C-3' B), 117.84 (C-3' A),
118.52 (C-3' C), 118.99 (C-3' D ) , 126.00, 126.36, 126.64, 126.69, 126.80, 127.23,
127.33, 127.42, 127.51, 127.57, 127.71, 127.90, 128.74, 128.79, 129.04, 129.25,
130.00, 130.12, 130.18, 132.45 and 132.79 (aromatic CH's), 132.91 (C-2'C), 133.18,
133.19, 133.83, 134.02 (quaternary aromatic C's), 134.70 (C-2* A ) , 135.06 (C-2' B),
136.25, 136.69, 138.45 (quaternary aromatic C's), 168.27 (carbonyl C);
CI-MS: m/z 356/358 (100%/97%, M H + ) , 314/316 (22%/24%, M H + - propene),
276/278 (24%/22%), 132 (25%, (3,4-dihydroisoquinoline+H)+).

Free-radical cyclisation of the bromobenzamide
A solution of tributyltin hydride (0.98mL, 3.6mmol) and A I B N (4.6mg, 0.28mmol) in
dry toluene (80mL) was added slowly over a period of 2h
to a stirred refluxing solution of 2-(2-bromobenzoyl)-l(prop-2-enyl)-1,2,3,4-tetrahydroisoquinoline 197 (0.89g,
Me
2.5mmol) in toluene (70mL) under argon. Refluxing was
6

continued for a further 2h after which the solvent was
removed under reduced pressure. Diethyl ether (25mL) and aqueous potassium fluoride
( 8 % w/v, 25mL) was added and the mixture stirred for 20min. The organic phase was
separated and dried. Solvent was removed under reduced pressure. Flash silica column
chromatography eluting with dichloromethane afforded three pure compounds. The
first to elute appears to be 2-(2-tributylstannylbenzoyl)-l-(prop-2-enyl)-1,2,3,4tetrahydroisoquinoline 221 (7mg, 0.5%). Fractions 29 to 36 gave 2-benzoyl-l-(prop-2enyl)-l,2,3,4-tetrahydroisoquinoline 220 (84.8mg, 12%) as a colourless oil (measured
278.1546, calculated for C 1 9 H 2 0 N O 278.1545).
CI-MS: m/z 278 (100%, M H + ) , 236 ( 5 7 % M H + - propene), 105 (62%, C 6 H 5 C O + ) .

Fractions 43 to 84 gave the desired product 198/199(0.44g, 64%) as a mixture of
diastereomers. Multi-sweep P T L C gave one pure diasteBomer, N-benzoyl-7-methyl6,7,8,9-tetrahydro-5H-benzocylcohepten-5,8-imine 198 (55.5mg), as a colourless oil
(measured 278.1547, calculated for C 1 9 H 2 0 N O 278.1545). N M R revealed this to be a
mixture of 2 rotomers in a ratio of majonminor equal to 1.2:1.
•H N M R (300MHz, CDC1 3 ): 8 1.03 (3H minor, d, JMe>7 6.3Hz, Me-7 minor), 1.19 (3H
major, d, JMeJ 6.8Hz, Me-7 major), 1.64-1.78 (1H, m, H-6 minor and major), 2.12-2.28
(2H, m , H-6 minor and major and H-7minor and major), 2.70 (1H minor, d, J9a>9b
16.8Hz, H-9a minor), 2.79 (1H major, d, J9a>9b 16.8Hz, H-9a major), 3.26 (1H minor, dd,
J9b)9a 16.7H, J9b?8 5.0Hz, H-9b minor), 3.52 (1H major, dd, ./9bj9a 16.8H, J9b)8 4.9Hz, H9b major), 3.86 (1H minor, d, J 89b 4.6Hz, H-8 minor), 4.74 (1H major, d, J8)9b4.4Hz, H8 major), 4.78 (1H major, d, JSfi 6.3Hz, H-5 major), 5.60 (1H minor, d, JSfi 6.3Hz, H-5
minor), 6.84 (1H major, d, ./7.3Hz, Ar-H major), 7.09-7.52 (8H + 1H minor, m, Ar-H);
13

C N M R (75MHz, CDC1 3 ): 8 21.71 (Me minor), 21.83 (Me major), 36.02 (C-9 major),

36.51 (C-7 major), 37.34 (C-9 minor), 38.18 (C-7 minor), 44.14 (C-6 minor), 45.58 (C-6
major), 56.56 (C-5 minor), 58.50 (C-8 major), 61.48 (C-5 major), 63.36 (C-8 minor),
124.34, 125.63, 126.04, 126.29, 127.10, 127.23, 127.38, 128.13, 128.36, 129.28,
129.83, 129.91 (Ar-CH), 131.51 (Ar-4°C minor), 132.70 (Ar-4°C major), 136.10 (Ar4°C minor), 136.24 (Ar-4°C major), 140.44 (Ar-4°C major), 140.69 (Ar-4°C minor),
167.82 (carbonyl major), 169.03 (carbonyl minor);
CI-MS: m/z 555 (17%, (2M+H) + ), 278 (100%, M H + ) , 105 (15%, C 6 H 5 C O + ) .

Attempted cleavage of the benzamide product 198 using LiOH and NH3

Lithium hydroxide (1M in water, 0.54mL, 0.54mmol) was added to a stirred soluti
A^-Benzoyl-7-methyl-6,7,8,9-tetrahydro-5H-benzocylcohepten-5,8-iminel98(49.9mg,
0.18mmol) in tetrahydrofuran (0.8mL) at room temperature. Vigorous stirring of the
biphasic mixture was continued for 16h. T L C showed starting material only.
Concentrated aqueous ammonia (28%, lmL) and further tetrahydrofuran was added

(lmL) and stirring continued for a further 4.5h where T L C still showed only starting
material. Ethanol (95%, l m L ) was added to give a homogeneous solution that was
stirred at room temperature for 18h. The organic solvents were removed under reduced
pressure. Further water was added and the suspension extracted with dichloromethane
(15mL, lOmL). The combined organic extracts were washed with water (lOmL) and
dried. Solvent was removed under reduced pressure to give starting material 198 (46mg,
9 2 % mass recovery) as a colourless oil (correct ! H N M R and T L C behaviour).

Attempted reduction of the benzamide product 198 with DIBAH

A^-Benzoyl-7-methyl-6,7,8,9-tetrahydro-5H-benzocylcohepten-5,8-imine 198 (38mg,
0.14mmol) was dissolved in dry toluene (0.9mL) and cooled to 0°C. Di-isobutylalluminium hydride (1M in cyclohexane, 1.2mL, 1.15mmol) was added slowly to
the stirred solution under nitrogen. Stirring was continued for 20min at 0°C then lh at
room temperature. The reaction was quenched by the careful addition of a mixture of
methanol (2mL) and water (O.lmL). The resulting white residue wasfilteredoff and
washed with methanol. Solvent was removed under reduced pressure from thefiltrateto
give a white solid which was taken up in dichloromethane (lOmL). The organic phase
was washed with water and any product was extracted with 2 M hydrochloric acid. The
organic phase was then dried and solvent was removed under reduced pressure to give
the starting material 198 (28.5mg, 7 1 % mass recovery) as a colourless oil (correct *H
N M R and T L C behaviour). The acidic aqueous phase was basified with solid sodium
hydroxide and then back-extracted with dichloromethane (2x9mL). Drying and removal
of solvents gave no product.
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Cleavage of the benzamide product 198 using 6 M H C 1
1 9

8

2

f^y'^^ym

N-Benzoyl-7-methyl-6,7,8,9-tetrahydro-5H-benzocylcohepten-

^ ^ ^ X y T "

5,8-imine 198 (55.5mg) was heated under reflux with aqueous

6

hydrochloric acid (6N, 8mL) for 3.5 days. The resulting solution
was washed with dichloromethane (2x15mL), basified with aqueous sodium hydroxide
(ION, ca. 4 m L ) and extracted with ethyl acetate (2xl5mL). The combined organic
extracts were dried and the solvent removed under reduced pressure to give 7-methyl-

6,7,8,9-tetrahydro-5H-benzocylcohepten-5,8-imine 200 (15.4mg, 44%) as a colourless
(measured 174.1280, calculated for C 1 2 Hi 6 N 174.1283).
*H N M R (300MHz, CDC1 3 ): 8 1.22 (3H, d, JMeJ 6.8Hz, Me-7), 1.62 (1H, ddd, J6a,6b
11.5Hz, y6a,5 « ^6a,7 5.7Hz, H-6a), 2.10 (1H, dq, J7Me« J7>6a 6.8Hz, H-7), 2.14 (1H, d,
J6bM 11.2Hz, H-6b), 2.52 (br. s, N H ) , 2.64 (1H, d, J9a>9b 16.8Hz, H-9a), 3.14 (1H, dd,
79b>9a 16.8Hz, J9bj8 5.1Hz, H-9b), 3.39 (1H, d, J8>9b 4.9Hz, H-8), 4.23 (1H, d, J5M
6.1Hz, H-5), 6.96 (1H, dd, Jlj2 7.1Hz, J1>3 1.7Hz, H-l), 7.04 (1H, d, J4>3 7.3Hz, H-4),
7.10 (1H, dd, J2A = J2t3 7.1Hz, H-2), 7.13 (1H, ddd, J3>2 * J3>4 7.1Hz, J3>1 1.7Hz, H-3);
13

C N M R (75MHz, CDC1 3 ): 8 22.10 (Me-7), 37.20 (C-9), 37.42 (C-7), 45.93 (C-6),

59.61 (C-5), 61.12 (C-8), 125.05 (C-4), 125.60 (C-2), 126.68 (C-3), 129.59 (C-l),
132.23 (C-9a), 142.99 (C-4a);
CI-MS: m/z 174 (100%, M H + ) , 132 (17%, M H + - propene), 130(21%, M H + propane).

D M A P coupling of o-bromobenzoyl chloride with the T B D M S protected key
intermediate 155
MeO OTBDMS
Me0
v^\>A\s^
4|

2|

T o a stirredsomtion

of the key intermediate 155 (25mg,

r

X..L M^ ^O
x
MeO 5 ^ l ^
Br^^sU.

0.072mmol) in dry dichloromethane (1.2mL) under argon was
added, sequentially, triethylamine (54uL, 0.39mmol), 4-

*l 1
%^x

dimethylaminopyridine (1.5mg, 0.012mmol) and obromobenzoyl chloride (12.5}iL, 0.095mmol) in dry
dichloromethane (0.6mL). The resulting pale yellow solution was stirred for 20h when
T L C showed complete reaction. Water (5mL) and further dichloromethane (5mL) were
added. The organic phase was separated, washed with aqueous hydrochloric acid (1M,
5mL) then saturated aqueous sodium hydrogen carbonate (5mL). After drying the
solvent was removed under reduced pressure to give (1 'S, 2R, 3R, 4R, 5S)-l-(2-

bromobenzoyl)-2-(l -tert-butyldimethylsilyloxyprop-2-enyl)-3,4,5-trimethoxypipe
202 (27.6mg, 72%) as a pale blue oil (measured M H + 528.1807 (LSIMS), calculated for
C 2 4 H 3 9 BrN0 5 Si 528.1781);
'H N M R (300MHz, CDC1 3 ): mixture of 4 rotamers, data reported for the major
rotamer only: 8 0.08 (3H, s, MeSi), 0.15 (3H, s, MeSi), 0.92 (9H, s, *BuSi), 2.79 (3H, s,
M e O ) , 3.16-3.22 (1H, m , H-5), 3.26 (1H, dd, J4>3 - J4,5 4.8Hz, H-4), 3.32-3.46 (2H, m,
H-6), 3.53 (3H, s, M e O ) , 3.58 (3H, s, M e O ) , 3.56-3.62 (1H, m, H-3), 4.41 (1H, dd,
JX3 8.3Hz, J2,r 1.2Hz, H-2), 4.57 (1H, dd, Jr<r 7.8Hz, Jr,2 1.2Hz, H-l"), 5.18 (1H, d,
JYcisX 10.3Hz, H-3" cis to H-2"), 5.30 (1H, d, Jytrans,2<< 17.1Hz, H-3" trans to H-2"),
6.17 (1H, ddd, J2..,3w 17.1Hz, JT,rcis 10.1Hz, Jrr 7.7Hz, H-2"), 7.21 (1H, ddd, J5V, *
Jyfi 8.1Hz, JSy 2.0Hz, H-5*), 7.34 (1H, ddd, J4^ = J*,? 7.6Hz, J4.& 1. 1Hz, H-4*), 7.42
(1H, dd, J3.,4. 7.6Hz, Jy,y 1.7Hz, H-3*), 7.52 (1H, dd, Je? 8.1Hz, J6A 0.73Hz, H-6*);
13

C N M R (75MHz, CDC1 3 ): 8 -4.87 (MeSi), -3.75 (MeSi), 18.09 (Me3CSi), 25.95

(M&CSi), 44.65 (C-6), 55.61 (MeO), 59.24 (MeO), 59.75 (C-2), 59.85 (MeO),75.41
(C-l"), 76.81 (C-3), 82.92 (C-5), 85.33 (C-4), 116.04 (C-3"), 127.27 (C-4'), 130.04 (C5'), 130.45 (C-3*), 132.08 (C-6*), 139.07 (C-2"), 169.22 (carbonyl C);

CI-MS: m/z 528/530 (77%/100%, M H + ) , 396/398 (57%/67%, M H + - T B D M S O H ) ,
356/358 (16%/21%, M H + - T B D M S O C H 2 C H C H 2 ) .

DMAP coupling of o-bromobenzoyl chloride with the unprotected key
intermediate 115

To a stirred solution of (2i?,3i?,4i?,55)-2-(l-hydroxy-2-propenyl)-3,4,5trimethoxypiperidine 115 (88.0mg, 0.38mmol) in dry dichloromethane (2mL) under
argon, was added consecutively triethylamine (0.26mL, 1.9mmol), 4dimethylaminopyridine (23mg, 0.19mmol), and o-bromobenzoyl chloride (70uL,
0.54mmol). The resulting solution was stirred at room temperature for 18h to give a
white suspension. Sodium hydroxide (0.44g in lOmL of water) and dichloromethane
(5mL) were added and the organic phase was separated. The aqueous phase was
extracted with further dichloromethane (5mL) and the combined organic extracts were
washed with 1 M hydrochloric acid (lOmL). The acidic aqueous phase was then
extracted with further dichloromethane and the combined organic extracts were dried and
solvent removed under reduced pressure to give a crude oil (112.3mg).
P T L C (silica, dichloromethane:ethyl acetate 90:10, 2 sweeps)

cc

3- bromobenzoyl)prop-2-enyl)-3,4,5-trimethoxypiperidine 219

O

(17.9mg, 8 % yield) as a white solid (measured M H + 596.0298

eO

gave (l'S, 2R, 3R, 4R, 5S)-l-(2-bromobenzoyl)-2-(l-(2-

(LSIMS), calculated for C 2 5 H 2 8 7 9 Br 2 N0 6 596.0284);
*H N M R (CDC1 3 , 300MHz): 8 2.93 (3H, s, M e O ) , 3.12-3.20
(1H, m , H-5), 3.39-3.43 (1H, m , H-6a), 3.45 (3H, s, M e O ) ,
3.46-3.48 (1H, m , H-4), 3.51 (3H, s, M e O ) , 3.52-3.60 (2H, m , H-3 and 6b), 5.35 (1H,

dd, J2,Y 9.3Hz, J2>3 2.7Hz, H-2), 5.45 (1H, d, Jycis>2. 10.4Hz, H-3' cis to H-2'), 5.58 (1H,

d, Jytrans? 16.8Hz, H-3' trans to H-2'), 6.00-6.17 (2H, m , H-l' and 2'), 7.13-7.19 (1H, m ,
ArH), 7.27-7.45 (5H, m , ArH's), 7.66 (1H, dd, J7.6Hz, J 1.7Hz, ArH), 8.09 (1H, dd, J
7.8Hz, J 2.2Hz, ArH);

1J

C N M R (CDC1 3 , 75MHz): 8 40.97 (C-6), 53.17 (c-2), 56.98 (MeO), 58.38 (MeO),

58.64 (MeO), 72.41 (C-l*), 75.56 (C-3), 76.98 (C-5), 79.21 (C-4), 131.16 (C-3*),
127.28, 127.31, 129.98, 130.41, 132.04, 132.84, 133.58 and 134.50 (ArCH), 133.77 (C2'), 138.01, 132.16, 132.94, 133.50, 133.58 (Ar4°C's), 164.39 (ester carbonyl), 169.84
(amide carbonyl);
CI-MS: m/z 596/598/600 (51%/100%/47%, M H + ) , 396/398 (89%/88%, M H + - o bromobenzoic acid), 356/358 (45%/46%, M H + - allyl o-bromobenzoate), 274 (63%).
MeO OH
MeO ^I^= JL ^
^V-X*^^ ^s^X*^1 u^*s^^

4|

2|

l

„

(l'S, 2R, 3R, 4R, 5S)-l-(2-bromobenzoyl)-2-(l-hydroxypr

J

2"

•k N ^ O
MeQf 5^£ \^*r
BrVv^Jvi'
l^JI

2-enyl)-3,4,5-trimethoxypiperidine 201 (33.4mg, 2 1 % yield)
a colourless oil (measured M H + 414.0932 (LSIMS), calculated
for C 1 8 H 2 5 7 9 BrN0 5 414.0916);.
l

H N M R (300MHz, CDC1 3 ): mixture of 4 rotamers, data

reported for the major rotamer only: 8 3.04 (3H, s, M e O ) , 3.09-3.45 (4H, m, H-4, 5 and
6), 3.46 (3H, s, M e O ) , 3.49 (3H, s, M e O ) , 3.51-3.59 (1H, m, H-3), 4.58 (1H, ddd, Jr,r
= JV\2~A",OH

6.5Hz, H-l"), 4.70 (1H, dd, J2r 7.6Hz, J2>3 3.9Hz, H-2), 5.32 (1H, d,

Jyas,T 10.5Hz, H-3" cis to H-2"), 5.42 (1H, d, J 3 W ) 2 " 17.1Hz, H-3" trans to H-2"),
6.06 (1H, ddd, J 2 »,3w 17.1Hz, J2«>3V/, 10.5Hz, Jrr 6.6Hz, H-2"), 7.25 (1H, ddd, J5.4. =

Jyfi 7.3Hz, J5.ty 2.0Hz, H-5'), 7.36 (1H, ddd, y4.3- - Jv,y 7.4Hz, J4.6. 0.98Hz, H-4'), 7
(1H, dd, JyA, 7.8Hz, Jyt5- 2.0Hz, H-3'), 7.56 (1H, d, J&,y 8.1Hz, H-6');
13

C N M R (75MHz, CDC1 3 ): 8 42.53 (C-6), 56.89 (C-2), 57.01 (MeO), 58.42 (MeO),

58.55 (MeO),71.78 (C-l"), 76.22 (C-3), 78.01 (C-5), 80.63 (C-4), 117.71 (C-3"),
127.42 (C-4'), 129.57 (C-5*), 130.27 (C-3*), 132.36 (C-6*), 138.01 (C-2"), 170.73
(carbonyl C);
CI-MS: m/z 414/416 (85%/100%, M H + ) , 396/398 (16%/16%, M H + - H 2 0), 356/358
(9%/9%, MH + -propenol).
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D M A P coupling of o-bromobenzoyl chloride with the T M S protected key
intermediate 156 - small scale

MeO OTMS
MeO^ lL z JL ^
^^y^

4|

^s2/^i it^s^^
i

2|

2"

• V ^N ^.0
MeOs 5^f l y
B k i ^

2f

,„ To a stirred solution of (2i?,3i?,4i?,55)-2-(l-hydroxy-23

propenyl)-3,4,5-trimethoxypiperidine 156 (42.2mg,
0.14mmol) in dry dichloromethane (0.5mL) under nitrogen,

jl

l^^l
was added consecutively triethylamine (93 uL, 0.66mmol), 4dimethylaminopyridine (1.5mg, 0.013mmol), and o-

bromobenzoyl chloride (23uL, 0.18mmol). The resulting solution was stirr

temperature for 23h to give a white suspension. Saturated aqueous sodiu

carbonate (5mL) and dichloromethane (5mL) were added and the organic ph

separated and dried. Solvent was removed under reduced pressure to give

(66.1mg). PTLC (silica, dichloromethane:ethyl acetate 90:10,2 sweeps) ga

3R, 4R, 5S)-l-(2-bromobenzoyl)-2-(l-trimethylsilyloxy)prop-2-enyl)-3,4,

trimethoxypiperidine 203 (16.6mg, 25% yield) as a colourless oil (measu
486.1336 (LSIMS), calculated for C21H33BrN05Si 486.1312);

'H NMR (CDC13, 300MHz): appears as a mixture of four rotamers in a ratio

4:3:1.4:1 8 0.15, 0.17 and 0.18 (9H, TMS), 2.84 (3HA, MeO A), 2.95 (3

2.95 (3HB, MeO B), 3.04 (3HC, MeO C), 3.17-3.57 (11H, m, 2xMeO, H-3,4,5

6b A and C, H-2 B), 3.65 (1HD, d, J2X 8.8Hz, H-2 D), 4.40 (1HD, dd, Jr,
8.1Hz, H-1"D), 4.50-4.61 (2HA + 1HB+C, m, H-1"A, B and C and H-2A), 4.73

dd, J2,3~J2y 5.1Hz, H-2C), 4.87-4.96 (1HB+D, m, H-6b B and D), 5.17-5.22

1HZ + 1HC, m, H-3" trans to H-2" B and D, H-3" cis to H-2"), 5.30 (1HA+C, d

Jytrans,r 17.1Hz, H-3" trans to H-2" A and C), 5.57 (1HB, ddd, J^-w 17.1

10.0Hz, Jry 1.6Uz, H-2"B), 5.66 (1HD, m, H-2"D), 5.99 (1HC, ddd, JVtytrans 1

Jr,yas 10.0Hz, JTy 5.6Hz, H-2"B), 6.12 (1HA, ddd,JT,ytrans 17.1Hz, Jr,ycis 1
JTX 7.1Hz, H-2"A), 7.14-7.62 (4H, m, H-3', 4*, 5* and 6');
,3

C NMR (CDC13, 75MHz): 8 0.44, 0.51 (TMS A), 0.58, 34.48, 43.90 (C-6 A), 4

55.97 (MeO A), 56.32, 56.39, 56.71, 57.03, 57.29, 58.47 (C-2 A), 59.12 (M
151

59.40 ( M e O A ) , 59.75, 61.31, 70.16 (C-l" B), 71.02 (C-l" D ) , 73.62, 74.17 (C-l" A ) ,
74.70, 75.12, 75.81, 76.70 (C-3 A ) , 79.73, 79.91, 81.64 (C-5 A ) , 83.58, 84.12 (C-4 A ) ,
115.83 (C-3"), 116.40 (C-3" A ) , 118.49 (C-3" B), 118.97 (C-3"), 126.09, 126.43,
126.79, 127.23 (C-4'A), 127.85, 129.53, 129.83, 129.97, 130.07, 130.41, 132.11,
132.94, 133.50, 137.91 (C-2"), 138.79 (C-2"), 139.01 (C-2"), 139.02 (C-2"), 169.27
(carbonyl carbon A ) , 169.76 (carbonyl carbon B);
CI-MS: m/z 486/488 (77%/100%, M H + ) , 396/398 (20%/20%, M H + - T M S O H ) ,
356/358 (14%/14%, M H T - T M S O C H 2 C H = C H 2 ) , 256/258 (36%/34%);
and (VS, 2R, 3R, 4R, 5S)-l-(2-bromobenzoyl)-2-(l-hydroxyprop-2-enyl)-3,4,5trimethoxypiperidine 201 (17.7mg, 3 1 % yield) as a colourless oil (correctJ H N M R and
T L C behaviour).

DMAP coupling of o-Bromobenzoyl chloride with the TMS protected key
intermediate 156 - larger scale

DMAP coupling using (2i?,3i?,4i?,5JS)-2-(l-hydroxy-2-propenyl)-3,4,5trimethoxypiperidine 156 (301.4mg, 0.14mmol) following the above procedure gave
exclusively (VS, 2R, 3R, AR, 5S)-l-(2-bromobenzoyl)-2-(l-hydroxyprop-2-enyl)-3,4,5trimethoxypiperidine 201 (288.9mg, 7 0 % yield) after silica column chromatography
(dichloromethane: ethyl acetate 50:50).

Free-radical cyclisation of the hydroxydiallyl compound 201

To a stirred refluxing solution of (VS, 2R, 3R, AR, 5,S)-l-(2-bromobenzoyl)-2-(l
hydroxyprop-2-enyl)-3,4,5-trimethoxypiperidine 201 (201.3mg, 0.48mmol) in toluene
(16mL) under argon was slowly added a solution of tributyltin hydride (170uL,
0.63mmol) and A I B N (15.1mg, 0.09mmol) in toluene (15mL) over a period of 2.75h.
Refluxing was continued for a further 3.75h whereupon the solvent was removed under
reduced pressure. Diethyl ether (lOmL) and 8 % aqueous potassium fluoride (lOmL)

was added to the residue and the biphasic mixture was stirred for 50min. The organic
phase was separated and the aqueous phase extracted with further diethyl ether
Combining of the organic extracts, drying and removal of solvents under reduced

pressure to give a crude oil (169.3mg). Purification by PTLC afforded two produ
v
MeO
MeO ^ j / i ^
(lS)-(2-exo, 3-endo, 4-exo, 6-endo, 7-exo)-8-benzoyl- 7-meth
2

,L ® NBz/"'0H 2,3,4-trimethoxy-8-azabicyclo[3.2. lJoctan-6-ol 204 (71.4mg,

MeON

i\/
; 7

4 4 % yield) as a colourless oil (measured M H + 336.1816

(LSIMS), calculated for C18H26N05 336.1811);
'H NMR (CDC13, 300MHz): two diastereomers were visible in the NMR, each as a

mixture of two rotamers - only data for the major diastereomer is reported her

(3H minor, d, JMs,7 7.1Hz, Me-7 minor), 1.28 (3H major, d, JMe<7 7.1Hz, Me-7 ma

1.96 (1H minor, qd, J7)Me 7.0Hz, J7>6 3.7Hz, H-7 minor), 2.04 (1H major, qd, J7Me

7.0Hz, Jlfi 3.7Hz, H-7 major), 3.10 (3H major, s, MeO major), 3.16 (3H minor, s,

minor), 3.19 (1H minor, br., H minor), 3.37 (1H major, d, J 12.2Hz, H major), 3.44
(2H + 1H major, m), 3.52 (3H, s, MeO major and minor), 3.55 (3H minor, s, MeO

minor), 3.58 (3H major, s, MeO major), 3.69 (1H minor, s, H-l minor), 3.74 (1H min

s, H-4 minor), 3.82 (1H major, ddd, J 12.2Hz, J65 6.8Hz, J6;7 3.7Hz, H-6 major), 3.

(1H minor, ddd, J 12.2Hz, J6;5 6.8Hz, J6J 3.4Hz, H-6 minor), 4.29 (1H major, d, J
6.1Hz, H-5 major), 4.68 (1H major, s, H-l major), 5.24 (1H minor, d, J5)6 6.8Hz,
minor), 7.37-7.38 (3H, m, Bz H*s), 7.52-7.59 (2H, m, Bz H's);
13

C NMR (CDC13, 75MHz): 8 20.39 (Me-7 minor), 20.92 (Me-7 major), 41.15 (C-7

major), 42.89 (C-7 minor), 54.60 (C-5 minor), 57.06 (C-l major), 57.50, 57.54, 58.
and 58.25 (MeO's), 60.56 (C-5 major), 63.09 (C-l minor), 77.21 (C-4 minor), 78.08
2 major), 78.21 (C-6 minor), 79.58 (C-2 minor), 80.64 (CHOMe minor), 80.71 (C-4
major), 127.48, 127.94, 128.05 and 128.11 (benzoyl meta and ortho CH's), 129.51
(benzoylpara CH minor), 129.56 (benzoylpara CH major), 135.73 (phenyl 4°C
minor), 135.95 (phenyl 4°C major);
CI-MS: m/z 336 (100%, MH+);

6

(ls)-(2-ex°.3-endo,4-exo,6-endo)-9-benzoyl-2,3,4-trimethox

9 H
" N ^ O H

azabicyclo[3.3.1]nonan-6-ol 205 (20.5mg, 1 3 % yield) as a

;NBz[
MeO^

> N ^

7

colourless oil (measured M H + 336.1816 (LSIMS), calculated for

o

C 1 8 H 2 6 N 0 5 336.1811);
"H N M R (CDC1 3 , 300MHz): 8 1.55-1.91 (4H, m , H-7 and 8), 2.31 (1H major, br. O H
major), 3.12 (1H major, dd, J2,3 7.3Hz, J2,l 2.2Hz, H-2 major), 3.25 (1H minor, dd,
J2,3 7.3Hz, J2,l 2.2Hz, H-2 minor), 3.27 (3H major, s, M e O major), 3.31 (3H minor, s,
M e O minor), 3.38 (1H, ddd, J3,2 « J3,4 8.3Hz, J 2.2Hz, H-3), 3.45 (1H minor, d, J4,3
8.5Hz, C-4 minor), 3.48 (3H minor, s, M e O minor), 3.51 (3H major, s, M e O major),
3.55-3.58 (1H, m , H-4 major and 6 minor), 3.86 (1H major, m , H-6 major), 3.94-4.02
(1H, m , H-l major and 5 minor), 4.84-4.90 (1H, m , H-l minor and 5 major), 7.40-7.53
(5H, m , B z H's);
13

C N M R (CDC1 3 , 75MHz): 8 25.68 (C-8 major), 26.32 (C-8 minor), 28.62 (C-7

minor), 30.47 (C-7 major), 50.03 (C-l minor), 55.73 (C-l major), 56.77 (C-5 major),
57.20(MeO), 57.26 (MeO), 57.38 (two MeO's), 60.72 (two MeO's), 61.66 (C-5 minor),
66.76 (C-6 major), 68.35 (C-6 minor), 78.08 (C-4 major), 78.50 (C-4 minor), 83.28 (C-2
minor), 83.90 (C-2 major), 84.04 (C-3 minor), 84.27 (C-3 major), 127.61, 128.40
(benzoyl meta and ortho CH's), 130.08 (benzoyl para C H ) , 134.83 (phenyl 4°C),
170.16 (amide carbonyl C);

Free-radical cyclisation of the TBDMS-protected diallyl compound and
subsequent desilylation

To a stirred refluxing solution of (VS, 2R, 3R, AR, 55)-l-(2-bromobenzoyl)-2-(
butyldimethylsilyloxyprop-2-enyl)-3,4,5-trimethoxypiperidine202 (74.3mg,
0.14mmol) in toluene (5mL) under nitrogen was slowly added a solution of tributyltin
hydride (46uL, 0.17mmol) and A I B N (3.3mg, 0.02mmol) in toluene (75mL) over a
period of 2h. Refluxing was continued for a further 2.5h whereupon the solvent was
removed under reduced pressure. Diethyl ether (lOmL) and 8 % aqueous potassium

fluoride (lOmL) was added to the residue and the biphasic mixture was stirred for

50min. The organic phase was separated and the aqueous phase extracted with

diethyl ether (lOmL). Combining of the organic extracts, drying and removal
under reduced pressure afforded a crude oil (89.3mg). Purification by PTLC

dichloromethane:hexane: ethyl acetate 64:36:2) afforded starting material 2

20%o yield) as a colourless oil (correct 1H NMR and TLC behaviour) and a pr

mixture (29.2mg, 46% yield). An attempt to purify the product mixture furth

PTLC gave again a mixture of products (18.7mg)(measured MH+ 450.2687 (LSMS),

calculated for C^H^NOsSi 450.2676) which was then refluxed in 6M hydrochlo

(2mL) for 22h to give a pale yellow solution. Water (8mL) was added and the

was extracted with dichloromethane (lOmL). Drying and removal of solvents u

reduced pressure afforded a residue (1 l.Omg) which was purified by PTLC (

acetate: dichloromethane 60:40) to give \S-(2-exo,3-endo,A-exo,6-endo ,l-exo

benzoyl-7-methyl-2,3,4-trimethoxy-8-azabicyclo[3.2.1]octan-6-ol 204 (1.6mg,

yield over two steps) as a colourless oil (correct LH NMR and TLC behaviour

(2-ejco,3-e«cto,4-exo,6-e«Jo)-9-benzoyl-2,3,4-trimethoxy-9-azabicyclo[3.3.1

205 (5.0mg, 11% yield over two steps) as a colourless oil (correct lH NMR a
behaviour).

9.7 INVESTIGATIONS INTO 1,3-DIPOLAR CYCLOADDITIONS

A1C13 mediated amide formation between piperidine and y-butyrolactone
5*

4' /\ & A solution of triethylamine (4.0mL, 29mmol) in chloroform

L rN 1

2 4

3- \ / Y ^ - ^ " O H (7-5mL) was added drop-wise to a stirred suspension of
aluminium chloride (3.03g, 22.7mmol) in chloroform (15mL)

at 0°C under nitrogen. The resulting pale yellow-tan solution was allowed t
room temperature whereupon a solution of piperidine (2.0mL, 20mmol) and y-

butyrolactone (1.4mL, 18mmol) in chloroform (lOmL) was added slowly over 15

The mixture was then stirred for a further 2h then quenched by pouring onto ice-water

(90mL). The pale orange organic phase was separated and the aqueous layer furthe

extracted with chloroform (25mL). The combined organic extracts were washed with
water (30mL) and then brine (30mL) and dried. Solvent was removed under reduced

pressure to give piperidinyl 4-hydroxybutanamide 238 (2.58g, 83%) as an orange o
(measured MH+ 172.1338, calculated for C9H18N02 172.1338 );
'H NMR (300MHz, CDC13): 8 1.49 (4H, m, H-3' and H-4'), 1.57 (2H, m, H-5'), 1.82

(2H, tt, J3>2=J3A 5.9Hz, H-3), 2.43 (2H, t, J2>3 7.0Hz, H-2), 3.36 (2H, t, J6.,5
6'), 3.48 (2H, t, JTty 5.2Hz, H-2'), 3.60 (2H, br., H-4), 3.78 (1H, br., HO-4);
13

C NMR (75MHz, CDC13): 8 24.28 (C-5'), 25.36 (C-4'), 26.26 (C-3'), 27.70 (C-3),

30.46 (C-2), 42.63 (C-6'), 46.58 (C-2'), 62.08 (C-4), 171.56 (C-l);
EI-MS: m/z 172 (MlT), 154 (MH+- H20), 140 (MH+- CH3OH), 127 (M+#- C2H40),
112 (MIf- nPrOH), 99, 84 (100%, piperidenyl cation), 69 (C4H60+), 56,
41(H2C=CHCH2+);

IR: v 1626 (str., amide CO stretch), 1776 (med.), 2857 and 2936 (str., CH stretch),
(str. and br., OH stretch) cm-1.

A1C13 mediated amide formation between piperidine and y-valerolactone

A solution of triethylamine (4.0mL, 29mmol) in
OH
chloroform (7mL) was added drop-wise to a stirred
suspension of aluminium chloride (2.9lg, 22.7mmol) in
chloroform (15mL) at 0°C under nitrogen. The resulting pale yellow-tan solution
allowed to warm to room temperature whereupon a solution of piperidine (2.0mL,

20mmol) and y-valerolactone (2.44g, 18mmol) in chloroform (lOmL) was added slowl

over 20min. The mixture was then stirred for a further 2.25h then quenched by po

onto ice-water (90mL). The pale orange organic phase was separated and the aqueou

layer further extracted with dichloromethane (2x25mL). The combined organic extr
were washed with water (lOOmL). On addition of brine (60mL) an emulsion formed

which was slowly allowed to settle, and then crudely separated. The organic layer was
then dried. Solvent was removed under reduced pressure to give piperidinyl 5hydroxypropanamide 239 (2.58g, 77%) as an orange oil (measured M H + 186.1494,
calculated for C 1 0 H 1 9 N O 2 + H 186.1494);
»H N M R (400MHz, CDC1 3 ): 8 1.53 (2H, tt, Jy>2,= JyA 5.7Hz, H-3'), 1.55-1.69 (6H, m,
H-4, 4' and 5'), 1.74 (2H, tt, J3<2« J3A 7.3Hz, H-3), 2.37 (2H, t, J2>3 7.2Hz, H-2), 3.41
(2H, t, y6.t5. 5.5Hz, H-6'), 3.55 (2H, t, JTty 5.6Hz, H-2'), 3.63 (2H, t, J5A 6.2Hz, H-5);
13

C N M R (CDC1 3 , 75MHz): 8 21.04 (C-3), 24.44 (C-5'), 25.49 (C-4'), 26.43 (C-3'),

32.27 and 32.63 (C-2 and 4), 42.67 (C-2'), 46.58 (C-6'), 61.76 (C-5), 171.38 (C-l
carbonyl);
EI + -MS: m/z 186 ( M H + ) , 168 ( M H + - H 2 0 ) , 154 ( M H + - C H 3 O H ) , 140 ( M H + - EtOH),
112 ( M H + - "BuOH), 84 (100%, piperidenyl cation), 69 (C 4 H 6 0 + ), 55, 41
(H2C=CHCH2+);
IR: v 1608 (str., amide C O stretch), 1727 (med.), 2859 and 2940 (str., C H stretch), 3419
(str. and br., O H stretch) cm-1.

Preparation of the amide alcohol 224

A solution of triethylamine (1.2mL, 8.6mmol) in
4"

OH

chloroform (lOmL) was added drop-wise to a stirred
suspension of aluminium chloride (0.78g, 5.8mmol) in
chloroform (20mL) at 0°C under nitrogen. The solution

was allowed to warm to room temperature whereupon a solution of 1-allyl-1,2,3,4tetrahydroisoquinoline 116 (l.OOg, 5.7mmol) and y-butyrolactone (0.45g, 5.9mmol) in
chloroform (lOmL) was added slowly over 14min. The mixture was then stirred for a
further 18h then quenched by pouring onto ice-water (lOOmL). The organic phase was
separated and the aqueous layer further extracted with dichloromethane (40mL). The
combined organic extracts were washed with aqueous hydrochloric acid (1M, 50mL)
then with saturated aqueous sodium hydrogen carbonate (50mL). The organic layer was

dried and solvent removed under reduced pressure to give a crude mixture. Purification
by flash silica chromatography (ethyl acetate) gave l,2,3,4-tetrahydro-2-(4-hydroxy-l-

oxobutyl)-l-(2-propenyl)isoquinoline 224 (fractions 5-10, 0.96g, 6 5 % ) as a colourless oil
(measured M H + 260.1652, calculated for C i 6 H 2 2 N 0 2 260.1651);
'H N M R (CDC1 3 , 300MHz): 8 1.87-1.97 (2H, m , H-3"), 2.49-2.65 (4H, m , H-2" and
1'), 2.76 (1H minor, ddd, J4aAb 16.4Hz, J4a>3a 4.7Hz, J4a)3b 2.7Hz, H-4a minor), 2.83-2.94
(2H major, m , H-4a major and 4b major), (2.94 (1H minor, ddd, J4bM 16.1Hz, /4b)3a
10.5Hz, J4b>3b 5.6Hz, H-4b minor), 3.12 (1H minor, ddd, J3a,3b 13.2Hz, J3zAb 11.2Hz,
J3a>4a 4.4Hz, H-3a minor), 3.25 (1H, br., 4"-OH), 3.57 (1H major, ddd, J3a>3b 13.5Hz,
y3a>4b 9.9Hz, J3a,4a 5.1Hz, H-3a major), 3.65-3.71 (2H, m , H-4"), 3.85 (1H major, ddd,
./3b3a 13.1Hz, J3bAa~J3bAb A.lUz, H-3b major), 4.68 (1H minor, ddd, J3bj3a 13.2Hz,
J 3 M b 5.9Hz, J 3 M a 2.7Hz, H-3b minor), 4.93 (1H minor, dd, J1>lb- 9.2Hz, J Ua . 5.5Hz, H-l
minor), 5.00 (1H major, d, Jytrans,? 15.9Hz, H-3' trans to H-2'), 5.01 (1H major, d, JyciSyX
11.2Hz, H-3' cis to H-2'), 5.14 (2H minor, d and dd, Jycis>x 11.5Hz, Jytrans,2< 15.6Hz,
Jytrans,v l-5Hz, H-3' cis and H-3' trans to H-2'), 5.69 (1H major, t, Jx%v 7.1Hz, H-l
major), 5.75-5.89 (1H, m , H-2*), 7.10-7.21 (4H, m , H-5, 6, 7 and 8);
l3

C N M R (CDC1 3 , 7 5 M H z ) : 8 27.61 (C-3" major), 27.66 (C-3" minor), 27.97 (C-3

minor), 28.98 (C-4 major), 31.00 (C-2"), 35.29 (C-3 minor), 40.11 (C-3 major), 41.04
(C-l' major), 41.31 (C-l* minor), 52.15 (C-l major), 56.50 (C-l minor), 62.33 (C-4"),
117.13 (C-3* major), 118.74 (C-3* minor), 126.05, 125.73, 127.02, 129.21 (C-5, 6, 7 and
8 minor), 126.29,126.58,127.32, 128.48 (C-5, 6, 7 and 8 major), 122.27,136.81 (C-4a
and 8a major), 133.71 (C-2* minor), 134.24,136.25 (C-4a and 8a minor), 134.80 (C-2*
major), 172.30 (C-l" carbonyl major), 172.43 (C-l" carbonyl minor);
CI-MS: m/z 260 (100%, M H + ) , 242 (7%, M H + - H 2 0 ) , 218 (21%, M H + - propene),
132 (31%, (3,4-dihydroisoquinoline+H)+).
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Swern oxidation of the amide alcohol 224
5
6

4

[f^Y^|3 „ Dry dimethyl sulphoxide (0.33mL, 4.6mmol) in dry

8^ |^ |Y dichloromethane (0.74mL) was added slowly over 7min

rL O
|| 2'
to a stirred solution of oxalyl chloride (230uL, 2.6mmol)
in dry dichloromethane (5mL) at-75°C to -78°C under
nitrogen. After stirring for 14min, the alcohol 224 (0.6lg, 2.4mmol) in dry

dichloromethane (1.5mL) was added over lOmin. After stirring for 30min at -75°C to
-65 °C, triethylamine (1.7mL, 12mmol) was added and the suspension stirred for a

further 15min at -65°C. After warming to room temperature the mixture was stirred
a further 2h. Water (lOmL) was added and the organic phase separated. The aqueous
phase was washed with dichloromethane (lOmL). The combined organic phases were
washed sequentially with dilute aqueous hydrochloric acid (2M, 12mL) and brine
(lOmL) then dried. Solvents were removed under reduced pressure and the resulting

crude product was purified with silica column chromatography (dichloromethane:die
acetate, 1:1) to give starting material mBl (45.0mg, 7.4% recovery) in fractions
and 1,2,3,4-tetrahydro-l-(3-formyl-l-oxopropyl)-l-(2-propenyl)isoquinoline 225
(fractions 5-6, 391.lmg, 65% yield) as a colourless oil (measured MH+ 258.1491,
calculated for C16H20NO2 258.1494);
*H NMR (CDC13, 300MHz): 8 2.56 (2H major, dd, Jr>2.« JVA 7.1Hz, H-l'), 2.60-3.02
(6H and 2H minor, m, H-2", 3" and 4, and H-l' minor), 3.14 (1H minor, ddd, J3%3b
13.2Hz, J3Mb 11.2Hz, J3a>4a 4.4Hz, H-3a minor), 3.60 (1H major, ddd, J3a,3b 13.3Hz,

J3a>4b 9.8Hz, J3a,4a 5.0Hz, H-3a major), 3.85 (1H major, ddd, J3b,3a 13.4Hz, J3bM «

4.8Hz, H-3b major), 4.65 (1H minor, dddd, J3b>3a 13.2Hz, J3b>4b 6.1Hz, J3bM 2.7Hz, J
0.98Hz, H-3b minor), 4.93 (1H minor, dd, Juw 8.8Hz, J1>la. 5.1Hz, H-l minor), 5.00

(2H major, d and d, Jycis,2< 11.5Hz, Jytm# 15.6Hz H-3* cis and H-3* trans to H-2* ma

5.15 (2H minor, d and d, Jycis>x 11.5Hz, Jytrans,2< 15.6Hz, H-3* cis and H-3' trans t

minor), 5.64 (1H major, t, J u . 7.1Hz, H-l major), 5.79 (1H major, ddt, 7 2 , 3 W 17.1Hz,

J2,ycis9.3Hz, J2,r 7.1Hz, H-2' major), 5.86 (1H minor, ddt, J2,ytrans 17.1Hz, J ^ * 9.
J2X 7.4Hz, H-2' minor), 7.10-7.23 (4H, m , H-5, 6, 7 and 8), 9.85 (1H minor, s, C H O
minor), 9.86 (1H major, s, C H O major);
,3

C N M R (CDC1 3 , 75MHz): 8 26.13 (C-3" major), 26.31 (C-3" minor), 27.97 (C-2"

minor), 28.90 (C-2" major), 35.47 (C-4 minor), 38.58 (C-4 major), 38.72 (C-3 minor),
40.01 (C-3 major), 41.03 (C-l* major), 41.31 (C-l* minor), 52.47 (C-l major), 56.34 (C-l
minor), 117.17 (C-3' major), 118.87 (C-3' minor), 126.09, 125.79, 127.06, 129.25 (C-5,
6, 7 and 8 minor), 126.31, 126.63, 127.36, 128.50 (C-5, 6, 7 and 8 major), 123.37,
136.81 (C-4a and 8a major), 133.76 (C-2' minor), 134.28, 136.20 (C-4a and 8a minor),
134.80 (C-2' major), 169.70 (C-l" carbonyl major), 169.91 (C-l" carbonyl minor),
201.21 (CHO);
CI-MS: m/z 258 (100%, M H + ) , 216 (34%, M H + - propene), 132 (24%, (3,4dihydroisoquinoline+H)+).

Oxime formation from the aldehyde 225

Hydroxylamine hydrochloride (45.4mg, 0.65mmol)
4"
Ss

•

rL

was added to a stirred solution of the aldehyde 225

O
l| 2'

3

<^NOH

(122.5mg, 0.47mmol) and sodium acetate (95.0mg,
1.2mmol) in methanol (2mL) at 0°C. Stirring was

continued for 96h. T L C showed starting material only. Water (0.5mL) was added and
stirring continued for 30h. Brine (lOmL) was added and the mixture was extracted with
diethyl ether (2x1 OmL). The combined organic extracts were dried and solvent was
removed under reduced pressure to give l,2,3,4-tetrahydro-2-(4-hydroxyimino-loxobutyl)-l-(2-propenyl)isoquinoline 227 (111.3mg, 86%yield) as a colourless oil
(measured M H + 273.1604, calculated for C 1 6 H 2 iN 2 0 2 273.1603);
"H N M R (CDC1 3 , 300MHz): 8 2.55-2.62 (2H, m , H-l'), 2.68-2.84 (4H and 1H minor,
m, H-2" and 3", and H-4 minor), 2.90-2.95 (2H major and 1H minor, m , H-4 major and
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H-4b minor), 3.154 (1H minor, ddd, J3a>3b 13.2Hz, J3aAb 11.7Hz, J3a,4a 4.5Hz, H-3a
minor), 3.59 (1H major, ddd, J3a>3b 13.2Hz, J3a,4b 8.9Hz, J3aM 5.6Hz, H-3a major), 3.73
(1H major, ddd, J3b)3a 13.3Hz, J3b>4a = J3b4b 5.0Hz, H-3b major), 4.70 (1H minor, dddd,
J3b>3a 13.3Hz, J3bAb 6.2Hz, J3b>4a 2.3Hz, J0.88Hz, H-3b minor), 4.79 (1H minor, dd,

71>lb. 9.6Hz, y Ua .4.8Hz, H-l minor), 5.01 (1H major, dd, J 3 W , 2 . 17.1Hz, Jytrans>v 1.8Hz

H-3* trans to H-2* major), 5.02 (1H major, d, Jycis<7 10.4Hz, H-3' cis to H-2' major), 5.
(1H minor, dd, Jytrans?17.1Hz, Jytrans,v 1.2Hz, H-3' trans to H-2' minor), 5.19 (1H
minor, d, Jyeis? 10.4Hz, H-3* cis to H-2' minor), 5.65 (1H major, t, JXtV 7.2Hz, H-l

major), 5.80 (1H major, dddd, J 2 . 3 W 16.6Hz, JTtycis 10.5Hz, Jx,v 7.5Hz, JTX 6.9Hz, H2' major), 5.83 (1H minor, ddt, Jvptno* 16.6Hz, J2\yciS 10.5Hz, J2<x 7.6Hz, H-2' minor),
7.11-7.23 (4H, m , H-5, 6, 7 and 8);
13

C N M R (CDC1 3 , 75MHz): 8 13.05 (C-3"), 27.92 (C-2" minor), 28.80 (C-2" major),

29.56 (C-4 major), 29.59 (C-4 minor), 35.47 (C-3 minor), 39.93 (C-3 major), 41.07 (C-l'
major), 41.17 (C-l* minor), 52.64 (C-l major), 56.36 (C-l minor), 117.45 (C-3' major),
119.48 (C-3* minor), 126.27, 126.75, 127.28,129.36 (C-5, 6, 7 and 8 minor), 126.50,
126.83, 127.34, 128.56 (C-5, 6, 7 and 8 major), 132.97, 135.77, 136.45 (C-4a and 8a),
133.38 (C-2' minor), 134.59 (C-2' major), 167.54 (C-l" carbonyl major), 167.64 (C-l"
carbonyl minor);
CI-MS: m/z 273 (29%, M H + ) , 255 (100%, M H + - H 2 0 ) , 213 (14%, 255 - propene),
132 (35%, (3,4-dihydroisoquinoline+H)+).

Attempted 1,3-dipolar cycloaddition of the oxime 227

The oxime 227 (97.4mg, mmol) was sonicated with and then refluxed in dry toluen
(5mL) under nitrogen for 38h. Solvent was removed under reduced pressure to give a
crude residue (95.9mg). P T L C (dichloromethane) afforded only starting material 227
(11.6mg, 12%). N o other discernible products were isolated.
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Preparation of the allylalcohol 230
4

f| ^ ^
l

|

3-Bromo-1 -propanol (0.57mL, 6.3mmol) was added to a

H

L^O^N^J^ .OH .
r
;
II 3,

3-

stirr

ed mixture of 1-allyl-1,2,3,4-tetrahydroisoquinoline 116
(1 -01 g, 5 J m m o l ) and potassium carbonate (2.24g, 16mmol)

in dry acetonitrile (50mL) under nitrogen. Stirring was
continued under reflux for 16h to give a green mixture. Solvent was removed under
reduced pressure. The residue was taken up in ethyl acetate (70mL) and washed with
water (60mL). The aqueous phase was extracted with ethyl acetate (20mL). The
combined organic phases were extracted with hydrochloric acid (2M, 3x40mL). The
acid extracts were basified with concentrated aqueous ammonia solution and then backextracted with ethyl acetate (60mL, 30mL). The organic phases were dried and solvent
was removed under reduced pressure to give a crude residue (1.1427g). Silica column
chromatography (ethyl acetate) afforded l,2,3,4-tetrahydro2-(3-hydroxypropyl)-l-(2propenyl)isoquinoline 230 (745.7mg, 5 6 % yield) as a colourless oil (Measured M H +
232.1711, Calc. for C 1 5 H 2 2 NO 232.1701);
J

H N M R (300MHz, CDC13): 8 1.63-1.85 (2H, m, H-2"), 2.44-2.66 (3H, m, H-l' and

4a), 2.79-2.98 (4H, m, H-l", 3a and 4b), 3.23-3.32 (1H, m, H-3b), 3.75-3.85 (3H, m, H1 and 3"), 4.61 (1H, br., 3'-OH), 5.06 (1H, d, Jytrans>2< 16Hz, H-3' trans to H-2*), 5.07

(1H, d, Jycisa 11Hz, H-3' cis to H-2'), 5.83 (1H, ddt, Jx,ytrans 15.9Hz, J7<ycis 11.0Hz,
7.1Hz, H-2'), 7.05-7.15 (4H, m, H-5,6,7 and 8);
,3

C N M R (75MHz, CDC13): 8 24.00 (C-4), 27.44 (C-2"), 40.40 (C-l'), 42.52 (C-3),

53.95 (C-l"), 62.06 (C-l), 64.47 (C-3"), 116.92 (C-3'), 125.71, 126.18 (C-6 and 8),
127.79, 128.82 (C-5 and 7), 133.78 (C-4a), 135.63 (C-2'), 137.00 (C-8a);
CI-MS: m/z 232 (100%, M H + ) , 190 (39%, M H + - propene).

Attempted Swern oxidation of the alcohol 230

Dimethyl sulphoxide (67uL, 0.95mmol) in dry dichloromethane (0.2mL) was slowly
added over 5min to a stirred solution of oxalyl chloride (50uL, 0.57mmol) in dry

dichloromethane at -80 to -78°C under nitrogen. After stirring for 15min, the alco
230 (115mg, 0.50mmol) in dry dichloromethane (LOmL) was added slowly. Stirring

was continued for a further 25min at -80 to -73°C whereupon triethylamine (0.33mL,
2.4mmol) was added and the suspension slowly allowed to warm to room temperature

over a period.of 4h. Water (2mL) was added and the mixture stirred to give a bipha

solution. Further dichloromethane (6mL) was added. The organic phase was separated

and extracted with 1M hydrochloric acid (2x8mL). The combined aqueous extracts wer
basified with concentrated aqueous ammonia solution (2mL) and back-extracted with

dichloromethane (2x8mL). Drying of the combined organic extracts followed by solve
removal under reduced pressure gave a crude brown oil (84.2mg). *H NMR of this
material showed absence of starting material and an aldehydic CHO resonance. This
material was subsequently lost on the plate when purification by silica PTLC was
attempted.

Preparation of the methyl butanoate 233
5 4
SfX^X^

3

l-Allyl-l,2,3,4-tetrahydroisoquinolinell6(513.4mg,

J
: N

P
\^\^
Y
T

c

°2

M e

3.0mmol), potassium carbonate (896.0mg, 6.3mmol)

a

and methyl 4-iodobutyrate (0.44mL, 3.3mmol) in dry

3' acetonitrile (18mL) were refluxed under nitrogen for

22h. After solvent was removed under reduced pressure the resulting residue was t
up in ethyl acetate (40mL), washed with water (25mL) and then extracted with
hydrochloric acid (2M, 2x25mL). The combined aqueous extracts were basified with
aqueous sodium hydroxide (10M, 12.5mL) and then back-extracted with ethyl acetate
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(2x25mL). The combined organic extracts were dried and solvent was removed under

reduced pressure. Silica column chromatography (dichloromethane/ethyl acetate,
to 80:20 to 70:30) afforded methyl l,2,3,4-tetrahydro-l-(2-

propenyl)isoquinolinebutanoate 233 (319.3mg, 39%) as a pale yellow oil (measure
MH+ 274.1807, calculated for C17H24N02 274.1807);
'H NMR (300MHz, CDC13): 8 1.84 (2H, tt, J^J^ 7.1Hz, H-[3), 2.38-2.57 (3H, m,

H-l' and 4a), 2.40 (2H, t, J^ 7.4Hz, H-cc), 2.60 (2H, t, Jy$ 6.8Hz, H-y), 2.74-2

m, H-3a and 4b), 3.19 (1H, ddd, y3b>3a 12.7Hz, J3bA 9.5Hz, J3bA 4.9Hz, H-3b), 3

s, Me), 3.69 (1H, dd, JhVa 7.1Hz, Ju-b 5.6Hz, H-l), 5.00 (1H, d, Jycis,T 10.5Hz,

to H-2'), 5.01 (1H, d, J3W,2' 16.6Hz, H-3' trans to H-2'), 5.87 (1H, ddt, J2.,3W
16.7Hz, J2;ycis 10.6Hz, JTX 7.0Hz, H-2'), 7.04-7.13 (4H, m, H-5, 6, 7 and 8);
13

C NMR (75MHz, CDC13): 8 23.08 (C-f3), 25.14 (C-4), 31.71 (C-a), 40.10 (C-l'),

43.73 (C-3), 51.40 (Me), 52.68 (C-y), 61.47 (C-l), 115.78 (C-3*), 125.47, 125.89,

127.81, 128.82 (C-5,6,7 and 8), 134.72, 138.23 (C-4a and 8a), 136.79 (C-2*), 17
(carbonyl C);
CI-MS: m/z 274 (100%, MH+), 232 (56%, MH+- propene).

DIBAH reduction of the methyl butanoate 233
5 4 .

3

Di-wo-butylaluminium hydride (1.5M m toluene,

p
^/s^^CHO

o.7lmL, l.lmmol) was slowly added to a stirred pale

Y

a

orange solution of the methyl butanoate 233 (259.7mg,
2,
3- 0.97mmol) in dry toluene (4mL) at -78°C under nitrogen.

After stirring for a further 4h 20min at this temperature, saturated aqueous s
hydrogen carbonate (6mL) and water (20mL) was added. The biphasic mixture was
extracted with dichloromethane (40mL). Drying of the organic phase and removal

solvents under reduced pressure gave a crude orange oil (232.6mg). Silica colum

chromatography (52:48 dichloromethane/ethyl acetate) gave starting material 23
(fractions 4-6, 71,4mg, 27% mass recovery), methyl l,2,3,4-tetrahydro-l-(2-

propenyl)isoquinolinebutanal 234 (fractions 7-12, 30.7mg, 13%) as a colourless oil
(measured M H + 244.1710, calculated for C 1 6 H 2 2 N O 244.1701);
*H N M R (300MHz, CDC1 3 ): 8 1.85 (2H,tt,J^J^

6.8Hz, H-J3), 2.42 (1H, ddd, Jla. w

14.6Hz, Jla-;2. 7.1Hz, Jla. t 5.6Hz, H-la'), 2.51 (3H, td and m , J ap 7.1Hz, Ja(CHo l-7Hz,
H-a and H-lb')2.60 (3H, t and m , JY>p 6.8Hz, H-y and H-4a), 2.75 (1H, ddd, J3a,3b
12.7Hz, 7 3 M b 5.5Hz, J3aAa 3.3Hz, H-3a), 2.88 (1H, ddd, J4bM 16.4Hz, J4b>3b 9.5Hz,
/4b;3a 5.9Hz, H-4b), 3.18 (1H, ddd, J3b)3a 12.8Hz, J3b>4b 9.8Hz, J3bM 5.0Hz, H-3b), 3.67
(1H, dd, J1>rb 6.8Hz, JhVa 5.6Hz, H-l), 5.01 (1H, dddd, Jycis>x 10.7Hz, Jycis,ytrans Jyas,\* * ^3-cB.ib' 0.98Hz, H-3* cis to H-2*), 5.02 (1H, dddd, J 3 W j 2 , 16.6Hz, J3W,3'C« *
JytransM = Jytnms.W L 5 H z , H-3' tTOHS tO H-2'), 5.86 (1H, ddt, J^'tram 16.8Hz, J2<>ycis

10.7Hz, Jxy 7.0Hz, H-2'), 7.05-7.14 (4H, m , H-5, 6, 7 and 8), 9.79 (1H, t, JCH0,a 1.7Hz,
CHO);
13

C N M R (75MHz, CDC13): 8 20.78 (C-(3), 25.00 (C-4), 40.16 (C-l'), 41.72 (C-a),

43.57 (C-3), 52.64 (C-y), 61.63 (C-l), 115.94 (C-3*), 125.54, 125.99, 127.83, 128.87 (C5, 6, 7 and 8), 134.61, 138.12 (C-4a and 8a), 136.78 (C-2'), 202.41 (CHO);
CI-MS: m/z 244 (100%, M H + ) , 202 (23%, M H + - propene).

Preparation of the nitrone 236 and attempted 1,3-dipolar cycloaddition

The aldehyde 234 (30.1mg, 0.13mmol), N-

©O0

methylhydoxylamine hydrochloride (16.8mg,
0.20mmol), pyridine (O.lmL) and ethanol (0.7mL)

3"

were refluxed under nitrogen for 3h. After cooling to

room temperature the mixture was poured onto ice-water (20mL) and extracted with
dichloromethane (5x1 OmL). The combined organic extracts wre washed with saturated
aqueous sodium hydrogen carbonate (15mL), dried and then solvent was removed under
reduced pressure to give the N-[A-( 1 -allyl-1,2,3,4-tetrahydroisoquinol-2yl)butylidene]methylamine JV-oxide 236 (25.7mg, 71%) as a crude brown oil (measured
M H + 273.1970, calculated for C 1 7 H 2 5 N 2 0 273.1967);

13

C N M R (CDC1 3 , 75MHz): 8 23.70 (C-b), 24.85 (C-a), 25.02 (C-l'), 40.11 (C-4),

43.58 (C-3), 52.23 (NMe), 53.16 (C-g), 61.42 (C-l), 115.85 (C-3'), 125.53, 125.96,
127.81 and 128.85 (C-5, 6, 7 and 8), 134.49 (C-4a), 136.82 (C-2'), 138.01 (C-8a),
140.64 (CH=N);
CI-MS: m/z 273 (91%, M H + ) , 257 (100%, M H + - C H 4 or O), 174 (55%), 132 (54%).

Preparation of the ethyl propanoate 231
5

4

6 jf^S^^I 3
7

^*^ > v ^
8

1

1

r

Vv

l

-Allyl-1,2,3,4-tetrahydroisoquinoline 116 (209.1 mg,

^ C02Et 1.2mmol), potassium carbonate (384.0mg, 2.8mmol) and

P

^ j | 2'

ethyl 3-bromopropionate (0.18mL, 1.4mmol) in dry
acetonitrile (20mL) were refluxed under nitrogen for 14h.

After solvent was removed under reduced pressure the resulting residue was taken up in
ethyl acetate (40mL), washed with water (25mL), and the aqueous phase re-extracted
with ethyl acetate (lOmL). The combined organic extracts were dried and solvent was
removed under reduced pressure. Silica column chromatography (dichloromethane/ethyl
acetate, 100:0 to 80:20 to 70:30) afforded ethyl l,2,3,4-tetrahydro-l-(2propenyl)isoquinolinopropanoate 231 (54.6mg, 17%) as a colourless oil (measured M H +
274.1813, calculated for C 1 7 H 2 4 N 0 2 274.1807);
*H N M R (300MHz, CDC1 3 ): 8 1.25 (3H, t, J C H 3 > CH 2 7.1HZ, O C H 2 C H 3 ) , 2.38-2.64 (5H,
m, H-a, 1' and 4a), 2.79-3.00 (4H, m, H-p\ 3a and 4b), 3.15-3.26 (1H, m, H-3b), 3.69
(1H, dd, JXXa 7.3Hz, JhVb 5.6Hz, H-l), 4.30 (2H, qd, J C H 2 ,CH 3 7.2HZ, J 1.1Hz,
O C H ^ C H A 4.99 (1H, dm, Jycisy 10.3Hz, H-3' cis to H-2'), 5.00 (1H, ddd, Jytrans,2>
17.1Hz, Jytma>v 2.0Hz, Jytram,v 1.5Hz, H-3' trans to H-2*), 5.86 (1H, ddt, J2<,ytrans
17.1Hz, JT,ycis 10.3Hz, J2X 7.0Hz, H-2'), 7.05-7.143 (4H, m, H-5, 6, 7 and 8);
13

C N M R (75MHz, CDC1 3 ): 8 14.21 (OCH 2 CH 3 ), 25.02 (C-4), 33.61 (C-a), 40.23 (C-

1'), 43.94 (C-3), 49.26 (C-|3), 60.30 (OCH 2 CH 3 ), 61.29 (C-l), 115.78 (C-3*), 125.57,
125.95, 127.81, 128.85 (C-5, 6, 7 and 8), 134.56,137.95 (C-4a and 8a), 136.65 (C-2'),
172.68 (carbonyl C);

Attempted reduction of 231 to the aldehyde 232

The ester 231 (53.8mg, 0.2mmol) was dissolved in toluene (lmL) to give a pale

solution which was cooled to -78°C under argon. Diisobutylaluminium hydride (1

in toluene, 140uL, 0.2mmol) was slowly added and stirring was continued for 3h

temperature. The reaction was quenched by the slow addition of saturated aqueo

sodium hydrogen carbonate (5mL) and water (5mL). The aqueous phase was extracte

with dichloromethane (2x1 OmL). The combined organic extracts were dried and s

was removed under reduced pressure to give a crude product mixture (40.5mg). PT
allowed for the separation of starting material 231 and the alcohol 230.

9.8 RING EXPANSION OF THE CARBAMATE 153
The alkene carbamate 153 (94.6mg, 0.33mmol),
Me

9 H C ^OCH2c°2Et sodium propoxide (1M in propanol, 0.65mL,
MeO.
Xs^jAj
81
19a |
0.65mmol) and ethyl mercaptoacetate (37.4uL,
«-\ N ^X 3
6 5 if4
0.34mmol) were refluxed for 6h under nitrogen. After

removal of solvents under reduced pressure, the

resulting yellow oily-solid was dissolved in dichloromethane (2.5mL) and washe

water (2.5mL). The aqueous phase was further extracted with ethyl acetate (2.5m

The combined organic extracts were dried and solvents were removed under reduc
pressure. Silica column chromatography gave (lS,7S,SR,9R,9aR)-l-[2-

(ethoxycarbonylmethoxy)ethyl]-7,8,9-trimethoxy-1,6,7,8,9,9a-hexahydropyrido[2,
c][l,4]thiazin-4(3H)-onc 243 (5.4mg, 4.2%) as a colourless oil (measured MH+
392.1744, calculated for C17H30NO7S 392.1744);
13

C NMR (CDC13, 75MHz): (DEPT analysis only) 8 10.2 (C_H2CH2), 27.7, 29.7, 33.8,

34.4, 42.2 (C-6), 58.6 (MeO), 61.0 (MeO), 61.2 (MeO), 61.3 , 66.8, 76.7 (C-l), 79.0
(C-8), 82.4 (C-9), 87.2 (C-7); CI-MS: m/z 392 (100%, MH+).
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FREE-RADICAL CYCLIZATION OF 2-(o-BROMOBENZOYL)-1-(2-PROPENYL)-1,2,3,4T E T R A H Y D R O I S O Q U I N O L I N E : S Y N T H E S I S O F 7-METHYL-6,7,8,9-TETRAHYDRO-5HBENZOCYCLOHEPTEN-5.8-IMINE

John B. Bremner,1* Alicia A. Monteith1 and Reginald J. Smith2
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2
Phytex Australia Pty Ltd, Sydney, N S W , Australia, 2156

Abstract: Free-radical cyclization of 2-(o-bromobenzoyl)-1-(2-propenyl)-1,2,3,4-tetrahydr
mediated with tributyltin hydride, proceeded to give /V-benzoyl-7-methyl-6,7,8,9-tetrahydro-5Hbenzocyclohepten-5,8-imine. One diastereomer was separated and the amide hydrolysed with aqueous
hydrochloric acid to give 7-methyl-6,7,8,9-tetrahydro-5/-/-benzocyclohepten-5,8-imine.

Whilst working with the readily available model system, 1-(2-propenyl)-1,2,3,4-tetrahydro

have investigated a series of reactions including a free-radical cyclization to the benz-

Reporting of our results in this area has been prompted by the recent publication of rela
(1).

2-(o-Bromobenzoyl)-1-(2-propenyl)-1,2,3,4-tetrahydroisoquinoline 4 was prepared from comm

available 1,2,3,4-tetrahydroisoquinoline 1 in a3-step sequence (scheme 1) and with a tota

Compound 4 can also be made in a one-pot reaction from 2 (80% yield) by direct AZ-acylatio
intermediate zinc precursor of 3.
Scheme 1: Preparation of the cyclization precursor 4.

1

2

3 ^

4

1

Reagents and Conditions: (i) NBS, CH2CI2, r.t., 1.2h (2) (ii) allyl bromide, Zn, THF, 0°C
r.t., 2d (iii) o-bromobenzoyl chloride, Et3N, DMAP, CH 2 CI 2 , r.t., 4.5h.

A solution of tributyltin hydride, and AIBN free-radical initiator, in toluene was slowly
solution of 2-(o-bromobenzoyl)-1-(2-propenyl)-1,2,3,4-tetrahydroisoquinoline 4 in toluene. After further

heating, work-up and column chromatography, a 64% yield of the desired product, A/-benzoy

6,7,8,9-tetrahydro-5H-benzocyclohepten-5,8-imine 5, was obtained together with debrominat
1-(2-propenyl)-1,2,3,4-tetrahydroisoquinoline 6 (12%) (scheme 2).
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S c h e m e 2: Free-radical cyclization of 4.
Bu3SnH, AIBN
toluene
>reflux
2h

Although cyclization gave exclusively the 5-exo-trig product, a mixture of diastereomers (ratio 2:1) was
obtained. These results are consistent with those from the analogous piperidine system reported by Ikeda et
al. (3). Preference for H-transfer from the 3-position to the aryi radical initially generated from 4 can be
explained in terms of the likely preferred amide rotamer being as shown in 4. The major diastereomer was
isolated by multi-sweep preparative thin layer chromatography. The exo cyclised structure was clearly
evidenced in the 1 H N M R of this diastereomer by the methyl doublets at 1.02ppm and 1.19ppm for the minor
and major rotamers respectively. Debenzoylation of this diastereomer with aqueous hydrochloric acid gave
the free amine, 7-methyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-5,8-imine 7.
(HSQC and H M B C ) were used to assign the 1 H and

13

2D N M R experiments

C resonances of this compound.

The relative

stereochemistry across the C7-C8 bond has been assigned as cis due to the H-8 resonance at 3.39ppm
being a doublet (J 89 =4.9Hz), and the H-7 proton a doublet of quartets (J7>6=J7iMe=6.8Hz) at 2.10ppm. High
resolution mass spectrometry (chemical ionisation) confirmed the molecular formula of C|2Hi5N for 7
(calculated for (M+H) + 174.1283, measured 174.1280).

A short, convenient and potentially flexible synthesis has thus been developed to the pharmacologically
interesting (4) reduced 5H-benzocyclohepten-5,8-imine system.
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